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Sélection d’anticorps recombinants dirigés contre des matériaux inorganiques pour 
des applications nanoscientifiques 
  
Résumé 
Les matériaux inorganiques ont des propriétés uniques à l'échelle nanométrique. Ces 
propriétés ont généré beaucoup d'intérêt pour fabriquer des nouveaux matériaux utilisant 
des nano-objets comme unité de construction. Nous avons suivi une approche 
biomimétique pour la fabrication de dispositifs à base de nanoparticules afin d'améliorer les 
méthodes actuelles de fabrication top-down et bottom-up. Certaines protéines naturelles se 
lient en effet spécifiquement à des matériaux inorganiques, et déclenchent notamment la 
croissance de cristaux inorganiques. Une première étape dans cette approche 
biomimétique est de comprendre comment des protéines se lient spécifiquement à des 
nanomatériaux inorganiques. Nous avons exploré ce mécanisme de reconnaissance en 
sélectionnant des anticorps (les protéines de notre système immunitaire spécialisées dans 
les interactions avec de nombreuses cibles) contre des matériaux inorganiques par la 
méthode combinatoire biotechnologique appelée "phage display". Cette technique permet 
d'obtenir la séquence génétique codante des anticorps sélectionnés se liant à leur cible à 
partir d'une banque aléatoire d'anticorps. L'analyse statistique des séquences des anticorps 
sélectionnés fournit de nouvelles informations sur les interactions protéines/matériaux 
inorganiques. Notre principale conclusion est l'identification de l'acide aminé arginine en 
tant que contributeur majeur dans les interactions protéine/or. L'ingénierie génétique des 
anticorps permet de fonctionnaliser ces nouvelles sondes de matériaux inorganiques en 
vue de leur utilisation pour des applications dans le domaine des nanomatériaux. Les 
anticorps recombinants sélectionnés et leurs dérivés fonctionnalisés peuvent être exprimés 
par sécrétion à l'aide d'un hôte eucaryote (Dictyostelium discoideum) mis au point au cours 
de cette thèse. 
 Mots-clés: biomimétisme, nanoparticules, anticorps, Phage display, or, arginine, 
Dictyostelium discoideum. 
 
 Selection of recombinant antibodies against inorganic materials for applications in 
nanosciences 
 
Abstract 
Inorganic materials have unique properties at the nanometer scale. These properties have 
generated a lot of interest among researchers to fabricate novel materials using nano 
objects as building units. In this PhD thesis, we have attempted to mimick nature in the 
fabrication of nanoparticle based devices in order to improve upon current top-down and 
bottom-up nanomaterial fabrication methods. Proteins can specifically bind inorganic 
materials and trigger crystal growth and thus are considered as the main building units for a 
biomimetic approach of fabrication. The first step towards mimicking nature is to explore 
how proteins bind specifically to nanomaterials. We have explored this recognition 
mechanism by selecting antibodies (the protein binders of our immune system) against 
inorganic nanomaterials using the combinatorial biotechnology method of phage display.  
This technique provides us with the genetic sequence of selected antibodies from a random 
antibody library exposed against a target. Statistical analysis of selected antibody 
sequences provides new information on proteins/inorganics interactions. Our main finding in 
this regard is the identification of the amino acid arginine as a major contributor to 
protein/gold interactions. Additional functionality to these new binders of inorganic materials 
is obtained by antibody engineering, allowing for their value added use in nanomaterial 
science applications. Selected recombinant antibodies and their engineered derivatives 
along with other recombinant protein can be expressed and secreted using a eukaryotic 
expression platform (Dictyostelium discoideum) developed during this thesis. 
 
Keywords: biomimetics, nanoparticles, antibody, phage display, gold, arginine, 
Dictyostelium discoideum. 
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Synopsis 
 
Inorganic materials at the nanoscale level (1 - 100 nano metre) exhibit different optical, 
electrical, photo-electrical, magnetic, mechanical, chemical and biological properties in 
contrast to  the bulk material that can have application in medical, energy, environment, 
production, and various other fields. In the context of this thesis, we have focused on two 
potential applications of nanomaterials; the use of metal and semiconductor nanoparticles 
as probes in bio-imaging and the production of self-assembled structures/devices based on 
nanoparticles. Both applications require a better control on nanoparticle surface chemistry. 
The objective of this thesis is to propose a new strategy for improving surface chemistry of 
nanoparticles by using proteins, more precisely antibodies, as ligands/probes for inorganic 
nanomaterials, thus altering the surface chemistry. To achieve this goal, it is of primary 
importance to understand how proteins specifically bind to inorganic materials. 
 
To understand protein/inorganics interaction we have used the combinatorial technique 
called phage display of antibodies. In this technique, a combinatorial random library of 
recombinant antibodies mimicking the immune repertoire is screened in vitro for selection of 
antibodies binding to a target of interest. This technique allows one to isolate specifically 
bound antibodies and their encoding genetic sequences. The technique has the major 
advantage of selecting protein binders under in vitro controlled conditions. One can tune the 
physical and chemical environment to create a selection pressure. Another major 
advantage of this technique is that there is no requirement for prior characterisation of the 
targets. In the case of inorganic surface targets, this is a crucial advantage over classical 
methods based on the rational design of inorganic surface ligands (molecular dynamics 
simulations, for instance). 
 
In this thesis, multiple inorganic materials were used as a target. We propose this technique 
to prove the concept that, in principle, any material (organic/inorganic) can be used as a 
target and thus specific antibodies (proteins) targeting the material of interest can be 
identified. So far, by screening a library containing 108 random antibody sequences, we 
have successfully identified 32 sequences of selected antibodies that specifically bind to 
micron-sized gold particles. The statistical analysis of the 32 gold-binding antibodies 
sequences has allowed us to identify particular amino acids that were strongly selected at 
the random positions of antibody sequences. Arginine was predominantly selected at many 
positions in gold binding antibodies. This finding is in agreement with the observation of 
other groups using sophisticated and dedicated strategies such as molecular dynamics 
simulations. This result supports our strategy based on relatively simpler technique of 
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phage display for material science studies. We have then tried to use our gold-binding 
antibodies as ligands for improving the surface chemistry of gold nanoparticles (size - 20 
nm). Preliminary results indicate the plausibility of the concept. The reasons for the inability 
to select antibodies against other inorganic targets used during thesis are partially identified. 
These challenges can be addressed by simply optimising the protocols for the other 
inorganic targets. 
 
As a next step, the sequence of selected antibodies can be modified by using recombinant 
antibody engineering. Antibodies can be engineered to acquire a new chemical function. 
Sequences of two scFvs can be fused in order to produce adapters called bispecific 
antibodies capable of binding simultaneously to two targets. All the applications based on 
antibodies acting as probes to modify the surface chemistry of nanoparticles require the 
production of selected and/or engineered antibodies. Antibody production is a challenge 
due to their sophisticated structure and large size. This challenge is addressed in this thesis 
by the development of a new recombinant antibody production system based on the 
eukaryotic organism Dictyostelium discoideum. So far, this system has allowed us to 
produce two forms of engineered antibodies. In addition, we have started to explore the 
benefits of using this system for the production of therapeutic antibodies. 
 
This thesis is divided into subparts; following is a brief description about the content of each 
subpart. 
 
Section 1.1 is a general introduction to antibodies and the development of antibody 
technology; their structure, function, and applications as binders and probes. 
 
Section 1.2 presents the combinatorial biotechnology technique of phage display and its 
application to select in vitro recombinant antibodies as binders of various biological and 
non-biological targets from random antibody libraries. 
 
Section 1.3 describes the engineering of antibodies to produce antibodies fused to other 
biological and chemical moieties, including other antibodies.  
 
Section 1.4 describes expression systems for the production of recombinant antibodies 
and their engineered forms. It also describes the new eukaryotic expression system that we 
have set up for this purpose (Dictyostelium discoideum). 
 
Section 1.5 illustrates the biomimetic approach for inorganic nanomaterials fabrication and 
functionalisation, with a focus on using protein-based binders for inorganics to generate 
new materials. 
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Section 2 covers our results. This section is divided into two parts. Section 2.1 describes 
the selection of recombinant antibodies binding inorganic materials using phage display and 
the possible use of antibodies as inorganic nanoparticle ligands. Section 2.2 is about our 
setting up of the expression and production of recombinant antibodies and their engineered 
derivatives in Dictyostelium discoideum. 
 
Section 3 covers the discussion which is divided into two parts: section 3.1- the successful 
selection of recombinant antibodies against gold, its potential applications in understanding 
interactions of proteins with inorganics and potential applications in biomimetic-inspired 
nanosciences and Section 3.2- the potential of Dictyostelium as a production system for 
recombinant antibodies and engineered constructs based on antibodies for therapeutical 
and nanoscience applications. 
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The process of scientific discovery is, in effect, a continual flight from wonder 
- Albert Einstein 
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1. Introduction 
 
The immune system response inside the body relies on antibodies that bind specifically to 
foreign molecules. This recognition has been exploited for many applications. In this thesis, 
we have applied it in our biomimetic approach to select inorganics-binding antibodies that 
could be used to fabricate novel materials with inorganic nano components. 
 
1.1 An Introduction to antibodies 
 
Antibodies are proteins produced by the immune system. They are secreted inside the body 
in response to harmful substances known as antigens. The production of antibodies is a 
major function of the humoral immune system and is carried out by plasma cells (a type 
of white blood cells). Antibodies have the remarkable ability to bind to antigens. Binding 
triggers signals that induce targeted immune response. Antibodies show a strong binding 
specificity towards antigens, often compared with a lock and key model. Antibodies are 
categorised under the superfamily of immunoglobulins, source- Kuby immunology, part ll, 
(Kindt, Goldsby, & Osborne, 2006). 
 
The aim of this thesis is to exploit the properties of antibodies and use them as versatile, 
specific binders of inorganic material targets for applications in nano-material science. 
 
1.1.1 Structure 
 
IgG antibodies are large molecules with molecular weight of approximately 150 kDa. They 
are composed of two different kinds of polypeptide chains. The classic structure of an IgG 
consists of two identical light chains (25 kDa) and two identical heavy chains (50 kDa) 
covalently linked by a disulphide bridge between the two heavy chains and between heavy 
and light chains.  
 
Based on structural difference in heavy chains, different kinds of antibodies exist that are 
grouped into isotypes. Five different antibody isotypes are known in mammals, which 
perform different roles in the immune system. These isotypes are named with an "Ig" prefix 
that stands for immunoglobulin, e.g. IgM, IgD, IgG IgA and IgE .Some of the isotypes are 
further divided into subclasses — for e.g., there are four IgG subclasses and two IgA 
subclasses. IgGs are the most relevant class of antibodies for pharmaceutical applications. 
 
Antibody molecules are roughly Y-shaped molecules (see figure 1.1a). The arms of the Y 
contain the sites that can bind antigens. This region of the antibody is called the Fab 
(fragment, antigen binding) region. It is composed of one constant and one variable domain 
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from each heavy and light chain of the antibody respectively. The variable domain is 
referred to as the Fv region and is the most important region for binding to antigens. More 
precisely, variable loops of β-strands, three each on the light (VL) and heavy (VH) chains are 
responsible for binding to the antigen. These loops are referred to as the complementarity 
determining regions (CDRs). The base of the Y shaped molecule is known as Fc (Fragment 
crystallisable or constant) region. This region is mostly constant in any antibody structure.  
source- Kuby immunology, part ll, (Kindt, Goldsby, & Osborne, 2006). 
 
 
 
Figure 1.1a: Modular structure of an IgG molecule. All immunoglobulin monomeric units are made 
up of two identical light (L) chains and two identical heavy (H) chains. Light chains include one 
constant domain (CL) and one variable domain (VL), whereas heavy chains include three constant 
domains (CH1, CH2 and CH3) and one variable domain (VH). The variable domains of both the heavy 
and light chains make the antigen-binding part of the molecule, termed as Fv. In the zoomed 
structure of Fv, three variable loops are depicted; these are called complementarity-determining 
regions (CDRs) 1, 2, and 3. Source- (Brekke & Sandlie, 2003) 
 
 
1.1.2 Function  
 
Antibodies recognize and bind foreign substances, such as bacteria or viruses, and alert 
other immune cells of body that can destroy them and flush them out of the body. 
 
Antibody molecules can perform two different functions that are carried out by different parts 
present in the antibody structure. First, antibodies have the unique ability to recognize and 
bind to substances that cause disease. This primary function is performed by antigen 
binding site of antibody (Fab). Binding of an antibody to an antigen has no direct biological 
effect. The significant biological effects are carried by secondary "effector functions" of 
antibodies that are carried by sequence in the Fc region of antibodies. The common effector 
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functions are complement-dependent cytotoxicity (CDC), phagocytosis and antibody-
dependent cellular cytotoxicity (ADCC) (Lucas & Oakland, 2001). 
 
1.1.3 Applications of antibodies as probes 
 
Antibodies can specifically bind to almost any target molecule. These target molecules do 
not necessarily need to be called antigens, it can be any molecule. Sometimes these 
targets are parts of proteins that are the important components of living cells or it can be 
non biological targets (such as inorganic materials in light of this thesis). Antibodies are, 
therefore, ideal sensors for detecting tiny amounts of a particular target molecule. 
 
Antibodies are used daily as tools or reagents by research laboratories and clinic. For 
clinical purposes, antibodies can be used as a diagnosis reagent or as a drug for 
therapeutics. Fluorescence microscopy is a routinely used scientific technique that uses 
antibodies to visualize particular protein in cells or even in whole tissues 
(immunohistochemistry). Antibodies are used in many routine laboratory works for many 
standard assays like ELISA, western blot, flow cytometry etc. All methods of research in 
biotechnology and medicine are based on an understanding of the fundamental biological 
processes and their inter connections. For instance, which structure in the cells of 
organisms carries out which function? How do these functional structures communicate with 
each other?  What are the consequences when they stop working? Antibodies are used in 
various laboratory techniques that address these questions. They are powerful tools in 
basic research because they recognize their antigens with outstanding specificity. This 
allows researchers to identify molecules and draw conclusions about the function of 
proteins of interest. Antibodies are also used in environmental analysis to provide evidence 
of contamination or the presence of harmful chemical substances (Killard, Smyth, Grennan, 
Micheli, & Palleschi, 2000). Last but not the least, we have tried to explore the applicability 
of this versatile molecule in nanomaterial fabrication and functionalisation. 
 
1.1.4 Development of antibody technologies 
 
Development of antibody technology is largely driven by the desire to use antibody as 
therapeutics. The mouse hybridoma technology described by Köhler and Milstein was an 
important step in the development of antibody technology and paved the way for the use of 
monoclonal antibody as therapeutics (Köhler & Milstein, 1975). However, antibodies derived 
from mouse are not suitable as therapeutic agent in humans. Strong immune response to 
non-human antibodies in humans had put end to this achievement in pharmaceutical 
sectors. Later developments in this field had again raised hope to use antibody as potential 
therapeutics. In an attempt to reduce the immunogenicity of mouse antibodies, genetic 
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engineering was used to generate chimeric antibodies. Further minimization of the mouse 
component of antibodies was achieved through CDR (complementarity determining region) 
and grafting (Bendig & Jones, 1996). Finally two major developments made antibodies 
completely independent from the animal immune system. These include development of 
selection by display technology and production of antibodies as recombinant proteins. The 
demonstration of displaying antibody fragments by phage and the functional expression of 
antibody fragments in bacterial periplasm are the pioneer experiments which provided 
strong platform for further development in the  selection of antibodies by display techniques 
(Skerra & Plückthun, 1988) (McCafferty, Griffiths, Winter, & Chiswell, 1990). This selection 
is performed in vitro using library which contain many antibody fragment variants of human 
origin. Now the selection of fully human variable domain has become extremely simplified 
by the use of display technique (see section 1.2 for detailed technique of phage display). 
The initial product of display screen may be a fragment of antibody “ScFv” (see next 
paragraph). Small fragment can be further engineered to get full antibody construct (see 
section 1.3 for antibody engineering). Further development in antibody technology lead to 
explore various expression systems to produce antibodies and its engineered derivatives 
(see section 1.4 for production of recombinant antibodies). 
 
1.1.5 Single chain fragment variable (ScFv) 
 
Fv fragment (shown in figure 1.1a) is one of the smallest units of immunoglobulin molecule 
that can mediate function of antigen binding. However, Fv fragment did not show stability 
under in vitro conditions. This fragment is not a very stable structure because the interaction 
energy between two variable regions present in this structure is low. Varieties of 
approaches have been taken to build a functional and stable complex of VH and VL. As a 
solution to this problem, new structure was generated by using a soluble and flexible 15-20 
amino acid peptide linker to connect the V regions in order to build “ScFv” fragment (Bird et 
al., 1988) (see figure 1.1b). The resulting scFv exhibits substantial antigen-binding activity 
compared to the monoclonal antibodies whose VH and VL sequences were used. Progress 
in phage display has opened the opportunity of in vitro selection of scFv from a large library 
of variable domains (McCafferty, Griffiths, Winter, & Chiswell, 1990). ScFv molecule can be 
easily expressed in functional form using E. coli (Skerra & Plückthun, 1988). The genetic 
sequence can be further engineered using this small fragment as building units. Small 
dimensions, elevated stability and capability to recognise antigens that are difficult to 
access by conventional antibodies make this fragment an interesting tool for several 
research and biotechnological applications (de Marco, 2011). 
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Figure 1.1b: Antibody model showing different domains along the polypeptide chains. Single-chain 
fragment variable (scFv) antibody is shown in shaded area.(CDR- complemetarity determining 
region, FW- framework)  Source (Ahmad et al., 2012) 
 
 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phage display is the presentation of (poly) peptides on the surface of 
bacteriophage (bacterial virus).  The gene encoding the protein product will be 
found inside the virus particle while the function encoded in the gene (such as 
the binding properties of an antibody) will be displayed on the surface of the 
virus. Year 2012 marks the 27th anniversary of the invention of this powerful 
technique. It has allowed rapid, specific, controlled in vitro selection of 
proteins/peptides as binders for various targets. 
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1.2 An introduction to display techniques 
 
Display technique is a family of molecular biology techniques that allow for the in vitro 
selection of protein/peptide binders from random protein/peptide libraries for many kinds of 
targets. The concept of display technology is based on physical linkage between the 
genotype and the phenotype. A protein with the desired binding ability is selected; 
simultaneously the genetic sequence corresponding to this protein is co-selected. This 
concept was successfully applied to small peptides by G P Smith by using phage as display 
system (Smith, 1985). Display of functional folded protein required several methodological 
improvements, which were initially done by groups at the MRC laboratory of molecular 
biology with Winter and McCafferty and the Scripps Research Institute with Lerner and 
Barbas for display of functional proteins such as antibodies. Later display method also 
extended to various forms such as ribosome display, mRNA display, cell surface display on 
bacteria and yeast. In this thesis we have used phage display of antibodies for screening 
against inorganic targets. 
 
1.2.1 Antibody phage display technique 
 
Antibody phage display technique empowers display of many antibody molecules on 
surface of small bacterial virus (bacteriophage). Collection of these displayed molecules is 
known as library. Initially phage display of antibodies was demonstrated by using small 
fragment of antibody molecules (scFv). ScFv fragment was displayed as a fusion protein on 
the surface of bacteriophage (see figure 1.2a) (McCafferty et al., 1990). Now this 
technology has been adapted for other antibody molecules including Fab fragment 
(Wieland, Orzáez, Lammers, Parmentier, & Schots, 2006),  diabody (Takemura et al., 
2000).  
 
Library of phages displaying different antibodies can be used to rapidly identify antibodies 
that bind with high specificity and affinity to any desirable target molecule. This is possible 
because of presence of random antigen binding region.  
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Figure 1.2a: Diagram of filamentous phage displaying scFv molecules. The phage consist of circular 
ss DNA surrounded by coat protein. p8 is major coat protein and p3 (on tip of the phage) is one of 
the minor coat proteins. The genes encoding variable domains of scFv are fused to gene3 (g3) in the 
genome of the filamentous phage, as a result scFv is displayed as a fusion to p3 protein at the tip of 
the phage. Source - (Azzazy & Highsmith, 2002) 
 
 
1.2.2 The link between genotype and phenotype: bacteriophage 
 
The display concept is based on the link between the phenotype and the genotype and this 
link is provided by the bacteriophages or simply phages. The link is created by a foreign 
protein in frame with the coat protein gene of the phages. The filamentous phages are most 
widely used for phage display systems, among them M13 is most commonly used. The M13 
phages can infect a variety of gram-negative bacteria using their pilus as receptors (Carmen 
& Jermutus, 2002). The filamentous phages do not produce lytic infection in E. coli. After 
infection, they replicate inside E. coli and make them phage production factory. The 
bacteria, which are infected, do not lyse, but undergo reduced growth due to stress of 
phage production.  
 
The phages are cylindrical shaped particles, which are approximately 7 nm wide and 900 to 
2000 nm in length. The M13 phage has 6.4-kb genome, which contains circular, single-
stranded DNA. The phage genome codes for 11 phage proteins. Five of these proteins are 
coat proteins. The major coat protein (p8) is present in approximately 2,700 copies and 
protects the genome in a cylindrical manner. The minor coat proteins p7 and p9 are 
necessary for efficient particle assembly, while other minor coat proteins p3 and p6 are 
necessary for particle stability and infectivity. The p3 protein mediates the binding of the 
phage to the F pilus and is necessary for viral uncoating and phage DNA transfer to the 
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cytoplasm of the bacterium. Host enzymes then convert the ssDNA into supercoiled dsDNA, 
known as the replicative form (RF) (source- chapter 1, phage display of peptide and protein, 
Winter, McCafferty et al.). The RF is essential to the phage display system because it can 
be purified and manipulated just like a plasmid. Through the manipulation of the RF of M13, 
some of the earliest cloning vectors were created. (Messing, 1991) (See next paragraph for 
phage display cloning vector). 
 
The minor coat protein 3 (p3) and the major coat protein 8 (p8) are the most common 
proteins used for fusions. The Phage display system that uses the p3 and the p8 proteins 
has different advantages. Use of p8 protein as the fusion protein enables high copy display 
of the recombinant protein because there are over 2,700 copies of the p8 protein on the 
surface of the phages. However, the p8 protein can only display small size peptides. When 
p8 protein displays large size particles, the function of the coat protein becomes 
compromised and the number of infectious particles gets decreased (larger size peptide 
fusion become possible by use of phagemid vector, described in next paragraph). The p3 
protein is present in 5 copies at the tip of bacteriophage. A recombinant fusion of larger 
peptide is possible using the p3 protein. Potential disadvantage is possibility of less 
infection due to sterical hindrance by displayed peptides. This can be better described as 
polyvalent display and this problem was solved by use of the phagemid vectors. (Source- 
book chapter 1, Introduction to phage biology, and phage display, Marjorie Russel et al.) 
 
1.2.3 Phage display cloning vector:  phagemids 
 
Phagemids are cloning vector created by combining best features of plasmids and phages. 
They are designed to have origin of replication for both M13 phages and E. coli. The 
important difference between phage based vector and phagemid vector is phagemids code 
for only fusion gene protein and not for other phage proteins. This feature was gained in the 
phagemid vectors by fusion of displayed protein gene under control of weak promoter which 
led to monovalent display of fusion proteins. However, monovalency is possible only for p3 
fusion, p8 fusion still remains polyvalent. The valency of display can be an important factor 
as monovalency lead to selection of strong binders. 
 
The phagemids vector alone can not generate complete phage particles because they do 
not code for other structural proteins. The other structural and functional proteins necessary 
to accomplish life cycle of phagemid are provided by the helper phages (e.g. M13KO7 or 
VCSM13) as co infection to E. coli cells harbouring phagemids. The helper phages have 
slightly defected origin of replication that causes less effective replication than phagemids. 
This process is termed as “phage rescue”. In addition, other elements such as molecular 
tags and selective markers are introduced into the phagemids to facilitate the subsequent 
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operations, such as gene manipulation and protein purification. (Source- book chapter 1, 
Introduction to phage biology, and phage display, Marjorie Russel et al.) 
 
 
Figure 1.2b: General scheme for phage display using phage and phagemid vectors. The 
difference in both vectors is illustrated by using p3 fusion protein as an example. The 
sequences of display proteins are introduced in the vector between the signal peptide and the 
gene3. Both vector carry Ff origin of replication, which allow them to replicate as M13 phages. 
The phagemid vectors also carry origin of replication in E. coli (pBR322 in this figure) and an 
antibiotic selection marker, which allows them to replicate as plasmids in E. coli. In the 
phagemid vectors an amber stop codon (TAG) is introduced between the display protein gene 
and the gene3, which facilitates soluble protein expression by transforming phagemids in a 
non-supE suppressor strains. Source- book chapter 1, Introduction to phage biology, and 
phage display, Marjorie Russel et al. 
 
 
The phages and the phagemids are the most common vectors used in phage display 
systems, while the phagemids are more widely used than the phages due to the following 
reasons. The smaller genome of the phagemids in comparison to the phages might facilitate 
efficient transformation. The phagemid vectors have wider choices of restriction sites. The 
phagemids are generally genetically more stable than the recombinant phages (Qi, Lu, Qiu, 
Petrenko, & Liu, 2012). The phagemids are more desirable if the monovalent display is 
preferred (in case of p3). The polyvalent display of larger peptides can be achieved by using 
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the phagemid p8 display system.  The expression level of fusion proteins can be controlled 
easily in the phagemid vectors. 
 
1.2.4 Antibody display libraries 
 
It is possible to create a large library in which the proteins displayed on each phage are 
slightly different from each other; the process is called as library construction. Total number 
of different phage/phagemid particles displaying unique antibody fragments in the library 
defines the size of the library, which is a critical parameter for the success of the antibody 
phage technology. The larger size of a library increases chances of finding antibodies that 
bind to any given target with higher affinities. The second parameter that defines library 
performance is the number and location of variable positions. As in the immune system, the 
antibodies have a common framework, while diversity is present in the CDR loops that 
determine the specificity of binding. CDR3 loops represents the antibody region in which 
diversity is mainly concentrated in naturally occurring antibodies. Therefore, also for 
synthetic libraries, the amino-acid diversity is generally localized in the CDR3 residues 
(Griffiths et al., 1994). The other important parameters for library construction are: antibody 
gene should be well expressed, design of library should allow easy engineering of 
antibodies and finally overall handling of library should be easy (Kretzschmar & Von Rüden, 
2002). 
 
There are different ways to create diversity while building an antibody phage display 
libraries. On the basis of the strategy followed to obtain diversities, it can be classified in 
“Immune repertoires” (antigen-biased), and “Singlepot” libraries (antigen-unbiased). Both 
kinds of libraries are explained in the following paragraph. 
 
Immune antibody phage display libraries 
 
This type of libraries takes advantage of diversity created in vivo by the immune system. 
The source of variable immunoglobulin gene in this case is the B cells from immunised 
animal or immune patient (for human origin B cell) (Clackson, Hoogenboom, Griffiths, & 
Winter, 1991). This library needs custom preparation for each antigen, which slims its scope 
for universal use. Another limitation with this library is the requirement of an anitigen to be 
immunogenic to provoke immune response. This feature makes use of such library less 
convenient for targets like inorganic materials used during this thesis, for which the immune 
responses are not yet fully known. 
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Single-pot libraries 
 
The single-pot libraries contain virtually all possible binding specificities and are not biased 
for a particular antigen (Pini & Bracci, 2000).  This type of library is suited for our application 
to find binders for various inorganic materials. 
 
The single-pot libraries can be classified as naïve or synthetic. In the naïve library, variable 
genes are isolated from unimmunized animals or human donors and are assembled to 
create large diversity of antibodies. It is theoretically possible to select antibody against any 
target (antigen) by using this library. The major disadvantage is the requirement of very 
large library size to isolate high affinity binders as a consequence library has many 
unknown and uncontrolled contents.  In the next step of artificial affinity maturation, these 
unknown contents need to be sequenced and that require preparation of customised 
primers.  
 
In the synthetic library, diversity is entirely created outside the natural host. To construct a 
synthetic antibody library, germ line variable region is isolated from source and amplified; 
subsequently CDR region is randomised, and assembled (Griffiths et al., 1994). The source 
of germ line gene could be any organism. To mimick natural antibodies, generally VH CDR3 
region is chosen to insert maximum diversities. In the synthetic library, contents are well 
defined: antibody structure, knowledge of the antibody regions that are randomized and 
those that are kept constant. This library is not biased against self antigens. Main 
disadvantage of this library is that it needs to be highly diverse to obtain high affinity binders 
and while increasing the diversity of library, the chances of accumulating nonviable 
antibodies sequences also increase (Carmen & Jermutus, 2002), (Pini & Bracci, 2000).We 
have used Tomlinson (I+J) library for screening of inorganic materials. The Tomlinson 
library is single pot, synthetic library comprised of approximately 1 x 108 random phagemids 
derived from non-immunized human donors (see appendix A for details). 
 
1.2.5 In vitro selection of binders in controlled conditions 
 
The phage display of antibodies provides selection of the binders against desired target 
under in vitro controlled conditions. Selection process can be divided into five main steps: 1) 
preparation of antigen/target 2) blocking 3) incubation of phage with antigen 4) washing to 
remove nonspecific phage and 5) elution. We can have great control during each step of 
selection, which are described in the following paragraph. 
 
During the in vitro incubation step of the library with the target, physical (e.g. temperature), 
chemical (e.g. buffer composition, salt concentration, pH) and other parameters such as the 
 24 
time of incubation (typically 1h) and the amount of target can be controlled to select 
antibodies which are able to bind the antigen under these defined conditions. Any molecule 
that remains stable in aqueous buffer for 1h can be used as a target. All these features 
make this technique applicable beyond biological targets. By playing with these selection 
conditions, it is possible to isolate binders (antibodies) with controlled affinity (nanomolar 
concentrations of the target will select for subnanomolar affinity), pH-dependence (selection 
at low pH and elution at high pH will select for pH-sensitive binders) etc. 
 
1) There are many possibilities to prepare antigen/ target for screening: antigen/ target can 
be directly mixed (like in figure 1.2c (box2), for e.g. polycrystalline inorganic material is 
directly mixed with library of phages), or can be immobilized by direct adsorption to a plastic 
surface or can be used in solution (by using biotinylated antigen). 
 
2) Blocking is done to avoid nonspecific binding which are mostly hydrophobic interactions 
with target entity. Generally, the target and the incubation device are immerged in buffer 
containing milk, BSA (Bovine Serum Albumin) or casein. 
 
3) The mixture of library and target can be shaken or agitated for improving chances for 
phages to bind to the target. Phages which show affinity for target through displayed scFvs 
remain bound and those which do not show any affinity, either remain in solution or may 
bind non specifically (as shown in figure 1.2c (box 2). 
 
4) Washing step can remove non-specific and unbound phages (see figure 1.2c (box 3). 
Washing is done by quick rinsing using appropriate buffer containing mild detergent. 
Washing step can also be performed under controlled condition by increasing or decreasing 
stringency of washes (usually by using different concentration of mild detergent or by 
increasing or decreasing number of washes or combination of both). 
 
5) Elution is done to isolate target specific clones (see figure 1.2c (box 4).There is enough 
choices for elution conditions - one can chose pH dependent reagents (triethylamine, 
glycine/HCl), or enzymatic reagents (trypsin, chymotrypsin) or competitive elution with 
soluble antigen. After elution phages are infected to E. coli to amplify population of target 
specific clone, (see figure 1.2c (box 5). Subsequently, the phagemid bearing E. coli are 
infected with a helper-phage to produce new phage particles that can be used for further 
selection rounds until a significant enrichment of the target specific clones is achieved. 
 
At the end of screen (typically 10th day), bacterial colonies can be randomly picked (these 
colonies appear as result of infection of phages from last round of selection). Each 
bacterium is capable of secreting scFv, which should be ideally specifically bind to target. 
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ScFv can be purified using bacterial strain (see appendix B). Genetic sequence of scFv can 
be obtained (by plasmid DNA purification) and analysed using various bioinformatics tools.  
Additionally target specific clones can be modified by using various methods of affinity 
maturation.  
 
                                              
 
Figure 1.2c: Different steps of phage display technique and selection of scFv specific for target. 
screening box1-phage library, box2- incubation with target, box3 – washing step, box4- elution step, 
box5- infection and amplification in bacteria, box 6,7,8 – further choices after obtaining target specific 
scFv. 
 
 
                                                      
 
 
 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With advanced genetic engineering it is possible to remove or add any key 
protein domain or any other entity in order to create engineered antibodies. 
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1.3 Antibody engineering 
 
The modular structure of antibodies allows a wide array of domain rearrangements by 
performing antibody engineering. The antibody engineering can provide more value to 
applications in nanoscience based on antibody fragments as inorganics binders. 
Engineering of this molecule allows us to modify an original antibody fragment (scFv) 
selected by phage display for controlled valency, geometry and many other functionalities 
(refer section 1.1.5 for structural details of scFv molecule).  
 
Engineered antibody constructs are not only useful for applications in nanoscience but also 
in providing effective pharmacokinetic properties to therapeutic antibodies. Some of the 
engineered constructs have already been taken to the clinic to serve the purpose as better 
therapeutics (Jain, Kamal, & Batra, 2007). 
 
* There are many ways to engineer antibody molecules, the examples given here are more 
based on the work done during this thesis. 
 
1.3.1 Engineering IgGs into small fragments  
 
The large size of IgG can slim its scope for use as a small size binder for nanomaterials and 
as a therapeutic tool in few cases. Few limitations of using IgG are inefficiency to produce 
full size antibody, inefficiency to use IgG for display technique, increased circulation time in 
blood that affects its therapeutic applications and high background in imaging (Jain, Kamal, 
& Batra, 2007).These limitations have encouraged development of small antibody 
fragments. Initial attempts to make smaller fragments were based on digestion of intact 
IgGs by proteolytic enzymes (pepsin or papain).  
 
With the advancement in various displays system and recombinant DNA technology, it is 
very easy to generate small antibody fragments. One of the smallest fragments of antibody 
that can recognise antigen was identified as “Fv” fragment. Due to instability of this unit it 
was engineered to more stable structure called scFv (explained earlier in section 1.1.5). 
Small size of scFv is a favourable characteristic for our aim to use scFv as small sized 
ligand for surface modification of nanoparticles. Due to small size, most scFvs have short 
serum half life (<10 min) compared to the intact IgG, which makes it useful for some 
diagnostic application such as imaging (Colcher, Batra et al.,2002). ScFv is a very 
interesting molecule for various research purposes.  
 
Another popular fragment is Fab, where VH and VL regions are held together by CH1 and CL 
domains as well as by inter chain disulphide bond. These four regions including the inter-
 28 
chain disulphide bond comprise of a Fab fragment. A Fab fragment is more stable than Fv 
or scFv fragment but this stability comes with relatively high molecular weight.  
    
                       
Figure 1.3a: Intact immunoglobulin molecules and its antigen binding fragments. Dark blue color 
fragment is VH domain, orange color is VL domain. In the structure of a Fab, VH and VL regions are 
held together by CH1 and CL domains as well as by inter chain disulphide bond. In the structure of an 
scFv, peptide linker of 15-20 amino acids is used to link VH and VL.. Source (Tikunova & Morozova, 
2009)  
 
       
1.3.2 Engineering the valency of antibody molecules 
 
The Fab and scFv fragments derived from phage display antibody library are monovalent, 
whereas in many in vitro and in vivo conditions, multivalency of Antibody molecule is 
preferred. 
 
ScFv expression vector is designed in such a way that the cDNA, which encode for VH and 
VL chain of an antibody are assembled by a sequence that codes for a peptide linker. The 
most common linker has 15-20 amino acid residues. Holliger et al have demonstrated that if 
the peptide linker length is reduced to 5 amino acid, VH and VL of scFv are not able to bind 
to each other (Holliger, Prospero, & Winter, 1993). The small size of linker causes a 
displacement in the equilibrium and as a result, scFv dimer is formed (this structure is called 
diabody, shown in figure 1.3b). The dissociation rate of diabody is lower than its parental 
scFv. Diabodies are rigid structures and can be expressed in bacteria. Further reduction in 
linker length to just one residue results in tetrabody formation.  scFv tends to form a tribody 
in absence of a linker (Le Gall, Kipriyanov, Moldenhauer, & Little, 1999). Another approach 
to create multivalency in antibody fragment is the fusion of CH3 domain to a scFv or Fab 
fragment and the resulting molecule is called minibody.  
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Figure 1.3b:  Presentation of diabody, tribody and tetrabody with their molecular masses. Source- 
(Olafsen et al., 2010) 
 
 
To develop artificial antibody with multiple valencies, in one report, scFv sequence is fused 
to core streptavidine (Kipriyanov et al., 1996). Resulting fusion protein was termed as 
scFv::streptavidine. Streptavidine is a stable tetrameric protein and it has high affinity for 
biotin. This fusion protein was expressed in periplasmic inclusion body of E. coli. After 
purification, tetrameric complex scFv::streptavidine demonstrated binding with both antigen 
and biotin. This complex was found stable over wide range of pH and at high temperature. 
However, expression level of streptavidine fused protein was observed to be low. 
 
In designing strategies for multimerisation of antibody fragments, several issues need to be 
addressed like stability, resistance to proteolytic cleavage during in vivo assembly, efficient 
production of preferably soluble protein, easy gene engineering steps, efficient expression 
level, sufficient activity and specificity maintenance, thermal stability etc. Among these 
issues related to multimerisation of antibody fragments, we have attempted to address the 
issues of easy gene engineering steps by our antibody engineering platform and efficient 
expression level by using a new expression system (explained in section 1.4). 
 
1.3.3 Bispecific antibodies 
 
Naturally occurring antibodies are directed against a single antigen: they are monospecific. 
Advances in antibody engineering have made it possible to combine the specificities of two 
antibodies into a single molecule - this combined molecule is known as a bispecific 
antibody. Bispecific antibodies do not occur in nature, it is a man-made construct. Initially, 
bispecific antibody was designed for therapeutic purposes. The initial use of bispecific 
antibody was based on the design in which one arm is specific for the tumor cell surface 
antigen and the other arm recognizes and activates the signalling receptor on the effector 
cells (Dafne M,RE Kontermann,2010). The combination results in using patient’s own 
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immune effector cells to target tumor cells which ultimately resulted in the killing of the 
tumor cells.  
 
                                                
 
Figure 1.3c: Concept of BiTE constructs, Two scFvs having different specificity (one for tumor cell, 
other for T cell activation) joined together by a linker. This construct can use patient’s own killer cell 
to eliminate tumor cell. Source - Wikipedia 
 
  
 
This particular subset of bispecific antibody, which engages T cell receptor is also known as 
BiTE construct (Bi-specific T-cell engagers). Concept of BiTE is shown in figure 1.3d. These 
engineered bispecific molecules also caught the attention of material scientists for building 
bio-inspired or biomimetic material (explained in details in section 1.5). 
 
There are some technical hindrances related to the construction and production of bispecific 
antibodies in terms of quantity and quality. Earliest bispecific antibodies were made by 
fusion of two hybridomas producing antibodies of two desired specificities. This construct 
had issues related to yield and purity because pairing between heavy and light chains was a 
random event with this technique. Over the years, many advanced construction and 
production techniques of bispecific antibody have come up. One of the recent techniques 
consist of using scFv from phage display selection and engineering them to make bispecific 
antibody. This engineering can be done by joining VH or VL of one scFv with VH or VL of 
another antibody by flexible linker. In this thesis we have attempted to make such bispecific 
antibody construct, using flexible linker. One bispecific antibody having therapeutical 
importance has already entered into the market and many others are in the clinical phase 
(www.f-star.com). Recently, Macrogenics and Boehringer Ingelheim have inked a deal of 
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$2.2 billion for development of a bispecific antibody. Another important collaboration is 
between f-star and the German pharmaceutical worth $1.7 billion (Moran, 2011).  
 
1.3.4 Fusion with other molecules  
 
Antibody fragments can be fused with other proteins or protein fragments. This fusion gives 
additional properties to the antibody fragments. Antibody fragments can be fused with other 
agents (e.g. radioisotopes) by chemical conjugation. Most widely engineered products in 
this category belongs to immunotoxins (scFv specific to tumor and toxin capable of killing 
target cells) (Kreitman, 2006). 
 
There is also one report on the production of biotinylated antibody fragments by utilising the 
activity of E. coli biotin ligase BirA (Saviranta, Haavisto, Rappu, Karp, & Lövgren, 1998). 
The 13-residue sequence, recognised by enzyme BirA, was fused with antibody fragment 
and later purified fragment was incubated with enzyme that allowed addition of biotin to the 
sequence. This method of biotinylation is advantageous over chemical modification as the 
resulting biotinylated molecule is homogeneous, fully active and can be tetramerised by 
interaction with streptavidine. 
 
Conjugation of antibody with GFP can be used as an important tool to study cellular 
mechanism. One such example is intracellular expression of GFP + scFV construct that 
allows study of dynamics of endogenous target protein within living cells (Nizak et al., 
2003). Traditionally, GFP fusion is done by in vitro chemical conjugation of organic 
fluorophores. This procedure requires large quantity of purified protein and optimization for 
level of conjugation. But fusion of GFP with antibody fragments and ability to produce 
functional protein has lead to the use of GFP fused antibodies for a wide range of 
biotechnological applications. Functional production of GFP fused protein is questionable 
because GFP is a cytoplasmic protein. Attempt has been made to produce it functionally in 
our new expression system. 
 
1.3.5 Back to IgG like structure 
 
For some applications described above, scFv or other small fragments are the desired 
format but monovalent binding and lack of Fc mediated effecter function of the scFv make it 
less viable for therapeutic purpose. There is a possibility to fuse scFv (selected by antibody 
phage library) to Fc region (shown in figure 1.3b). This construct has potency similar to a full 
length antibody. This fusion might improve the stability of the antibody. It may lead to the 
increase in the serum half-life of the antibody (increased half-life is important for in vivo 
antigen neutralisation). It may also add effector mediated functions to a molecule by ADCC 
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and CDC (Powers et al., 2001). One such example of re-engineering back to IgG like 
structure for therapeutic antibody is adalimumab (Humira), an FDA approved TNFα 
antibody. This antibody was selected using human Fab library and later engineered into 
IgG1 (Teillaud, 2005). 
 
 
Figure 1.3d: ScFv (selected by phage display technique) is fused with Fc to construct scFv+Fc.  
 
 
Another example is fusion of a multispecies (rabbit, mouse, human) Fc with scFv selected 
by phage display (Moutel et al., 2009). This work presented many multiplexing options and 
gave additional value to scFv by making antibody free from its species-specificity reaction. 
These multispecies Fc fusion scFvs were also tested for their applicability as a tool for 
western blotting and immunofluroscence. In future, scFv+ Fc conjugation can be used as a 
multifunctional and more stable probe for inorganic targets. 
 
1.3.6 Antibody class switch  
 
Immunoglobulin class switching (or isotype switch) is a biological mechanism that changes 
B cell's production of antibody from one class to another, for example, IgM to IgG. During 
this process, the constant region of the antibody heavy chain is replaced with different 
chains, but the variable region of the heavy chain remains same. Since the variable region 
does not change, class switching does not affect specificity on the antibody. It retains the 
same affinity for a given antigen but this different molecule can mediate different effector 
functions. From the five main immunoglobulin classes (IgG, IgD, IgA, IgE and IgM), IgG1 
has been mostly used for engineering therapeutic antibodies. More recently, IgG2 and IgG4 
have been used for better effector functions. IgG1 shows the most predominant effector 
function because of its unique Fc portion. Fc portion of IgG1 can be fused to therapeutic 
antibodies to enhance effector-mediated functions of immunoglobulins (Filpula, 2007). So 
far, such isoform switching seems to benefit only therapeutic antibodies; it may have null 
effect on improving probes for inorganic molecules. 
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The production of recombinant antibodies and their engineered forms is 
performed in both prokaryotic and eukaryotic expression systems, each 
having its own pros and cons. In this section, we have compared three 
common expression systems and have introduced a new eukaryotic 
expression system, Dictyostelium discoideum. 
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1.4 Production of recombinant antibodies  
 
The practical realisation of all the possible applications (nanoscience and therapeutics) 
based on antibodies and their engineered derivates may not be possible in absence of 
production of recombinant antibodies in their active form. The production of antibodies in 
large amounts is a challenge because of the sophisticated structure of immunoglobulin (see 
figure 1.1a) and the large size of engineered constructs. The production of antibodies using 
recombinant DNA technology was a great achievement to fulfil these demands. The 
recombinant DNA technology has also opened doors for using various expression systems 
for the production of recombinant antibodies. Three of the currently used expression 
systems along with a new system developed during this thesis for the production of 
recombinant antibodies and their engineered constructs are described in this section. 
 
It could be interesting to learn about the current economic status of recombinant antibodies 
as this is one of the key motivations to develop new expression system for production of 
antibodies. Recombinant antibody production is a big market and monoclonal antibodies 
(mAbs) are the best selling class of biologics, Sales of mAbs constitute ~36% of the total 
biologics market (Aggarwal, 2011). The major pharmaceutical industries which were 
focusing only on traditional monoclonal antibody (mAb) therapies until now are looking for 
the next generation of therapeutics—conjugates, fragments or other derivatives such as 
bispecific antibody (Moran, 2011). 
 
1.4.1 Challenges faced by expression systems for production of recombinant 
antibodies 
 
Most of the expression systems could not provide the optimal conditions for the production 
of a full size IgG molecule. In general, the yield and the biological activity of any 
recombinant molecules depend on factors such as solubility, stability and size  
(Dingermann, 2008). 
 
Size limitations can be overcome by the use of scFv (antibody fragment). Small antibody 
fragments can be produced even in bacteria in high amounts (Dübel, Breitling, 
Klewinghaus, & Little, 1992). However, production of large size constructs is often suffered 
from insufficient yield in most of the expression systems. This can be one of the major 
limiting factors for the applicability of antibody engineering technology as engineering may 
achieved by increased size of antibodies.  Apart from size, every protein impose unique 
problems in its expression because of its unique amino acid composition (Verma, Boleti, & 
George, 1998). 
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In some therapeutic applications, only binding with antigen is not sufficient, further Fc 
mediated effector functions are required. In such conditions, scFv can be fused with Fc 
region. Fc region of an antibody molecule bear conserved N-linked glycosylation (Nezlin & 
Ghetie, 2004). Prokaryotic expression systems are not the most appropriate choice for the 
production of glycosylated proteins as they lack the machinery required for post 
translational modifications.  
 
The antibody based proteins have been produced in E. coli, yeast, filamentous fungi, insect 
cells, mammalian cells, transgenic plants and transgenic animals. Currently around 20% of 
biopharmaceutical proteins are produced in yeast, 30% in E. coli and 50% in higher 
eukaryotic cells, mainly mammalian cells (Ferrer-Miralles, Domingo-Espín, Corchero, 
Vázquez, & Villaverde, 2009). Despite the several advantages offered by microorganisms, a 
large number of therapeutic antibodies are produced in mammalian cells. Microbial cells are 
more convenient for production of recombinant antibodies in terms of handling (Graumann 
& Premstaller, 2006). Improved microbial production platform can benefit industrial 
production of recombinant antibodies. In this thesis, a eukaryotic expression system 
Dictyostelium discoideum (commonly known as slime mold) is described for the first time as 
a production system for recombinant antibodies. 
 
1.4.2 Expression systems for recombinant antibody production 
 
There are various expression systems that can be used for the production of whole 
antibodies and antibody fragments. The choice of system is partially dependent on intended 
use of antibodies. In this section, we are restricting ourselves to the production of antibody 
fragments and their large size engineered constructs along with the production of 
therapeutically important antibodies. Both requirements are benefitted if the yield of protein 
is better which, in turn, influences the cost of production. Below is the description of three 
commonly used expression systems on industrial scale along with a newly established 
eukaryotic system (Dictyostelium discoideum). 
 
1.4.2.1 E. coli  
 
E. coli is the most widely used organism for expression and production 
of recombinant proteins. It is a well-studied organism with adequate knowledge about its 
genetics and physiology. It offers several advantages for production of any recombinant 
protein (including antibody fragments). Some of these advantages are as follows: (a) it can 
grow very fast and reach high cell density (b) medium requirement is simple and 
inexpensive(c) it is suitable for large scale fermentation (d) recombinant protein produced 
by E. coli can be purified by simple and well established downstream processes.  
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Some major challenges for producing recombinant protein in E coli include - native disulfide 
bond formation, lack of post translational machinery and secretion of active proteins. Protein 
produced in E. coli often precipitates as insoluble aggregates in cytoplasm and form 
inclusion bodies that require tedious process of renaturation (Sahdev, Khattar, & Saini, 
2008). Lysis to recover the cytoplasmic proteins often results in the release of endotoxins 
that must be removed from the final product. Only heavily engineered cystein free mutant of 
scFvs were successfully produced in cytoplasm of E. coli that did not require refolding 
(Proba, Wörn, Honegger, & Plückthun, 1998). 
  
Major challenges that E. coli expression system can face in order to produce antibodies are: 
the secretory nature of the antibodies and the requirement of an oxidising environment for 
proper folding. In E. coli, periplasm is the only site that provides an oxidising environment 
that favors stable disulfide bond formation. There are many folding modulators present in 
the periplasm. However, such scheme works only for small fragments. The production of full 
length IgG in E. coli has been reported after fine adjustment of translation strength of IgG 
sequence and mutation in leader sequence to achieve optimal periplasmic transport 
(Simmons et al., 2002). There are many strategies for directing secretion of proteins into the 
periplasmic space. Some protein having periplasmic leader sequence may seep out protein 
in the extra cellular medium (Neumann-Haefelin, Schäfer, Müller, & Koch, 2000). 
 
The most serious disadvantage of using bacteria includes problems in post-translational 
modifications of proteins. It is widely believed that bacteria cannot glycosylate its protein but 
cellular processing of some oligosaccharides might take place in the periplasm. One such 
example of N linked glycosylation was recently reported in gram-negative bacteria 
Campylobacter jejuni(Weerapana & Imperiali, 2006). However, bacterial glycans are 
chemically very different from human ones. Proteins that do not undergo glycosylation in 
their native form like insulin or growth hormone  can still be produced in bacteria (Graumann 
& Premstaller, 2006). Antibody production in E. coli is also related to host toxicity, which 
result in low yield of antibody (Schirrmann et al., 2010). 
 
1.4.2.2 Yeast  
 
Yeast is an attractive system for production of recombinant proteins/antibodies. It is a 
eukaryotic organism and hence can provide glycosylation to eukaryotic proteins. However, 
the capacity to generate human glycosylation varies in different expression systems (see 
detailed explanation in the following section). There are many advantages that yeast offers 
for production of recombinant proteins/antibodies. For e.g. (a) Short generation time, which 
allows it to grow rapidly and reach high cell density (b) ease of genetic manipulation, (c) 
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simple medium requirement, (d) high compatibility with fermentation, (e) post translational 
modification, (f) low number of secreted proteins that helps higher recovery of secreted 
heterologus protein at significantly lower costs (g) many yeast strains have GRAS 
(Generally Recognized As Safe) status and they do not produce endotoxins. This can 
favour their approval for therapeutic use. 
 
Many strains of yeast have been used for the production of recombinant antibodies. 
Particularly, Saccharomyces cerevisiae and Pichia pastoris have been studied for 
recombinant antibody production. The first expression of a scFv fragment in P. pastoris was 
demonstrated by Ridder et al (Ridder, Schmitz, Legay, & Gram, 1995) and later very high 
yield (upto 1.2 gm/L) of scFv was reported in P. pastoris under optimized fermentation 
conditions (Freyre et al., 2000). The yield of scFv+Fc fusion product has been reported to 
be 10-30mg/L using fermentor (Liu et al., 2003). Another scFv+Fc fusion protein product 
that was able to mediate antibody dependant cellular cytotoxicity against tumor cells was 
also produced in P. pastoris (Powers et al., 2001). Secretion of tetravalent scFv (15-20 
mg/L) has also been reported in this strain  (Goel et al., 2000). 
 
Some reported disadvantages of yeast as an expression system are:  lower transformation 
frequencies than E. coli, failure to express AT-rich genes due to premature transcriptional 
termination, proteolysis of secreted proteins during high cell density fermentation and 
inappropriate glycosylation of human glycoproteins (Schirrmann, Al-halabi, Dübel, & Hust, 
2010). Even though yeasts are able to perform many post-translational modifications such 
as O-linked glycosylation, phosphorylation, acetylation and acylation, the main 
disadvantage of this expression system is related to its ability to perform N-linked 
glycosylation. The patterns of N linked glycosylation in yeast is different from higher 
eukaryotes (Ferrer-Miralles et al., 2009). Yeasts are reported to hyperglycosylate 
heterologous proteins even at positions not glycosylated in the native protein. They are also 
reported to add many mannose residues to glycoproteins. Hypermannosylation of the 
glycoprotein might affect pharmacokinetic properties of therapeutic antibodies (Sethuraman 
& Stadheim, 2006). However, P. pastoris mediates comparatively lesser hyperglycosylation 
than S. cerevisiae.  
 
The strain P. pastoris has been reported to exhibit N-linked carbohydrate structures similar 
to the mammalian high-mannose core unit Man5-6GlcNAc2. Recently, production of human 
IgG showing humanised N linked glycosylation in P. pastoris has been reported (Li et al., 
2006). Some yeast strains have been used for production of FDA-approved therapeutic 
proteins such as hormones (insulin, insulin analogues, non glycosylated human growth 
hormone, somatotropin, glucagon) and vaccines (hepatitis B virus surface antigen) (Ferrer-
Miralles et al., 2009). Several groups of researchers have investigated the possibility of 
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reprogramming glycosylation pathways in yeast by substituting yeast enzymes with the 
human ones. This strategy presents good opportunity for the production of complex 
glycoprotein in yeasts. 
 
1.4.2.3 Mammalian cells  
 
Most of the proteins for therapeutic use and all currently approved therapeutic antibodies 
are produced in a mammalian cell lines (Chadd & Chamow, 2001). The success and 
popularity of the mammalian production system is due to its favourable features such as 
advanced folding and ability to perform post translational modifications. These features lead 
to the production of antibodies that are structurally very close to those produced in the 
human body. Another advantage of this system is that the recombinant protein is secreted 
into the media in natural form which makes purification of proteins/antibodies easier.  
 
Major disadvantages of mammalian system are: (a) expression techniques in mammalian 
cells are time consuming and difficult to scale up, (b) large-scale antibody production 
requires stability of antibody gene that can only be achieved by chromosomal integration of 
antibody genes into the host cell genome, (c) clonal selection in the mammalian cell lines is 
time consuming (Schirrmann et al., 2010). (d) mammalian cells grow slowly, (e) They 
require complex medium including animal sera that are very expensive, they increase the 
overall cost of production,  (f) the yield of recombinant proteins are  also lower than other 
expression systems, (g) mammalian cell lines are under critical observation for viral 
contaminations (Taylor et al., 2001) and release of factors with oncogenic or pathogenic 
potential.  
 
For recombinant protein production, chinese hamster ovary cells (CHO) cells, mouse 
myeloma NSO cells, baby hamster kidney (BHK) cells and a few other cell lines have 
gained regulatory approval. It should, however, be noted that oligosaccharide processing is 
species and cell type dependent among mammalian cells. Differences in glycosylation 
pattern are reported in rodent cell lines and human cell lines. Glycosylation is cell system 
dependent activity and this activity changes during differentiation, development and under 
different physiological and cell culture conditions. So secreted protein may not always be 
homogenous (Brooks, 2004). It may contain modified protein with different glycans and 
pharmaco-kinetic properties. 
. 
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1.4.2.4 Dictyostelium discoideum 
 
Dictyostelium discoideum (Dd) is recommended as a model organism by the National 
Institute of Health as part of its model organism initiative. The genome of this organism is of 
34Mb, which contains many genes, homologous to higher eukaryotes. Genomic complexity 
of Dd is greater than yeast but simpler than plant or animals (Eichinger et al., 2005). Main 
areas of studies for Dd are functional analysis of gene, cytokinesis, cell motility, 
phagocytosis, chemotaxis, signal transduction and cell differentiation during development 
(Annesley & Fisher, 2009). In this thesis we have tried to study a new prospect for this 
organism- as a production system for secreted recombinant antibodies. The advantages of 
using this organism as an expression system are as follows.  
 
Short life cycle 
 
Life cycle is divided into two phases- vegetative growth phase and developmental phase. 
Growth phase is accomplished during favourable growth condition (presence of food) 
(dictybase.org). During its life cycle, the organism produces spores that can be used to start 
fresh culture leading to high cell density in a few days. The generation time in liquid culture 
is approximately 10 hours, suggesting much faster growth rate compared to the mammalian 
cells. During our experiment of recombinant protein production, we have only utilised growth 
phase of Dd. 
 
The main advantage of Dd as an expression system is its relatively simple growth condition 
in contrast to other tissue cultures (mammalian or insect cells). Dd can be cultured 
axenically in growth medium. It can be easily grown upto a volume of 1 L in a shaking flask 
with control on gene expression. Growth mediums for Dd are simple and inexpensive. Dd 
can also be grown in synthetically defined medium (e.g. FM, SIH etc). These media do 
not require any protein of animal origin (commonly used axenic media HL5 contain yeast 
extract). So far, Dd is not known to have adventitious agents like viruses (discussion in 
Francodicty meeting, 2012). 
 
Long-term storage 
  
Dd cell lines do not required to be maintained for long time as cell lines can be stored in 
liquid nitrogen. Alternate option is storing spores. Dd cells produce spores that are highly 
resistant to desiccation, oxidising agent, and solvents. These properties of spores can be 
utilised for storing inocula. Spores do not loose their viability on silica gel for years and fresh 
culture can be started from spores (dictybase.com). 
 
 40 
Informatics and Genetics 
 
Information regarding all aspects of Dd is available on the internet. Dictybase provides news 
of research development in this field. Information on vectors, promoter, gene sequences, 
codon usage table and mutants are also available on dictybase. Dd is an extensively 
studied model organism. Because of its attractive biology this organism has been studied 
for various purposes that have resulted in the availability of powerful molecular techniques. 
These techniques provide a strong platform to explore Dd as an expression system. Most 
importantly, the genome of Dd is now known to us (Eichinger et al., 2005). 
 
Most of the strains of Dd are grown at 220c. Dd cannot grow above 280c. Therefore, the 
organism itself might be non-pathogenic to humans (MB Slade, KR Emslia, KL 
Williams,1997). 
 
Transformation can be done by electroporation. Selection of mutants takes less time than 
CHO cells as transformant cells start to be seen after 4 days of electroporation in Dd, 
whereas, in CHO cell, transformants can be seen after 2 weeks. 
 
Economic 
 
For recombinant protein expression at larger scale, the cost of production plays an 
important role. A expression system should be able to produce good amounts of protein in a 
cost effective manner. Dd has advantages over some other eukaryotic expression systems. 
As mentioned above, culture condition and medium requirement are simple. The medium is 
not expensive unlike mammalian culture medium. Dd culture does not need any animal-
based additional expensive serum for growth. Dd can secrete recombinant protein/antibody 
in the culture medium. This can make downstream processing easy and less expensive. A 
group of researchers have systematically compared protein yield from Dd and mammalian 
cells using 100 ml culture and have observed 20 to 60 fold increase in  yield in Dd (R. Arya, 
Aslam, Gupta, et al., 2008). 
 
Codon usage 
  
For efficient protein production the codon bias should be taken into consideration. The 
codon bias refers to the observation that all organisms do not use all the codons for one 
amino acid at the same frequency. AT content of Dd is 77.57%(Eichinger et al., 2005). Dd 
promoters are even 90% AT rich. In contrast, AT content of human is less than Dd (60%), 
which results in a different codon usage. The optimization of expression of human proteins 
in Dd would therefore, a priori, require codon usage adaptation. This is now easily done by 
 41 
gene synthesis. It is possible to order a synthetic DNA sequence with the desired codon 
usage bias encoding any protein of interest. 
 
Presence of extra chromosomal plasmid 
 
Plasmids are traditionally associated with bacteria. Plasmids in bacteria are important tools 
specially for production of recombinant protein production. The presence of extra 
chromosomal circular plasmid is relatively rare for eukaryotic organisms. The availability of 
extra chromosomal plasmid in Dd raises the hope to produce therapeutic protein in good 
amounts. Many different extra chromosomal plasmids have been described in Dictyostelium 
species; they all differ in size (1.3-27kb) and copy number (50-300 copies per cell) (Farrar & 
Williams, 1988). Ddp1 and Ddp2 based plasmids have been used to construct recombinant 
vectors. Studies have suggested that Ddp1 and Ddp2 plasmids have nuclear origin. 
Experiments have confirmed their location in nucleosomes (Ashktorab & Welker, 1988). 
Extra chromosomal vectors have high transformation efficiency and can circumvent the 
need for clonal selection. However, extrachromosomal vectors based on Dictyostelium 
plasmid Ddp1 are often big, therefore more difficult to clone, whereas those based on Ddp2 
are small but required to be co-transfected with a second vector in order to maintain 
extrachromosomal replication. These plasmids serve as excellent starting points for the 
construction of recombinant expression vectors.  
 
Post translational modification 
 
Eukaryotic proteins bear post translational modifications, specially glycosylation. Dd being a 
eukaryotic organism possesses the machinery to perform glycosylation. For therapeutic 
purposes, it is desirable to get human-like glycosylation pattern in proteins. There is no 
clear view about glycosylation pattern in Dd (see details in section1.4.6). So far, Dd is not 
found to hyperglycosylate proteins like yeast cells do. 
 
1.4.3 Tool box to regulate recombinant antibody expression level in Dd by secretion 
 
There could be many possible uses of recombinant antibodies expressed in Dd. One is for 
functional studies, which do not require high amount of proteins. Another is therapeutic 
purpose, which requires high level of correctly folded protein. Production of engineered 
antibodies is also required in high amounts. All these aspects can be fulfilled by the use of 
an appropriate Dd expression vector. Dd expression vector and its expression cassette 
(promoter, translational start site, signal peptide, multiple cloning site, affinity purification tag 
and termination signal) are described in genetic toolbox. Other parameters such as culture 
conditions are described in miscellaneous toolbox. 
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1.4.3.1 Genetic toolbox 
 
The presence of extra chromosomal plasmid in Dd allows the expression of recombinant 
proteins in Dd. One can choose low to high copy number vectors. Low copy number vectors 
are suitable for functional studies whereas high copy number plasmids are preferred for 
high level production of proteins. Ddp1 and Ddp2 based plasmids are characterised for 
recombinant protein expression (Manstein DJ, Schuster HP et. Al ,1995). Gene expression 
in Dd has been studied under natural conditions but increased expression level of 
recombinant proteins requires more regulation over gene expression. A better expression 
cassette in vector can introduce such regulation. Promoters can be chosen for best possible 
activity during axenic growth. Most of promoters available in the Dd are induced during 
different growth phase of its life cycle (MB Slade, KR Emslia, KL Williams,1997).  
 
During axenic growth condition, the actin 15 promoter is observed to be active during the 
entire growth. Strength of actin15 promoter is suggested by poly (dT) sequence containing 
45 dT residues adjacent to TATA box (Hori and Firtel,1994). Then next level is start codon. 
The start codon ATG in Dd is generally preceeded by several A residues. This sequence 
performs the same function as mammalian kozak sequence (GCCRCCATGG). Difference 
between mammalian kozak sequence and Dd sequence is the absence of several “A” 
residues in mammalian Kozak sequence. Absence of initial A residue in the sequences of 
mammalian genes may not provide an optimal environment in Dd for translation initiation, 
therefore, mammalian genes expressed in Dd can be modified to Dd kozak like sequence 
(AAAAATG). There is one study which has reported increased level (~1.5-fold) of 
expression of hCG in Dd due to Dd kozak like sequence adaptation (Vervoort et al., 2000). 
For secreted protein, it is necessary to introduce signal peptide at the N terminus. 
Introduction or replacement of start codon and secretion signal peptide can also remove 
rare codon from the beginning of the gene and might partially optimise codon in Dd for 
secretion of human protein. Multiple cloning sites give wide options to insert foreign genes 
at different restriction sites. Histidine tag or any other tag (e.g. MBP, TAP) can be used for 
affinity purification. There are suggestions regarding the importance of transcription 
termination signal for increased level of expressions (Dingermann et al,1989). In one report 
where stop codon UAG was replaced with Dd stop codon UAA for expression of malarial 
parasite protein (CSP), increased level of expression of desired protein was observed 
(Fasel et al., 1992). 
 
1.4.3.2 Miscellaneous toolbox 
 
Culture conditions can greatly influence the final yield of recombinant protein. If Dd cells are 
grown axenically then the medium composition can become an important factor for the 
 43 
growth of cells. Initial condition and concentration of inocula also influence proper growth. 
Apart from these, temperature, culture condition (shaking flask vs adhering cells), 
incubation time and selection marker can play determining roles for expression level. 
 
1.4.4 Overview of glycosylation and its importance 
 
Although glycosylation was not a focus of this thesis initially, it became a part of central 
theme when we started to develop a new eukaryotic expression system for the production 
of antibodies and their engineered forms. Apart from our aim to use engineered antibodies 
in materials science, the most important application of antibodies is in the therapeutics 
industry. As described in the details below, post translational modifications (PTMs) and in 
particular, the glycosylation profile of antibodies is of crucial importance for the latter 
application. The potential impact on the industrial terms of such results justified our focus on 
this secondary topic. 
 
Proteins can be modified pre-translationally, co-translationally or post-translationally. All 
protein modifications are generally referred to as PTMs because a majority of them occur 
post-translationally i.e. after the protein is folded. Proteins can display many types of post 
translational modifications (PTM). Currently only one subset of PTM is mainly characterised 
for therapeutic proteins. This subset is glycosylation as it is one of the common and least 
well-understood PTM of proteins.  
 
Glycosylation is an enzymatic process that attaches glycan (carbohydrate) to proteins. This 
process is a co-ordinated activity of enzymes present in the endoplasmic reticulum and 
golgi apparatus. Glycosylation types are classified according to the identity of the atom of 
the amino acid which binds the carbohydrate chain, i.e. C-linked, N-linked or O-linked (see 
appendix H for detailed description of glycosylation). Glycosylation is cell system dependent 
activity and this activity changes during differentiation, development and under different 
physiological and cell culture conditions (Brooks, 2004). The cells of non human species do 
not glycosylate their protein in the same way as human cells do  (Demain & Vaishnav, 
2009). 
 
Glycosylation is the most common and the most complex PTM associated with therapeutic 
proteins. This PTM can have several potential effects on proteins. It is estimated that up to 
50% of all native human proteins are glycosylated and between 1 to 2% of the human 
genome encodes proteins that contribute to glycosylation (Walsh & Jefferis, 2006). The 
glycosylation pattern can influence many significant properties of proteins that are described 
below: 
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a) Glycosylation can help in correct protein folding ,b)  it can participate in targeting protein 
to its final destination, c)  the glycan part can play a direct role in triggering the immune 
response – for example the carbohydrate moiety present at Fc portion of antibody helps in 
triggering immune effector cells, which ultimately leads to compliment activation d) sugar 
side chains can also stabilize glycoprotein in multiple ways like enhancing its solubility, 
shielding hydrophobic patches on its surface and protecting from proteolysis. e) It can also 
regulate protein half-life f) some glycoforms can be immunogenic to human. (Walsh & 
Jefferis, 2006) 
 
Most of the FDA approved biopharmaceuticals (specially antibodies) are glycoproteins 
(Jenkins, 2007). Glycosylation can add considerable heterogeneity in glcoproteins. In order 
to decrease heterogeneity in glycoforms owing to its significance in protein function (as 
explained above), most therapeutic glycoproteins are produced in eukaryotic organisms, 
specially in mammalian cell lines (CHO, BHK etc). Biochemical differences between the 
therapeutic proteins and their natural homologues are often considered as technical or 
biological limitations. Such variations may not necessarily affect the therapeutic value. (See 
discussion, section 3.2 for details). So the therapeutic potential and value should not be 
determined by the resemblance between therapeutic proteins and naturally occurring 
human proteins. 
 
1.4.5 Glycosylation profile of antibodies 
 
Antibody molecules (IgG class), have two Fab regions and one Fc region. The Fc region is 
a homodimer which contains hinge regions, CH2 and CH3 domains. The CH2 region has 
conserved N linked glycosylated regions. It is glycosylated through covalent attachment of 
oligosaccharide at Asn297 (Nezlin & Ghetie, 2004). The oligosaccharide is important to the 
Fc structure and is essential for the generation of Fc mediated effector function. This 
glycosylation is highly heterogeneous. Recombinant Monoclonal antibodies produced in 
currently used  cell systems (CHO, NSO etc) typically contain up to 30 different types of 
glycans at Fc N-glycosylation sites (Fernandes, 2005). The Fc glycosylation can 
significantly modify Fc effector functions such as Fc receptor binding and complement 
activation. It has been demonstrated that the success of several antibody therapeutics in 
oncology depends on their ability to mediate ADCC (Jefferis, 2005). Many studies have 
demonstrated that the ability to mediate ADCC can vary greatly between different antibody 
glycoforms. 
 
In addition to Fc glycosylation, some human IgG molecules may bear N-linked 
oligosaccharides within the Fab region. Sometimes both VH and VL chains may bear 
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oligosaccharides(Jefferis, 2005). For example, Cetuximab (Erbitux) contains an N-glycan at 
Asn 88 of the VH region. Such glycosylation can greatly influence antigen-binding affinity.  
 
Because of the diversity in Fc glycosylation and Fab glycosylation many glycoforms may 
exist. Variations in culture condition or different expression system can greatly influence the 
heterogeneity of IgG oligosachride. This variation can also affect the biological activity of a 
therapeutic antibody. 
 
1.4.6 Glycosylation in Dd 
 
Dd is able to produce both N and O linked glycosylation. But it may produce modified 
glycosylated structures. In this section, the existence of different glycosylation patterns in 
Dd has been explained. 
 
There is no evidence of hypermannosylation (either N or O linked) in Dd. This is in contrast 
with yeast cells that tend to add many mannose residues to their glycoforms. 
 
In an attempt to produce human insulin-like growth factor binding protein 6 (hIGFBP6 in 
Dd), protein size was observed to be larger than the predicted protein size from peptide on 
SDS gel. However, this size was smaller than the same protein produced in CHO cell. The 
difference in size not only indicates that the protein was glycosylated, but also that there 
were differences in the glycosylation structure compared to those found in mammalian 
cells(Asgari et al., 2001). Similar observation was found while producing human 
erythropoietin (EPO) (Vats & Padh, 2007). Human gonadotropin hCG and human 
antithrombin III, secreted in Dd showed lower biological activity than the protein produced in 
CHO cells. This could be due to small differences in the glycosylation patterns  
(T Dingermann, Troidl, Bröker, & Nerke, 1991) (Heikoop et al., 1998). 
 
It has been reported that Dd does not have the ability to add galactose, N-acetyle 
galactosamine or sialic acid,that has been observed in mammalian N linked glycosylation. 
But the basic structure of N-linked glycosylation in Dd is predominantly Man9GlcNAc2, 
similar to the mammalian high mannose structure (Sharkey & Kornfeld, 1991) This result 
was published before detailed analysis of Dd genome. Therefore, it is needed to be 
confirmed again. We have analyzed the Dd genome for the presence of glycosylation 
enzymes (see section 2.2). 
 
N linked glycosylation has been studied in many organisms but O linked glycosylation of 
secreted protein has been studied only in few organisms. O linked glycosylation is more 
varied throughout eukaryotic evolution than N linked glycosylation. The work of Jung et al is 
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among the few that has detailed the characterisation of O-linked glycosylation in 
mammalian proteins expressed in Dd. A group of researchers  has conducted in vivo 
studies on mucin MUC1 and MUC2 repeats and  has demonstrated  that  one class of O-
glycosylation  in Dd involves the addition of a single N-acetylglucosamine residue to Ser 
and Thr residues, on secreted or membrane-bound proteins, at an early stage of 
development (Jung, Gooley, Packer, Karuso, & Williams, 1998). The Dd glycosylation 
apparatus incorporates GlcNAc residues into peptide sequences similar to those reported 
for the addition of GalNAc residues in mammalian tissues. 
 
Most recent studies have been done on the production of human phosphodiesterase 
(PDEs) in Dd. PDE4B2 and PDE7A1 have been successfully expressed and purified in Dd 
(R. Arya, Gupta, et al., 2008)(R. Arya, Aslam, Gupta, et al., 2008). PDE4B2 expressed in 
Dd is very similar to the mammalian expressed hPDE4B2, specifically in its apparent 
molecular mass, predominant intracellular localization and interaction with substrate and 
various inhibitors.  
 
Glycosylation pattern of human antibody produced in Dd is not known yet. Our result 
will provide the first report on glycosylation of antibodies in Dd. 
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Table 1.4a: Comparison of expression systems for the production of recombinant antibodies 
 
Features E. coli yeast Dd mammalian 
Secretion yield 
per L of culture 
Up to 10 mg scFv, 
no or low  secretion 
of engineered scFv 
10-30mg/L using 
fermentor (Liu et 
al., 2003) 
1mg/L for 
scFv+Fc (our 
results) 
1mg/L for 
scFv+Fc (our 
results) 
Cost per L 
(medium + 
antibiotics) 
(LB + Ampicilllin) 
3$ 
(1L YPD + 
500mg G418) 
65$ 
(1L HL5 + 
10mg G418) 
15$ 
(1L DMEM + 
10% FBS + 
400 mg  G418) 
130$ 
Time from 
transformation 
to 1L 
production 
3 days 6 days 15-20 days 45 days 
Glycosylation 
 
 
Few reports of 
glycosylation in 
periplasm of gram 
negative 
bacteria.(Szymanski 
et al., 2003) 
Hyper-
mannosylation 
Both N and O 
linked 
glycosylation 
present, exact 
pattern is to be 
discovered 
(one of the 
goals of this 
thesis) 
Human-like 
 
* Cost of production is estimated from current price list at SIGMA, ForMediumTM and Gibco®. 
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Small world 
 
When we get to the very, very small world – say circuits of seven atoms – we 
have a lot of new things that would happen that represent completely new 
opportunities for design. Atoms on a small scale behave like nothing on a large 
scale, for they satisfy the laws of quantum mechanics. So, as we go down and 
fiddle around with the atoms down there, we are working with different laws, 
and we can expect to do different things. We can manufacture in different 
ways. We can use, not just circuits, but some system involving the quantized 
energy levels, or the interactions of quantized spins, etc.  - Richard Feynman 
(1959 talk at annual meeting of American Physical Society) 
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1.5 Selection of biological binder (scFvs) for inorganic materials 
 
The main goal of this thesis is to select recombinant antibodies (scFvs) against inorganic 
materials by using random antibody library displaying antibodies on phage surface. Such 
antibodies could enable new applications in inorganic nanoparticles by optimising their 
surface chemistry. We begin this section with the general introduction to nanoscience, 
description of inorganic nano materials used during this thesis and their scope in 
nanoscience applications, current strategies to modify surface chemistry of these materials 
and their limitations, our strategy to use protein based ligand (antibody fragment) as an 
alternate strategy to modify surface of inorganic materials and further examples of potential 
applications of using protein based ligand.  
 
1.5.1 Introduction to nanoscience   
 
Nanotechnology has come of the age in the last few years, mostly because of advances in 
precise measurements and precise manufacturing methods at the nanometer scale. Any 
material that has at least one dimension less than 100 nm can be classified as nanomaterial. 
These nanomaterials exhibit different electrical, thermal and spectral properties as compared 
to their corresponding bulk material (Source -book “nanostructures and Nanomaterials” 
chapter-1,Guozhong Cao). The differences in these properties can be attributed to their small 
size. At the nanometer size, all particles have high surface area to volume ratios (refer table 
1.5a). Such nanostructures have dominated surface effect as at nanoscale size, the ratio of 
the number of surface atoms to the number of interior atoms increases.  
Nanosphere 
Diameter (nm) Surface area (nm
2) Volume (nm3) Ratio Surface Area:Volume 
10 314 523 0.60 
20 1260 4190 0.30 
30 2830 14100 0.20 
40 5030 33500 0.15 
50 7850 65500 0.12 
60 11300 113000 0.10 
70 15400 180000 0.09 
80 20100 268000 0.08 
90 25400 382000 0.07 
100 31400 523600 0.06 
Table 1.5a Particles of different size (10 - 100nm), and their corresponding surface area: volume ratio. 
Source- nanocomposix.com. 
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The high surface area to volume ratios of nanoparticles is attributed for interesting properties 
of nanomaterial. For example, unique optical properties of gold particles at nano size and 
fluorescent properties of quantum dots are due to the high ratio (explained in details in 
section 1.5.3).  
 
1.5.2 Historical background and birth of modern nanoscience 
 
Solutions of liquid gold were first mentioned by Egyptian and Chinese scholars around the 5th 
century BC. Ancient people used to believe in their metaphysical and healing powers. 
Colloidal gold was used during ancient Roman times for colouring glass of intense shades of 
yellow, red, or mauve (most likely resulting from different sizes of gold particles). A fine 
example is the famous Lycurgus cup in the British Museum, dated 4th century AD 
(www.britishmuseum.com). The cup exhibits different colours depending upon the direction 
of illumination. Michael Faraday did the first “scientific” study of metal nanoparticles in 1850. 
Faraday was the first to recognise that the red colour of gold colloid was due to the small size 
of the gold particles and red coloured solution of gold nanoparticles can be turned blue by 
adding salt to it (Faraday, 1857).  
 
Many other synthetic (physical and chemical) methods for production of colloidal metal 
particles were developed in the early 20th century including the fundamental work of 
Turkevitch in 1951 (Turkevich, Stevenson, & Hillier, 1951). Turkevitch used transmission 
electron microscopy (TEM) analysis to optimise the preparative conditions for various 
methods of synthesis for gold nanoparticles. The resulting method is known as Turkevitch 
method. 
 
Currently, nanoparticles can be made from a variety of materials such as metals, metal 
chalcogenides (zinc oxide, iron oxide, zinc sulfide, cadmium selenide etc.), silicate or silicon 
oxide. Modern nanoscience is in its third decade; its impact is increasing in the fields of life 
science, energy, environmental science, and electronics (Mazzola, 2003). The birth of 
modern nanoscience can be traced to the invention of the so called building blocks of 
nanoscience “Quantum dots (QDs)”. QDs were literally invented as they are a completely 
human construct. Colloidal QDs were prepared in the mid 1980s in Bell laboratory by Louis 
Brus and his two post docs Alivisatos and Mike Steigerwald. Later, Maungi Bawendi joined 
the team of Louis Brus and this team developed many key concepts of photophysics and 
material synthesis that ultimately led to the birth of building block of modern nanoscience 
(Alivisatos, 2008). The methods and approach developed by this team to grow colloidal QDs 
in flasks are widely adapted and they are now standard fabrication methods in laboratories. 
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The icon of modern nanoscience - a picture of vials containing colloidal QDs of different size, 
showing different colors when illuminated under UV lamp - has its origin from Bell's lab. 
 
Lycurgus cup, example of gold nanoparticle from 
4th century, it exhibits different colours depending 
on direction of illuminated light. 
Source - www.britishmuseum.com 
Icon of modern nanoscience, emission 
wavelength of QD can be tunes on the basis of 
particle size. Source - (Alivisatos, 2008) 
 
Figure 1.5a: Example of nanoparticle (4th centuries – modern age)                      
 
 
1.5.3 Example of inorganic nanomaterials  
 
There are many examples of inorganic nanoparticles. Here, in this thesis we have used gold 
nanoparticles and semiconductor QDs. Following is the explanation for why these nano 
particles are important. In particular, we address what are the unique properties of these 
materials at nanoscale and what could be their potential areas of application.   
 
1.5.3.1 Gold nanoparticles 
 
Gold has been considered as a precious metal for ages. In contrast to nanoscience which is 
a recent branch of science, gold nanoparticles have a rich and fascinating history. Ancient 
people exploited the optical property of gold particles thousand years ago without knowing 
science behind it (as mentioned in section 1.5.2). To the extension of the old proverb 
“everything that glitter is not gold” gold nanoparticles do not glitter but their future is bright 
and glittery.  
  
Gold nanoparticles exhibit unique optical properties due to surface plasmon resonance 
(SPR) and thus gold nanoparticles are often called as plasmonic nanoparticles.  SPR is a 
phenomenon of collective oscillation of conduction electron when a specific wavelength of 
light incident on surface of nanomaterial (see figure 1.5b). This phenomenon is more 
prominent in metal nanoparticles.  
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Figure 1.5b Presentation of surface plasmonc resonance (SPR), the free conduction 
electrons at the surface of gold nanoparticles are driven into oscillation due to strong coupling 
with incident light. Source- Wikipedia 
 
The optical properties of gold nanoparticles can be tuned by changing their size and shape.  
For example, the extinction spectrums of 15 sizes of gold nanoparticles are displayed in the 
figure 1.5c. The reason for this size dependent shift is that smaller nanoparticles absorb light 
and have peaks near 520 nm. The larger spheres exhibit red shifting i.e. the absorption 
peaks shift towards longer wavelengths (nanocomposix.com).  
 
The brightness and tunability of gold nanoparticle's optical properties make them desirable 
for numerous applications including molecular detection and solar energy materials. 
Furthermore, gold nanoparticles also exhibit high chemical stability as well as photo-stability. 
Unusual optical properties and the stability of gold nanoparticles make them robust materials 
for imaging and diagnostic applications. There are already few gold nanoparticles based 
diagnostic products commercially available – a pregnancy testing kit that has specific DNA 
sequence bound to gold nanoparticles (marketed by Church and Dwight), a kit for detection 
of food borne pathogens (currently being developed by Merck). Gold nanoparticles can also 
be used to enhance contrast and resolution in cellular samples examined under electron 
microscopes (Pissuwan, Cortie, & Valenzuela, 2007). The US based company Cytimmune is 
exploiting biocompatible properties of gold to deliver therapeutic drug directly to the 
cancerous tissue. 
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Figure 1.5c:  Extinction (the sum of scattering and adsorption) spectra of gold nanoparticles with 
diameters ranging from 10 to 100 nm. The mass concentration for all the particles is 0.02 mg/ml. 
Source- nanocomposix.com 
 
 
1.5.3.2 Semiconductor QDs 
 
Quantum dots are tiny particles, or “nanoparticles”, of a semiconductor material. Usually they 
are metal chalcogenides (selenides or sulfides) such as cadmium selenide or zinc sulfide 
(source - nanocotechnologies.com). Semiconductor QDs  exhibit size and shape-dependent 
fluorescent properties (Biju, Itoh, Anas, Sujith, & Ishikawa, 2008).  
 
The fluorescent properties of the quantum dots are a result of their size which in turn affects 
the band gap energy. Band gap refers to the energy differences between the top of the 
valence band and the bottom of the conduction band (figure 1.5d). This gap is equal to the 
energy required to free an outer shell electron from its orbit. Thus, when a QD has a high 
band gap, higher energy is required to move the electron from valence band to conduction 
band. And when the movement of electron from valence band to conduction band takes 
place, it is called as an electron hole pair creation (or exciton) that emits a photon. The 
distance between an electron and hole is known as an exciton bohr radius (source - 
Wikipedia). When the size of QD is of the same order of exciton bohr radius, continuous 
band gap energy turns into discrete energy levels (source-
physics.schooltool.nl/quantumoptics). Thus, the band gap becomes dependent on the size of 
the QD and in fact, as the size of QD decreases, the band gap increases leading to blue shift 
in optical illumination. Thus, we can control the fluorescent properties of QDs by controlling 
the size of particle which is best described in iconic figure of nanoscience (see figure 1.5a). 
This property can be used to make an array of QDs (same chemical composition) which 
shows different fundamental properties depending on the size of the individual crystal. 
  54 
 
 
Figure 1.5d: Band gap diagram for insulator, metal and semiconductor. In metals, conduction band 
valence band overlap. In semiconductors, conduction band and valence band are spaced. In 
insulators, conduction band and valence band are widely separated. Source – miniphysics.com 
 
 
QDs are gaining major attention for their unique optical properties, which clearly distinguish 
them from organic fluorophores. Organic fluorophores were conventionally used for tagging 
nucleotides and proteins for visual analysis. But these molecules have several limitations 
because of their poor photo stability, narrow excitation bandwidth, and cross talking in 
multiplexed experiments (Arya et al., 2005). Several efforts are being made to make ideal 
fluorophores that can have large extinction co-efficient, high photo stability, and pH inertness. 
QDs can probably meet all these demands as they are bright, have excellent resistance to 
photo bleaching and can be observed over long periods of time with standard fluorescence 
microscopy.  
 
1.5.4 Synthesis of nanomaterials 
 
Synthesis of nanostructures with fewer defects is the key for further advances in 
nanoscience, specially for manufacture of higher ordered assembled products which hold 
promise to revolutionise the nanotechnology industry. Major techniques for synthesis of 
nanoparticles can be classified as 1) vapour condensation 2) chemical synthesis 3) solid 
state synthesis (chapter-1, book “nanostructures and Nanomaterials”, Guozhong Cao). Apart 
from these, there are couple of recent reports of biological synthesis of nanoparticles 
(Krumov et al., 2009). There have been several advances in the synthesis of homogenous 
size and shape of nano objects. Please note that synthesis of nanoparticles is not studied 
during this thesis. 
 
Two distinct approaches have been used to manufacture nanomaterial objects — ‘top-down’ 
and ‘bottom-up’.  Both approaches play important roles in the modern science and industry of 
nanotechnology. There are advantages and disadvantages in both approaches. 
 
  55 
The top-down development of materials is accomplished by fabrication tools. This is the 
classical approach where the bulk material is refined by cutting or modified by other physical 
or chemical methods to provide new functions. Techniques of lithography, embossing and 
contact printing are used to create micron or nanometer scale materials. The biggest 
problem with top-down approaches is the imperfection of the resulting surface structure. It is 
well known that conventional top-down approaches such as lithography can cause some 
crystallographic defects. Such imperfections can have significant impact on physical 
properties and surface chemistry of the nanostructure. In addition to surface defects, this 
technique can also introduce internal stress and contamination to the end product. 
 
A bottom-up approach refers to the building-up of materials from the bottom: atom by atom, 
molecule by molecule or cluster by cluster. This approach is not new; many examples of this 
approach can be seen in nature. Bone structures are made up of several small elements. It is 
a very rigid structure that can absorb several shocks under the activities of daily life. Bottom 
up approaches promise a better chance to obtain nano-structures with less defects and more 
homogenous chemical composition. (Source - chapter-1, book “nanostructures and 
Nanomaterials”, Guozhong Cao). Complexities in making higher ordered structure using 
nanoparticles as building block arise from difficulty in controlling the shape, size, crystalline 
structure and functional integration of assembled structures (Hiroshi et al, 2010). 
 
Once the desired size of the nanoparticles is achieved, the focus shifts towards making the 
nanoparticles stable, functional and self-assemble into higher order structure. These 
characteristics of nanoparticles can be achieved by surface modification which is described 
in detail in the following section.    
 
1.5.5 Stabilisation, functionalisation and self-assembly of nanoparticles: By surface 
modifications 
 
In this section we have explained importance of stabilisation, functionalisation and self-
assembly of nanoparticles for making them suitable for their potential applications. The 
surface of nanoparticles play an important role for their solubility, reactivity and stability 
(Burda, Chen, Narayanan, & El-Sayed, 2005). 
 
Stabilisation 
 
During growth of the nanoparticles, stabilizing agents are added to prevent nanoparticle 
aggregating and precipitating, these agents are also called capping agents. When 
aggregates are formed, particles are assumed to loss their nanoscale-related properties. 
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Thus, surface modification of nanoparticles is an important field of study. Various capping 
agents  (organic and inorganic materials) have been used through covalent or ionic 
interactions on the surface of nanoparticles (Heights, 2000). These capping agents can 
stabilise nanoparticles in solution.  Apart from stabilisation these agent can also protect 
electrical and optical properties of bare nanoparticles, they also play a role as the connecting 
link of the nanoparticles to the outside world. For instance, in nanoparticle based drug 
delivery, capping agent can connect the nanoparticles to the therapeutic agents (Berry & 
Curtis, 2003).  
 
One well known example of stabilisation of nanoparticles is by use of citrate as a capping 
agent for gold nanoparticles. The citrate layer weakly associates with the nanoparticle's 
surface, and provide long term stability.  It is important to note that surface of most 
nanoparticles is strongly influenced by the local environment. Different conditions can affect 
the nanoparticles in different way. For example high salt environment can destabilise citrate 
layer on gold nanoparticles and can cause aggregation of these particles. 
 
Functionalisation 
 
Different applications of nanoparticles require further functionalisation of the surface. For 
example, application in bio imaging requires nanoparticles to be photostable, bio-compatible, 
small, specific, and water soluble. All these properties can be gained with some further 
surface modifications of nanoparticles. The surface chemistry of nanoparticles is modified in 
order to functionalise them and make them biocompatible for use as molecular probes in bio 
imaging. This kind of functionalisation can be achieved by completely or partially substitution 
of capping agent by another tighter binding ligand. Coming again to example of gold 
nanoparticles - the citrate layer can be easily displaced by a range of other molecules 
including thiols, amines, polymers, antibodies, and proteins. Gold nanoparticles used in 
biological applications are commonly coated with polyethylene glycol (PEG), bovine serum 
albumin (BSA), or numerous other proteins, peptides, and oligonucleotides (source- 
nanocomposix.com) . The surface chemistry of gold nanoparticles provides possibility of 
controlled attachment and detachment of organic molecules from the gold particles surface 
due to stable thiol-gold bonds (Pissuwan et al., 2007). Due to this ‘simple’ surface chemistry, 
opportunities for engineering controlled structure in gold nanoparticles have increased. 
Current chemotherapeutic and hypothermal therapeutic treatment regimes for tumour are 
also exploiting unique property of gold nanoparticles. There are reports of using paclitaxel 
(anti tumor drug) attached to functionalised gold nanoparticles (Gibson, Khanal, & Zubarev, 
2007) for targeting tumor. 
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Self-assembly 
 
Other promising method of incorporating nanoparticles into functional structures is through 
self-assembly. The self-assembly of nanoparticles can result into unusual functionality and 
many potential applications (Grzelczak, Vermant, Furst, & Liz-Marzán, 2010). 
Microelectronics processing techniques (e.g. lithography) are excellent for creating small 
features. Alternate method of obtaining self assembled structures could be use of a 
ligand/binder. Self-assembly by using biological ligand/binders seems to be a sound strategy 
for creating materials and devices cheaply, while keeping molecular recognition, and 
thermodynamic stability as the main consideration in the construction. Biological molecules 
can be used for controlled placement and assembly of various practically important materials 
(Hiroshi et al, 2010). This organic-inorganic hybrid structure will be able to fabricate complex, 
sophisticated electronic and medical devices. Inspiration for such kind of assembly can be 
taken by looking at examples existing in nature and mimicking them, such biological 
examples are explained in section 1.5.7. 
 
1.5.6 Current strategies for surface modifications of nanoparticles and their limitations 
 
During the past few years, there are many developments in studies related to the surface 
chemistry of nanomaterials owing to their wide spread utility. Several strategies have been 
applied for achieving water solubility of nanoparticles to make them compatible with 
biological environments. These strategies can essentially be divided in two main categories: 
encapsulation (scheme A in figure 1.5e) and ligand-exchange (scheme B in figure 1.5e) 
(Medintz, Uyeda, Goldman, & Mattoussi, 2005).  
 
When nanoparticles are chemically synthesized, they are coated with hydrophobic ligand. 
These ligands prevent nanoparticles from aggregation. For specialised applications, surface 
of nanoparticles need to be modified further. One such scheme is by encapsulation, it is 
done by  amphiphilic molecules such as block copolymer or phospholipid micelles, whose 
hydrophobic units selectively interact and interdigitate with the hydrophobic ligands present 
on surface of nanoparticles (Dubertret et al., 2002). Water solubility of the nanoparticles 
results from the presence of charged groups and/or polyethylene glycol (PEG). Apart from 
solubilisation, this additional layers very well protect the optical and electrical properties of 
the nanoparticle. However, main limitation of this scheme is that the resulting nanoparticles 
are much larger than the bare ones, specially PEGylation results in increased hydrodynamic 
radius. In spite of above mentioned limitations, PEG chemical surface treatment is still the 
main one in use, particularly for commercially available quantum dots. The mixture of 
PEGylated nanoparticles is very viscous, which makes injection into biological host difficult 
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(Targeting of these nanoparticles is often achieved through its conjugation with antibodies, 
and they are introduced into a biological host via injection. Reference - during discussion with 
researchers using PEG treated nanoparticles, at ESF summer school, 2011).  
 
 
Figure 1.5e: Scheme to make NP soluble, scheme A- encapsulation of nanoparticle, scheme B- 
ligand exchange. (purple colored rigid structure – nanoparticle, green colored surface – hydrophobic 
ligand bound to NP, in (scheme A) additional structure – encapsulating material, in (scheme B) 
additional structure – ligand exchange material) 
 
 
The ligand exchange method involves the replacement of the original hydrophobic surface 
ligands (capping agent) with bi and/or multifunctional hydrophilic ligands (Uyeda, Medintz, 
Jaiswal, Simon, & Mattoussi, 2005). These multifunctional hydrophilic ligands can be 
attached to inorganic nanoparticles surface by a linker group (typically a thio group). Another 
layer of hydrophilic ligand can be coated by polyethylene glycol or zwitter ions. Ligand 
exchange with several multifunctional groups such as di-thiol, multi-thiol and mixtures of 
thiols and amines have been performed during the past decade, because ligands with one 
functional group are not stable. Moreover, if the ligand is too strong, it may slowly erodes the 
nanoparticle, while a too weak ligand get detached from nanoparticle surface. Ligand 
exchange by multifunctional ligands seem to be a better solution for unfavourable surface of 
nanoparticle. However, later multifunctionality of nanoparticles depend on various conditions 
(salt/pH/temperature). It has left us with questions such as what is the best ligand, and how 
should it be designed for different nanoparticle surface chemistry? These questions do not 
have clear answer yet. Apart from the stability approach, the ligand exchange approach still 
necessitates functionalisation for targeting.  
 
1.5.7 Biomimetic approach to self assembly of nanoparticles 
 
Promising solution to many technological and manufacturing problems can be learned from 
biology, and can be applied to nonbiological materials. Such approaches are called 
biomimetic approaches. This kind of approach is particularly appreciated for designing self 
assembled structures (M Boncheva, GM Whiteside, 2004). Most of the macroscopic 
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biological materials are fabricated at the nano scale; this fabrication is mainly done in a 
hierarchical manner. Most of these structures show unique and specialised functions. If we 
analyse the mechanisms of formation of these unique objects, we would see that these 
structures are highly mineralised (the process through which an organic substance becomes 
impregnated by inorganic substances). The majority of them are made up of inorganic 
crystals and biomolecules. The interaction between inorganic crystals and biomolecules is 
very specific. This specificity has been developed during several years of evolution through 
many cycles of mutation and selection. It is important to note that such biological processing 
or fabrication is accomplished at ambient conditions - aqueous medium, neutral pH and 
ambient temperature (Gilbert, 2005). Below are some examples of materials found in nature - 
these materials are fabricated at the nanoscale via specific interactions between inorganic 
materials and biomolecules (see figure 1.5f). 
 
Figure 1.5f: Examples of biological materials fabricated at nanoscale (A) Magnetotactic 
bacteria, e.g., Aquaspirillum magnetotacticum, (B) Nacre, mother-of-pearl is (C) Mammalian 
tooth ,Source-(Tamerler et al., 2010) Details of this figure are described in the text follows.  
 
Nature provides an abundance of examples of materials which show excellent correlation 
between function and structure. A few examples are shown in figure 1.5b – (A) single celled 
organisms (Aquaspirillum magnetotacticum) that can sense earth’s magnetic field (0.5 Gauss) 
and orient itself accordingly.  This property is achieved through presence of special organells 
called magnetosome in the cytoplasm of this bacterium. When the bacteria ingest iron, 
proteins inside their bodies interact with it to produce tiny crystals of the mineral called as 
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magnetite (Fe3O4, the most magnetic mineral on earth). It is present as perfect cubo-
octahedral single crystal (50nm diameter). Particles are crystallographically and 
morphologically aligned with respect to each other to maximize magnetic field sensing. Figure 
B shows a classic biomimetic example: the mother-of pearl of seashells, the natural armor of 
mollusks. The interior portion of the shell is layered and segmented hybrid composite of 
aragonite (orthorhombic CaCO3) and biopolymer mixture, which provide toughness to the 
shells. Figure C is an example of mammalian tooth. It has several layers with enamel as the 
top most layer. It is the hardest and most highly mineralised material in the human body. It 
provides protection to the tooth. Hierarchical structure of the enamel is fabricated by many 
proteins that control the formation of ordered woven fibers of 3 micro meter-diameter enamel 
rods, each consisting of thousands of 30 nm-diameters, crystallographically-aligned elongated 
hydroxyapatite (crystalline calcium phosphate) crystallites. This unique architecture provides 
good resistance to stresses. 
 
 
Some of the properties of the natural designs in above examples are rarely seen in man-
made engineered systems. Mimicking of the biological process for nanoscale device 
formation is not very straightforward. For making higher ordered structure through self-
assembly, it is important to choose building blocks carefully and one must ensure that the 
resulting system is thermodynamically stable. Biomimetic growth of nanomaterials in 
aqueous solution is significant as the resulting assembled structures, when applied to 
therapeutic imaging specially in vivo, need to be dispersed in the body (Hiroshi et al, 2010). 
One fine example of biological building unit is antibodies. Antibodies are protein based 
molecules and known for its specific interaction with antigens. We can adapt this kind of 
specificity for selecting binder of inorganic materials. Our methodology to select such 
antibody based binder is explained in section 1.2. Proposed methodology allows us to 
mimick natural selection of antibodies under forced laboratory evolution conditions.  
 
1.5.8 Motivation for surface modification by biological ligands 
  
The limitations of currently used methodology for surface modification for nanoparticles 
(mentioned in 1.5.6) motivates to find alternative strategy. One such strategy is finding 
specific biological binder and further use them as ligand for nanopaticle’s surface 
modification.  
 
In the examples shown in figure 1.5f, the common binder present in all structures is proteins. 
Proteins are synthesisers, they can direct nucleation, growth, and assembly of a variety of 
biological tissues with precise control. In addition to their role in mineralization, proteins play 
various important roles in living organism: as enzymatic catalysts, as transport and storage 
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molecules, in immune protection and cell differentiation. Proteins participate in virtually every 
possible process within cells. Proteins, therefore, could be the key molecules in developing 
biomimetic approaches for inorganic material based fabrication. 
 
In this thesis, we are proposing to use protein-based binder for surface modification of 
inorganic nanomaterials. There are many ways to find proteins, which can bind to 
nanoparticles or any inorganic material: 1) computational methods of molecular level 
description for protein-surface interaction (Makrodimitris, Masica, Kim, & Gray, 2007), 2) 
extraction of biomineralising proteins from hard tissue: by isolation, purification and then 
cloning, 3) combinatorial technique to find protein that can show specificity to inorganic 
materials. In this approach, a large, random library of protein based binders with the same 
number of amino acids, but varying compositions, is screened to identify specific sequences 
that strongly bind to an inorganic material of practical interest, this approach is described in 
section 1.5.9. Apart from protein, there is possibility to use DNA based binder for same 
applications, explained in details in the following text. 
 
1.5.9 Selection of protein based binders (potential ligands) for nanoparticles  
 
In an attempt to mimick nature for selecting binder/ligand in laboratory environment, we 
propose use of display techniques, which can allow in vitro controlled selection of binders. 
The three most common approaches used for display techniques are: phage display, cell 
surface display (e.g. yeast surface), and ribosome display. All technologies are based on the 
common theme of linking phenotype and genotype. Attempts have been made to select 
peptides and proteins through combinatorial technique like cell surface display and phage 
display methods. Following is the brief description of the concept and few pioneer works 
accomplished in the area.   
 
1.5.9.1 Selection of peptides or antibodies using combinatorial techniques 
 
Selection of peptide/antibodies is done by phage display methods. Random 
peptide/antibodies are displayed on the surface of phages (see section 1.2 for detailed 
method).  Refer fig 1.5g for the pictorial presentation for selection of peptide/antibodies 
specific to inorganic materials. Gene3 and gene 8 in phage genome are mostly utilised for 
selection against inorganic materials. Depending on choice of insert gene position, 
peptide/antibodies can be displayed either on the tip (with gene 3) or on entire surface (with 
gene 8) of phages. Inserted gene sequence could be of small polypeptides or of any 
functional proteins (e.g. Antibodies).  
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Figure 1.5g: Display and selection of peptide/antibodies using phage display technique (a) M13 
Phage with all phage protein, phage coat protein p3 is modified to display fusion protein on the tip (b) 
Representation of M13 phage with nanoparticles (black spheres) nucleated onto p3 (dark blue) (c) 
Schematic of M13 phage used as a template for the construction of one-dimensional structures. In this 
case, a metal or semiconductor-binding peptide is displayed on coat protein p8 and it can be used to 
nucleate nanoparticles (red spheres). Source (Kriplani & Kay, 2005) 
 
By using display methods many peptides have been identified which can bind to metals, 
metal oxides, metal alloys, semiconductors, carbon materials. Pioneer work in identifying 
peptide against solid surface was done by Brown. First few targets against which peptides 
were generated were iron oxide and gold (Brown, 1997) (Brown, 1992). Later this work has 
been extensively extended by A.Belcher (MIT), and M. Sarikaya (U. Washigton). Work by 
these two groups resulted in catalogue of various materials including semiconductor QD 
binding peptides. List of peptides showing specificity to metal and semiconductors is 
mentioned in table 1.5b. 
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Table 1.5.b List of selected peptide binder against metals and semiconductors 
Source ,1- (Nam et al., 2006), 2 - (Kim et al., 2010), 3 - (Rajesh R Naik, Stringer, Agarwal, Jones, & 
Stone, 2002), 4 - (R  R Naik et al., 2004), (5, 6) - (Zuo, Ornek, & Wood, 2005), (7, 8) - (Chiu, Li, & 
Huang, 2010), 9 - (Flynn et al., 2003), 10 - (Whaley, English, Hu, Barbara, & Belcher, 2000),  
11 - (Flynn et al., 2003) 
 
Another example of protein-based binder is antibody fragment (scFv). ScFv is more 
sophisticated molecule than peptide. It can also serve as strong binder for inorganic 
materials. There are just two examples of selection of scFv against any material : one is 
against gold, selected by Kumagai group in Japan (Watanabe, Nakanishi, Umetsu, & 
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Kumagai, 2008), and other is against GaAs, selected by research group in Israel (Schnirman, 
Zahavi, Yeger, & Rosenfeld, 2006). In both reports selection is done by using phage display 
technique.   
 
Apart from peptide and antibodies, other scaffold of proteins like protein cages, are also 
gaining interest (Flenniken et al., 2009). Container like protein architectures such as viral 
capsids and ferritin are examples of such biological templates. But two biological entities 
(peptides and antibodies) selected by phage display are currently considered to add 
information about interface between biology and inorganic material. Comparison of peptide 
and antibody based binder for inorganic material is mentioned in following paragraph. 
 
1.5.9.2 Comparison of protein based ligands: peptides vs antibodies 
 
Both peptides and antibodies recognise the interfacial surface with high affinity and 
selectivity because of their multiple point interaction by hydrogen bond, salt bridges and 
other surface complementarities (Hattori et al., 2010). Many peptides that can bind to 
materials like metal, metal oxide, metal alloys, and semiconductors have been identified. 
This peptide can be useful tool for further bottom-up fabrication of novel nanomaterials, 
functionalisation of nanoparticle and synthesis of unique crystal structure.  
 
In comparison to peptide there are very few reports on the selection of antibodies for 
inorganic surfaces. Two groups who have published their result for antibodies against 
inorganic material using phage display are Kumagai lab from Japan (antibody against 
gold)(Watanabe et al., 2008) and research group from Israel (antibody against 
GaAs)(Schnirman et al., 2006). Interestingly an antibody raised against GaAs can 
differentiate between different crystalline facets in terms of binding affinity. These results 
demonstrate a very high specificity of antibody against inorganic solid surfaces. However, 
there are fewer antibodies than peptide against inorganic material. The reason for this 
discrepancy can be attributed to the factors: a) less sensitivity of human immune system to 
inorganic material, b) selection of antibodies against solid surface as target is more difficult 
than soluble antigen, c) less diversity of clones in case of antibody library, d) may be other 
groups are just focusing on use of peptide without considering antibodies as substitute. 
However, we think that antibodies are novel tool as material binder as it posses better affinity 
and specificity than peptide. 
 
Peptides against metallic gold were first time identified by Brown and each polypeptide had 
repetition of identical units (14 or 28 amino acid long). One gold binding polypeptide showed 
difference in binding depending on number of repeats present in sequence. Reduction in 
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repeating unit showed less binding with gold. We can assume that polymerization of 
monomer unit change the properties, it can attain rigid structure with certain conformation. 
Researchers of  Seker and Sarikaya groups also tried to observe difference in binding 
behaviour of single peptide, and its multiple repeats (selected by display technique for 
different materials) in order to check the hypothesis of improved binding with repeating units 
(Seker, Wilson, Sahin, & Tamerler, 2009).Their result suggested that use of multiple repeats 
of a given peptide sequence did not have a uniform effect in binding behaviour of all 
peptides, as in some cases it increased the binding affinity and in other cases the affinity was 
reduced. However, this result also suggests that protein in three dimensional conformations 
may acquire different binding ability.  
 
Repetition of binding peptides can be introduced in several ways (tandem, with linker etc). 
With correct knowledge of binding behaviour due to multiple contact points, one can fine-tune 
the binding behaviour of peptides or any other protein conformation. Other researchers have 
also studied a peptide sequence, which binds to platinum in two conformations (linear and 
constrained) and observed higher binding by constrained form. For us it will be interesting to 
compare binding capacity of peptide and antibody, though it will be difficult to comment 
based on current knowledge. Kumagai group in Japan has identified material binding 
antibody which shows higher affinity than peptides (Hattori et al., 2010). They grafted 
material binding peptide (ZnO) into appropriate loop of CDR of camel type single variable 
(VHH) antibody fragment. Then this structure is promoted for affinity maturation by 
combinatorial technique. Their result suggested higher binding ability of grafted peptide 
antibody than selected antibody and peptide. This study clearly provides hint of the potential 
of antibody scaffold for creating high affinity building block. Further assay described in this 
article, provide additional hints in favour of antibody as better probes: intact binding affinity 
shown by VHH during competitive assay between VHH and peptide, synergistic effect of CDR1 
and CDR3 of VHH fragment in binding with target. Based on above-mentioned results, we 
can assume that antibody is more sophisticated tool than peptide and it has better binding 
affinity than peptide.  
 
1.5.9.3 DNA based binder for inorganic materials 
 
Biology is no longer the only branch of science which is benefitted by technology based on 
DNA, Remarkable structural features of DNA are now fascinating material scientists who 
construct 2D or 3D nanoscale constructs. The dimensions of DNA are inherently on the 
nanoscale:  The diameter of the double helix is about 2 nm, and the helical pitch is about 3.5 
nm; hence, construction involving DNA is fundamentally an exercise in nanotechnology. 
Apart from nanometer scale other features which provide programmability of hybrid 
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structures are-1) complementarity of DNA (2) ability of complementary strands to hybridize 
(3) programmability of intermolecular affinity (4) structural predictability of both sticky-ended 
cohesion products (6) specially designed branching DNA motifs. There are already few 
report on different structures based on DNA templates- unscaffold structure, DNA origami, 
two dimensional structures, three dimensional structures etc. There is recent report on DNA 
origami based nanoscale structure which yield higher production of plasmonic 
structure(Kuzyk et al., 2012). DNA origami has recently been used as a self-assembling 
agent to direct the organization of nanoparticles with successful diagnosis applications. 
Single stranded DNA or RNA can also be selected in vitro by using combinatorial technique 
called SELEX ("Systematic Evolution of Ligands by Exponential Enrichment") (Stoltenburg, 
Reinemann, & Strehlitz, 2007). 
 
Nucleic acids are made of a phosphate-pentose backbone and the chemical diversity of 
nucleic acids is limited to purine and pyrimidine bases, while proteins have a very stable and 
neutral polyamide backbone and benefit from the entire amino-acid side chain diversity. 
Therefore, there is little chance that the DNA approach can be applied to the specific 
recognition of the inorganic interfaces. 
 
1.5.10 characterization of the clones selected by phage display  
 
Phage display and cell surface display techniques were adapted for selection of binder in 
material science. Further characterization of selected binders selected by display system is 
not very convenient. There are many methods to determine protein-protein, protein-
carbohydrate interactions, but these methods can not be directly applied to study protein 
binding on inorganic material. Similarly there are reports on the adsorption of proteins on 
solid surfaces (Gray, 2004). But most of solid binding experiments are bulk experiment. Most 
preferred methods are fluorescence microscopy, ELISA assay, Competition binding assay, 
Atomic force microscopy. However, these methods provide semi quantitative measurement 
for binding. More advance techniques include surface plasmon resonance (SPR) and quartz 
crystal microbalance (QCM), solid state NMR etc.  
 
Computational analysis of selected sequence with material is also possible with molecular 
dynamics studies(Oren, Tamerler, & Sarikaya, 2005), such studies could be good start point, 
but they are done in simple environment .  
 
There are several known peptides against different materials, but quantitative affinity, binding 
kinetics, molecular recognition of these peptides are not fully understood. Primary 
characterisation of displayed peptide is possible by fluorescence microscopy when they are 
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displayed on the cell surface. Very few investigation is been done to know binding property 
by quartz crystal microbalance (QCM) ,surface plasmon resonance spectroscopy (SPR),and 
fluorometric peptide assays (Tamerler, Oren, Duman, Venkatasubramanian, & Sarikaya, 
2006). Few reports showed possible mechanisms of molecular binding due to secondary 
structure change by NMR or mutational analysis, One interesting example is characterisation 
of titanium binding peptide (selected by phage display )(Sano & Shiba, 2003).They 
conducted alanine scan on selected sequence and measured affinity for each mutant phage 
with titanium surface. Mutational studies were done by changing position of amino acid. By 
changing charged side chain of few polar amino acids, they observed great variation in 
binding, and suggested for electrostatic binding of peptide to the target. Additional 
information is also provided by same group, which suggest amphoteric nature of Titanium, in 
biological environment surface of metallic Ti is covered by titanium oxide, which display 
many oxygen atom and get negatively charged. It was been observed that lysine (positively 
charged) as well as negatively charged amino acid aspartic acid gets accumulated at the 
surface of titanium oxide, which suggests amphoteric nature of oxide film . The same 
Titanium binding peptide was utilised recently, and revealed that peptide and target 
interaction is not primarily initiated by electrostatic attraction but by ability of amino acid to 
sense the molecular solvent structure at the solid/liquid interface with precision(Schneider & 
Ciacchi, 2012). Electrostatic attraction is described for other materials like gold, 
semiconductors (CdS, CdSe, ZnS, ZnSe) (Peelle, Krauland, Wittrup, & Belcher, 2005) , 
Aluminium, Silicon nitride, Silicon oxide (Willett, Baldwin, West, & Pfeiffer, 2005), 
Polystyrene(Kumada, Kuroki, Yasui, Ohse, & Kishimoto, 2010). However, this rule can not be 
generalised for all conditions. Primary or secondary structure of protein can also play role in 
binding, beautiful work is done by using different conformation of gold binding 
peptide(Hnilova et al., 2008).So there are many unanswered questions about how genetically 
selected peptides or antibodies bind to target material and not to other material. There are 
many possible ways to find answers to these questions: identification of amino acid showing 
specificity towards any given target, conformation of protein, correlation with experimental 
condition and selection of particular amino acid (pH of experiment, overall net charge on 
target during selection process etc). In studies where binding is shown on phage particle, 
overall charge of the virus should be taken into consideration as virus have pH-dependent 
surface charge in polar media (e.g. water) (Michen & Graule, 2010) .For practical applicability 
of these biological binders more knowledge of their material specificity is required. 
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1.5.11 Potential use of inorganic material-binding proteins 
 
Phage display method has allowed evolution of protein based binder/ligand in laboratory 
condition to create new generation of materials with new functionality. There are few 
remarkable example of use of protein-based binders for advance level functions. 
 
The future of nanoscale device fabrication can benefit diverse applications including 
electronics, tissue engineering, biomedical imaging, drug delivery, catalysis, and photonics. 
Specific binding and ability to self assemble are the core properties for nanomaterial based 
fabrications. Protein based binder can functionalise nano material or can provide template for 
assembly for fabrication on bio-inspired materials. Few examples are mentioned below which 
show potential utilization of engineered proteins. 
 
1) Use of phage display selected peptide in controlling size and functionality of 
nanoparticles  
 
A Pd-binding peptide was selected by phage display technique. Further minor modifications 
were made in the peptide sequence, and this modified peptide was able to  control the size 
and functionality of nanoparticles by modulating peptide/Pd surface binding capabilities 
(Coppage et al., 2012). This result suggests that peptides can be used as unique ligands for 
the controlled morphogenesis of nanoparticles.  
 
2)  Use of a bispecific antibody for the immobilization of a biomolecule on gold 
surfaces 
 
Bispecific antibodies are attractive molecules for therapeutic purposes. The design of this 
molecule has inspired researchers from the Kumagai group for nanomaterials purposes. 
They fused a gold-binding antibody with an antibody binding the enzyme lysozyme  
(Watanabe et al., 2011). In figure 1.5g the construct binds tightly both the gold surface and 
lysozyme. They observed that this bispecific construct could work as interface molecule 
between lysozyme and gold. They also observed that none of the ScFv lost any substantial 
antigen binding activity. This construct can be a promising candidate for biosensing 
molecules and building blocks for nanoscale fabrication. 
 
This group has selected recombinant antibodies to gold. This result was published (in 2008) 
when we had barely started our project and confirmed the feasibility of our approach. The 
bispecific format is very promising for applications in nanodevice design as interface/adapter 
between two nano-objects. We are interested in making this construct showing specificity to 
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two nano-objects. This group has obtained the construct by purifying after refolding from 
bacterial inclusion bodies. We describe the development of a new eukaryotic host for 
production of such antibodies with more efficacy than in current production host. 
 
 
 
Figure 1.5h: Schematic representation of an engineered bispecific antibody (BsAb) with a modular 
structure. C-terminal end of A14P-b2, and the N-terminal end of HyHEL10 scFv are shown in green. 
Complementarity-determining regions of antibodies are shown in red. Source - (Watanabe et al., 2011) 
 
 
3) A transistor based on an antibody, gold nano particles and a quantum dot  
 
One of the encouraging examples of nanodevice fabrication based on inorganic-binding 
antibodies is the following.  Y-shaped IgG antibody binding to gold was put to use to bind 
simultaneously two gold nano-electrodes through its two antigen-binding arms. The base of 
the Y-shaped IgG (the Fc portion, see section 1.1) is covalently linked to a QD. By 
illuminating the QD at the proper wavelength, the researchers from National Chiao Tung 
University observed a transistor-like behaviour of the IgG nano-structure, with the nano-
electrodes as drain and source and the QD as gate (Chen, Hong, & Huang, 2012). 
 
This study was however limited by the use of polyclonal IgGs purified from rabbit serum. 
Each device will be different from the others because many IgG molecules are present, 
questioning the reproducibility of such approach. Monoclonal antibody would offer a much 
better control over the molecular structure of the device, and recombinant ones would offer 
even greater control through genetic engineering. 
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2. Results 
 
2.1 selection of antibody fragments (scFvs) binding to inorganic materials 
(In collaboration with B. Dubetret at UMR 8213 CNRS/ESPCI Paristech) 
 
We screened a phage display antibody library against various inorganic material targets 
(nano to micro sized). All screenings were performed under controlled in vitro conditions. Our 
goal was to select antibody fragments (scFvs) that have high binding affinity and specificity 
against inorganic materials. The selected antibody fragments (scFvs), then, can be used as a 
ligand to modify unfavourable surface chemistry of inorganic nanomaterials (refer section 
1.5). In context of this thesis, we expect the use such modified nanoparticles for two potential 
applications - using nanoparticle as a probe for bioimaging and making self-assembled 
structures. Apart from this, genetic sequences of the selected antibody fragments (scFvs) 
can provide important information about protein/inorganic interaction. Such information can 
be utilised for further improvement of antibody fragment based ligands, as explained in 
section 1.5.11 by an example of phage display selected peptide sequence.  
 
We used various inorganic materials as targets (see list in appendix A). We selected specific 
antibody fragments (scFvs) against the targets using the Tomlinson I+J library (see appendix 
A for a description). We screened these targets by applying the strategy, mentioned in 
section 1.2.5. The phage display method is mostly used for biological targets; inorganic 
targets used in this study were unusual targets for this technique. Moreover, inorganic 
targets were obtained in different physical states (suspension, powder etc); therefore 
protocol was adapted according to the target materials (see appendix B for the customised 
protocols). We performed three rounds of selections for each target to enrich the population 
of target specific binders (antibodies specific towards the inorganic materials). The phage 
recovery yield increased in the expected manner from round 1 to round 3 for most of the 
targets, which is a good indication of an effective selection. For few targets, we did not 
observe the expected pattern of enrichment during three rounds of selection, so we did not 
continue further experiments in those cases.  
 
The targets which showed enrichment of specific binders were processed further. After the 
third round of selection, we infected E. coli with the selected phages (as standard protocol), 
and after infection, we randomly chose 94 bacterial colonies (infected with phage) which 
appeared on the agar plate with a selection marker. Each bacterial clone can secret scFv, 
which may vary from each - other. We performed ELISA (enzyme-linked immunosorbent 
assay) to check the binding of secreted scFv with the corresponding target. Based on the 
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ELISA result for each target, we obtained a set of scFvs that showed strong, weak and no 
binding with the target. We discriminated strong binders and weak binders as positive 
binders and categorised rest as negative binders. We purified the plasmid DNA of all positive 
binders and sent them for sequencing and then analysed the sequences of each scFvs using 
bioinformatics tools. Then, we created sequence logo using MATLAB software. We used the 
sequences as a tool for analysis of the recognition mechanism of the scFv and the inorganic 
material. Following are the results obtained by screening of various inorganic targets. 
 
2.1.1 Surface treated CdS QDs and gold nanoparticles  
 
Before screening our library on bare inorganic surfaces directly, we tried to screen it against 
a priori easier target: nanoparticles coated with a known ligand. This ligand is a small organic 
molecule and would be in principle antigenic, whereas the antigenicity of inorganics is much 
less characterised. 
 
Samples were provided by our collaborator, B. Dubetret (ESPCI, Paris).  CdS QDs were 
capped with a novel a DHLA-SB (dihydrolipoic acid-sulfobetaine) ligand. DHLA provides a 
stable and compact surface to the QDs. This layer is further coated with a zwitterionic group 
(sulfobetaine) to limit nonspecific electrostatic interactions in biological environment. QDs 
capped with DHLA-SB are small, exhibit stability with time, pH and salt concentration (Muro, 
Pons, Lequeux, Fragola, & Sanson, 2010). The above modification of surface chemistry of 
QDs enabled them for use as probes in many biological imaging applications (long term 
single molecule tracking, simultaneous multicolor imaging etc). Similarly, gold nanoparticles 
were also capped with DHLA, and this layer was further coated with PEG. For 
functionalisation of gold nanoparticles and CdS QDs, surface of these particles can be 
treated with biotin or streptavidine. We received biotinylated DHLA-SB capped CdS QDs and 
biotinylated DHLA-PEG capped gold nano particles.  
 
We used classical biotin-streptavidine binding affinity to select antibodies against these 
materials. First we incubated the biotinylated targets with streptavidine coated paramagnetic 
beads and later used these magnetic beads (having immobilised targets on their surfaces) 
for interaction with an antibody phage library. We took precaution to avoid nonspecific 
selection, by incubation of the antibody phage library with streptavidine coated paramagnetic 
beads (no immobilised target this time).  Further we separated the antibody library and 
incubated with magnetic beads (having immobilised targets). We used magnetic bar for 
separation of selected phages. Please refer appendix B for detailed protocol.  
 
 
  72 
 
The screening results for (DHLA-SB) capped and biotinylated CdS QDs are presented in 
figure 2.1.1a. The screening results for (DHLA-PEG) capped and biotinylated gold 
nanoparticles are presented in figure 2.1.1b. Both screenings showed significant increase of 
target specific binders. Later we performed ELISA experiment to check specificity of selected 
binders for the targets. The guidelines for analysing the screening results are explained in 
box 2.1a. 
 
Box 2.1a 
 
1) Graphical bar presents yield during each round of selection - This graph represents the 
yield at each round of selection. The yield is more precisely defined as the ratio of the 
number of selected phages over the number of input phages. This ratio is obtained by 
indirect method of counting number of bacterial colonies obtained after infection of the 
selected phages from each round of selection and number of bacterial colonies obtained after 
infection of input phages.  We have performed three rounds of selection for all targets. In 
these graphs, the Y axis represents the yield (ratio of number of selected phages over the 
number of input phages), whereas the X axis represents the rounds of selection performed. 
 
2) ELISA result - ELISA is a sensitive test that is routinely used in molecular and cell biology 
laboratories to check antigen – antibody interaction. This assay provides specific color 
signals in the presence of specific antigen-antibody interaction. If an antibody is not specific 
to antigen/target, it gives no color response. 
 
Assay results are shown in the 96 well plates. The yellow color intensity increases with 
increasing binding affinity (i.e. dark yellow indicates a strong binder, light yellow indicates a 
weak binder, no color indicates no binder). In most of the results, wells A1 and H12 are 
control group (i.e. no scFv clone, only culture medium). 
 
 
 
 
 
 
 
 
 
 
  73 
2.1.1a Screening result for (DHLA-SB) capped and biotinylated CdS QDs 
 
The screening results against DHLA-SB capped and biotinylated CdS QDs as target showed 
significant enrichment of the target specific antibodies (fig. 2.1.1a). Therefore, we selected 94 
random bacterial clones appeared after infection of selected phages from the third round of 
screening for the target. Further, we performed ELISA experiment to find specificity of these 
clones for the target (see ELISA result in fig. 2.1.1a). We immobilised the biotinylated targets 
on streptavidine coated 96 well ELISA plate. We used streptavidine coated ELISA plate for 
control experiment as well (absence of immobilised targets) to check non-specific selection 
against streptavidine surface.  
 
 
Figure 2.1.1a: (A) yield during three rounds of selection for (DHLA-SB) capped and biotinylated CdS 
QDs.  (B)  ELISA result (performed in streptavidine coated 96 well plate) a) Experimental plate, 
streptavidine surface was coated with biotinylated target, b) control plate, uncoated streptavidine surface 
(absence of target). Wells A1 and H12 represent the control group i.e. no bacterial clone is used, only 
culture medium. 
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2.1.1b Screening result for (DHLA-PEG) capped and biotinylated gold nano particles 
 
The screening results against DHLA- PEG capped and biotinylated gold nanoparticles as 
target showed significant enrichment of the target specific antibodies (fig. 2.1.1b). Therefore, 
we selected 94 random bacterial clones appeared after infection of selected phages from the 
third round of screening for the target. Further, we performed ELISA experiment to find 
specificity of these clones for the target (see ELISA result in fig. 2.1.1b). We immobilised the 
biotinylated targets on streptavidine coated 96 well ELISA plate. We used streptavidine 
coated ELISA plate for control experiment as well (absence of immobilised targets) to check 
non-specific selection against streptavidine surface.  
 
 
Figure 2.1.1b: (A) yield during three rounds of selection for (DHLA+ PEG) capped and biotinylated 
gold nanoparticles. (B)  ELISA result (performed in streptavidine coated 96 well plate), a) Experimental 
plate, streptavidine surface was coated with biotinylated target, b) control plate, uncoated streptavidine 
surface (absence of target). Wells A1 and H12 represent control groups i.e. no bacterial clone is used, 
only culture medium. 
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Interpretation of ELISA results of surface treated CdS QDs and gold nanoparticles 
 
ELISA results for both targets showed binding of scFvs in both, the experimental as well as 
the control plates. The results indicate non-specific selection, thus failure of screens against 
these targets. The potential explanation for these failures is as follows- 
 
We used streptavidine coated magnetic beads in these screens for immobilisation of 
biotinylated targets (inorganic nanoparticles). Magnetic beads are micron size beads and 
they are covalently coated with streptavidine all over their surface. The biotinylated targets 
are expected to bind streptavidine coated magnetic beads. If biotinylated target fail to bind 
streptavidine coated magnetic beads, we may raise antibodies against streptavidine coated 
surface of magnetic beads and we actually ended up in this way. The selection of antibodies 
against streptavidine surface can be confirmed by their binding in control ELISA plate 
(control plate used in ELISA experiment is streptavidine coated).   THE ELISA result showed 
that all clones were selected against streptavidine target instead of biotinylated CdS QDs 
and biotinylated gold nanoparticles.  
 
A possible reason for the failure of immobilisation of biotinylated targets on streptavidine 
coated paramagnetic beads may be inefficient biotinylation of target surfaces. Unfortunately, 
we did not check the biotin-coating of the inorganic nanoparticle targets used in this study. 
However, on the other extreme if targets are over biotinylated, we might have ended up with 
selection of anti-biotin antibodies. 
 
Results from these screen pondered more emphasis on sufficient biotinylation of targets. 
This might not be efficient in the case of inorganic nanoparticles. So overall this approach is 
not safe due to increased chances of selection of non-specific antibodies.  It motivated us to 
use the bare surface of semiconductor materials and metal surfaces, which are not stabilised 
by any surfactants.  
 
2.1.2 Screen against micron size particles (ZnS, CdS, CdSe, gold particles) 
 
The micron size particles of ZnS, CdS, CdSe, and gold were bought from sigma Aldrich (for 
details, see the list in appendix A). Selection of binders (scFvs) against bare surface of the 
semiconductor materials and the metal was the primary goal of this thesis, but first we 
attempted to select binders against these materials coated with some organic ligand which 
did not result into any specific binders. The absence of surfactant or ligand on the surface 
allows selection of antibodies that can bind directly to the inorganic surfaces and infact the 
selected antibodies itself can act as ligand. Micron size particles came in powder (solid) form. 
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The physical state of these particles facilitated easy screening procedure during the selection 
and washing steps as these powders get settled by centrifuging for few seconds.  
 
The next step was to test the specificity of the antibodies selected against micron size 
particles to the nano size materials of same object. The selected antibodies might show the 
same, reduced or no affinity to nano size materials. The possibility of reduced or no binding 
affinities of antibodies towards nanoparticles can be explained by a fact that nanosize 
particles posses high curvature which produces highly corrugated surface at the atomic level. 
In the case of micron size crystals, the surface is flat as compared to the nanosize particles. 
Thus, the antibodies which are selected against relatively flat surface of micron size crystals 
may not recognise corrugated surface of the nano particles. If we observe reduced or no 
affinity then we would use alternate plan. This plan requires expertise technical platform of 
our collaborator at ESPCI, Paris. We can treat the micron size crystals with chemical 
methods in order to obtain similar corrugated surface as the nanoparticles and expect higher 
affinity of the antibodies for nano objects.  
 
Before the screening experiment by phage display method, it is advisable to characterise 
inorganic materials using a surface analysis tool. This analysis was performed at Benoit 
Dubertet’s lab at ESPCI, Paris. Electron micrographs after the analysis are shown in figure 
2.1.2a. Screening results of each target are explained in following text. 
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Figure 2.1.2a: SEM images of micron size particles. The gold powder contains 5 micron diameter 
quasi-spherical particles. The ZnS powder contains similarly micron-sized particles, of more irregular 
shape. CdSe particles are much more heterogeneous in size and shape. 
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A) ZnS powder 
 
Zinc sulfide (ZnS) is an inorganic, semiconductor compound. It is one of the first 
semiconductors discovered. It has shown versatile properties and a promises for novel 
diverse applications, including light-emitting diodes (LEDs), electroluminescence, flat panel 
displays, infrared windows, sensors, lasers, and biodevices, etc (Fang et al., 2011).  
 
ZnS is most often used as shell material of QDs. QDs are made up of core and shell that 
may consist of different materials. The shell of QDs plays an important role: it provides 
protection against environmental changes, photo-oxidative degradation. The shell material 
should be transparent, should have higher band gap, and should have structure similar to the 
core material (H. Arya et al., 2005). Coating with ZnS shell reduces the photochemical 
bleaching and dramatically increases the quantum yield (Hines & Guyot-Sionnest, 1996). 
Such combination is typically presented as CdS/ZnS, CdSe/ZnS (core/shell). We have used 
ZnS semiconductor powder as target for screening antibodies against it. The screening result 
with the ZnS particles is shown in figure A1.  
 
Interpretation of Figure A1 
 
The screening of antibodies against ZnS particles did not show any encouraging result, it 
might be a failure screen. The yield of antibodies specific to ZnS did not show any 
enrichment during the three subsequent rounds of selections. We are unable to provide any 
reason for such results except one argument that either ZnS material is not immunogenic or 
antibodies which can bind to this material were absent in pool of the Tomlinson library used 
for screening. We performed ELISA experiment for the few ZnS clones (total 6). We did not 
observe any binding with the ZnS target (data is not shown here as there were no color 
signal indicating binding with target). The results with other targets showed significant 
increase in yield, so we decided to focus on further characterisation of those clones first. 
Therefore we did not perform any further experiment with clones generated for ZnS target.  
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Figure A1: Yield for three rounds of selection for ZnS crystals . The Y axis represent indirect number 
of the phages by counting infected bacterial colonies as yield (ratio of output/input phages), whereas 
the X axis represent different rounds of selection performed.  
 
 
B) CdSe powder 
 
CdSe is an inorganic, semiconductor material. It has size dependent fluroscence spectrum. 
This property of CdSe can be utilised in making probe for imaging. Our collaborator (ESPCI, 
Paris) has already demonstrated live cell imaging by using CdSe QDs capped with 
appropriated ligand (Muro, Pons, Lequeux, Fragola, & Sanson, 2010). The screening results 
using the CdSe particles as target are presented in figure B1.   
 
Interpretation of Figure B1 
 
The screening of antibodies against CdSe particles did not show any encouraging results, it 
might be a failure screen. The yield of antibodies specific to CdSe did not show any 
enrichment during the three subsequent rounds of selections. We repeated the screening 
against CdSe particles, but we obtained similar results. We are unable to provide any reason 
for such results except the same argument mentioned for the ZnS crystals. We wanted to 
characterize clones for those targets which had shown significant increase in the yield, so we 
did not perform any further characterisation experiment with clones generated for CdSe 
target. 
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Figure B1: Yield during three rounds of selection for CdSe. The Y axis represent indirect number of 
the phages by counting infected bacterial colonies as yield (ratio of output/input phages), whereas the 
X axis represent different rounds of selection performed.  
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C) CdS powder  
 
CdS is an inorganic, semiconductor compound. It is mainly used in pigment and in 
manufacturing of photoresistor (light dependent resistors) sensitive to visible and near 
infrared light (source- Wikipedia). It has excellent properties that can be utilised as a 
flurophore. Our collaborator (ESPCI, Paris) has already demonstrated live cell imaging by 
using CdS QDs capped with appropriated ligand (Muro, Pons, Lequeux, Fragola, & Sanson, 
2010). The screening results using CdS powder as target are presented in figure C1.   
 
 
Figure C1: (A) yield during three rounds of selection for CdS crystals, (B) ELISA result, a) experimental 
plate, in presence of target (brown color dots are CdS powder), b) control plate, absence of target. Wells 
A1 and H12 represent control groups i.e. no bacterial clone is used, only culture medium. 
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Interpretation of Figure C1 
 
The screening results against CdS powder as target showed significant enrichment of the 
target specific antibodies (fig. C1, A). Therefore, we selected 94 random bacterial clones 
appeared after infection of selected phages from the third round of screening for the target. 
Further, we performed ELISA experiment to find specificity of these clones for the CdS target 
(see fig. B). The ELISA experiment showed many positive binders for the CdS target. In 
order to confirm this result, we repeated the ELISA experiment using same clones in 
duplicate, the result is shown in figure C2. Unfortunately we did not get reproducible result 
this time. 
 
 
 
 
Figure C2: Repeated ELISA experiment for CdS clones a) clone no 1 to 48 in duplicate, b) clone 
49 to 96 in duplicate. Controle plate not shown here, it came out clean 
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Figure C3: Restriction digestion with Nco l - Not l enzymes of 10 random clones of CdS target 
(above panel), Gold (below).  Clones selected for CdS target showed strange patterns of inserts 
whereas clones selected for gold (Au) as target showed insert pattern of full length scFv sequence, 
i.e. 750bp. 
 
 
 
 
 
 
     
 
Figure C4: Restriction digestion with Nco l – Not l of 10 random clones from each round of selection 
for CdS target, 1kb DNA marker is shown on side. In case of selection of full length scFv, size of insert 
is 750bp, which is very rare in all the selections. 
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Interpretation of Figure C2, Figure C3 and Figure C4 
 
In the repeated ELISA experiment for CdS, unfortunately we did not get reproducible results. 
At the point, we thought about two potential reasons for this failure of experiment – 
- An error in ELISA experiment as washing of the powdered form of the target in ELISA plate 
is difficult. 
- An error during screening process. 
 
To find out the exact reason, first we checked pattern of selected antibody fragments (scFvs) 
against CdS target. The Tomlinson library, which we used for screening, was designed in 
such a way that all scFv sequences are present between Nco l – Not l restriction sites. As a 
result if we digest selected clones using Nco l – Not l restriction enzymes, we can expect 
three possibilities of patterns: 1) no insert, which is shown by no insert band on gel. 2) ScFv 
insert, which can be seen as 750 bp band on gel. 3) Half scFv clones, seen rarely 
(unpublished data of PVP screening in the lab).  
 
We chose 10 random clones from the third round of selection for CdS target. We extracted 
plasmid DNA, performed digestion with Nco l and Not l restriction enzymes, ran DNA gel to 
check insert patterns. We also performed screening against gold powder in parallel with the 
screening against CdS powder. We chose 10 random clones from third round of selection of 
the gold powder. DNA gel is shown in figure C3. We observed unusual and random pattern 
of inserts in case of CdS clones whereas in the control experiment of the gold clones, insert 
patterns corresponded to full length scFv sequences i.e. 750 bp. The insert patterns between 
Nco I and Not I site for CdS clones were very different in gel picture (shown in figure C3) as 
compared to anything present in the library. This was the first time we observed this unusual 
insert pattern when using the Tomlinson phage antibody library. The reason for the non-
reproducible ELISA result was attributed to an experimental error during the screening 
process. Further, we wanted to find the origin of error, so we chose 10 random clones from 
each round of selection for CdS and checked the insert patterns by restriction digestion (see 
figure C4). We again observed an unusual and random pattern of inserts in all rounds of 
selections. We concluded that, there is some experimental error, which has occurred during 
the first round of selection and we have amplified this error in the following rounds. Further, 
we repeated screening with CdS target in order to rectify our assumed error. 
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Repeated screen with CdS 
 
The screening for CdS target was repeated. The yield obtained during the three rounds of 
selection was encouraging (see figure C5). Before going for ELISA experiment, we chose 
five random clones from the third round of selection for CdS target. We were surprised to see 
the same unusual and random patterns of inserts, which we observed during the previous 
experiment.  
 
 
 
Figure C5: (a) yield during three rounds of selection for repeated CdS target, (b) restriction digestion 
with Nco l – Not l of 5 random clones from the third round of selection for CdS target, clones selected 
during repeated experiment with CdS target again showed unusual patterns of inserts. 
 
Unusual insert patterns of scFvs selected against cadmium based semiconductor 
powders 
 
We picked five random clones from the third round of selection of CdSe and ZnS targets.  
We extracted DNA and performed restriction digestion with Nco l and Not l enzymes and ran 
DNA gel, see figure C6. We observed the same unusual and random pattern of inserts in 
case of the CdSe clones, while Insert pattern of ZnS clone was normal. Most of the ZnS 
clones showed expected insert pattern of full-length scFv (750bp). From our semiconductor 
QDs target screens, on three occasion we obtained unusual patterns of inserts while using 
cadmium based semiconductors as target - CdS twice (figure C3, C5) , CdSe ( figure C6. A) 
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and normal pattern with ZnS target (figure C6. B). This is a strong indication for cadmium 
generated toxicity. Potential reasons are mentioned in the discussion (section 3.1). 
 
 
Figure C6: (A) five random clones from screening of CdSe target ,M- DNA marker, lane 1-5 CdSe 
clones, digested with Nco l- Not l, (B) five random clones from screening of ZnS target, M – DNA 
marker, lane 1-5 ZnS clones, digested with Nco l- Not l, (C) 1 kb DNA marker. 
 
Conclusion to screening results obtained for CdS targets 
 
We have failed to generate specific antibodies against CdS target. The antibodies clones 
raised against CdS target have unusual insert pattern of scFvs. The failure of selection of 
CdS specific antibodies might be due to the possible toxicity of cadmium based 
semiconductor on library plasmid DNA inserts. The toxicity could have generated either due 
to release of cadmium metal or generation of reactive oxygen species (see section 3.1 for 
detailed explanation).  
 
To the solution to this problem, selection conditions can be altered to avoid direct contact of 
CdS powder and the bacteria (used for infection of selected phages). We can not avoid 
contact of CdS powder with phages, so we can alter the condition by using less amount of 
CdS target for the screening (we have used 21mg of CdS target for current screening). To 
circumvent the possible reason of generation of reactive oxygen species, we could try using 
some anti oxidant reagents while incubating of CdS powder with phages. 
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D) Gold powder 
 
Gold is member of group 11 in periodic table, which contains the transition metals. The 
unique properties of gold are already explained in section 1.5. One of the areas where gold 
nanoparticles have been extensively used as a contrast agent is in biological electronic 
microscopy.  
 
In this thesis, we performed screening using gold powder as target. The yield during the 
three rounds of selection for gold powder was encouraging (see figure D1). Thus, we 
proceeded for characterisation of gold binding clones by ELISA method. Here, we performed 
ELISA experiment for gold target in tubes. The reason for choosing tube ELISA over 96 well 
plate ELISA were based on the previous experience of using 96 well plate ELISA for CdS 
powder as target. The major problem occurred because target in powdered form can not be 
immobilised into the well and washing steps were performed by centrifuging the 96 well 
plates. While use of 96 well plate increased the difficulty of handling and moreover the 
method did not provide reproducible results in case of CdS target (before we suspected the 
toxicity issue). Therefore we performed the ELISA tests for all clones selected for gold 
targets (total 96) in 1.5 ml polypropylene tubes. ELISA experiment was performed in 
duplicate for all the clones, and we obtained reliable and reproducible results. The only 
drawback was tube ELISA took several days (around 2 weeks) instead of one day in 96 well 
plates.  The ELISA results are presented in figure D2.  
 
 
 
Figure D1: Yield for three rounds of selections for Au (gold) powder, Y axis represent indirect number 
of phages by counting infected bacterial colonies as yield, X axis represent number of rounds of 
selection performed. 
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Figure D2: Tube ELISA result for gold, a) Clone A3 to H3, first two wells are showing results in 
duplicate, last well is the control (with no target)   b) Clone A8 to H8, first two wells are showing 
results in duplicate, last well is the control (with no target) c) Positive control with gold binding clone 
(performed during every ELISA experiment), d) Negative control A1(no bacteria),performed during 
every ELISA experiment. All clones (96) have been done in duplicate and with control. The data are 
not shown for all cases. 
 
Interpretation of figure D1 and D2 
 
The screening results of using gold powder as target showed significant enrichment of the 
target specific antibodies (fig. D1). Therefore, we selected 94 random bacterial clones 
appeared after infection of selected phages from the third round of screening for the target. 
Further, we performed ELISA experiment to find specificity of these clones for the gold 
powder target. The ELISA experiment showed many positive binders for the gold powder 
target (fig. D2). Total 45 clones showed binding with gold target (either strong or weak) out of 
94 randomly selected clones. The ELISA result showed that we have successfully selected 
nearly 50% positive clones, which indicate great success of screening against gold powder 
target.  
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Control experiments for gold binding scFv 
 
We performed different control experiments for ensuring specificity of selected antibodies 
against the gold target. We used PVP binding antibodies against gold target. We also used 
different targets such as ZnS, silver during control experiments. Results of control 
experiments are shown in figure D3. All the control experiments ensured specificity of 
selected antibodies against the gold target. 
 
 
 
Figure D3: Control experiments for ensuring specificity of gold clones. a) PVP binding antibody with 
gold target, PVP binding ScFv did not show any binding with gold target. b) Gold binding scFv tested 
against another inorganic target ZnS, gold binding scFv did not show binding with ZnS. The gold binding 
antibody was also tested against silver, It did not show any binding with silver either (data not shown 
here). 
 
Interpretation of Figure D3 
 
Binding specificity was checked in many ways (fig. D3). In figure D3a, we showed that the 
antibody selected from the same library which strongly bind to another non-biological target 
(PVP synthetic polymer), do not show binding to the gold target. It is important to note that 
PVP binding antibodies share 75% sequence similarity with the gold binding antibodies. In 
figure D3b, we showed that the gold-binding antibody do not bind to other targets (ZnS or 
silver). This binding specificity reinforces the success of the screen. 
 
Sequencing of positive binders (scFvs showing binding with gold targets) and their 
analysis 
 
After ensuring the specificity of selected clones against gold target, we extracted the plasmid 
DNA corresponding to all positive clones and sent for sequencing. In total 45 clones were 
sent for sequencing, out of them 32 distinct sequences were identified. This is a large 
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number of sequence (in general) selected using the Tomlinson library. We did not expect 
such high number of distinct scFv sequences because usually the biological targets provide 
maximum 10 different antibody sequences (2-3 more commonly). Thus, the result of gold 
powder binding antibodies is even more successful than what we anticipated earlier. Also, 
this result is a major improvement over previous similar work on anti gold human antibody 
(Watanabe et al., 2008) which was based on only one sequence whose subparts (VH and VL) 
were selected from separate  libraries. 
 
The large number of different antibody sequences allowed us to perform statistical analysis.  
We found that some sequences are repeated several times, all unique sequences with their 
frequencies of appearance are shown in appendix C. The distinct DNA sequences were 
further aligned by using multiple sequence alignment tools. The sequence logo was created 
using MATLAB software, which is shown in figure D4. The guideline used to analyse the 
sequence logo is shown in Box 3.1b.   
 
Box 3.1b 
The sequence logo presented in figure D4 is a graphical presentation of the amino acids. Each letter 
represents one amino acid. The sequence logo is created from conserved multiple sequence 
alignment. It shows how well an amino acid is conserved at a particular position. If an amino acid is 
present more frequently at a particular position, It is depicted by a larger letter (e.g. in figure D4, letter 
R which is code for arginine, is shown in relatively larger letter at position 11). Source - Wikipedia 
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Interpretation of sequence logo 
 
There is clear a selection of arginine at many positions in particular at the VH and VL CDR3 
regions. These regions are the most variable and are directly involved in contacting the 
target antigens. The large number of sequences showing strong selection for arginine amino 
acid clearly indicate role of arginine amino acid for gold binding. Detailed explanation for 
selection of arginine is mentioned in section 3.1 of the discussion. 
 
ELISA experiment of gold binding clones using 96 well plate instead of polypropylene 
tube 
 
The ELISA experiment when performed in tubes took several days as compared to one day 
when performed in 96 well plate. Though the ELISA experiment when carried out in 96 well 
plate for CdS target had handling problems, we decided to try ELISA experiment for gold 
powder target using improved protocol in 96 well plate to save time. In order to check the 
 
 
Figure D4 Sequence logo of amino acid in CDR region for gold-binding scFvs. The sequence of scFvs 
from the Tomlinson library sequence has 200 amino acid including 18 randomized positions. The 
figure represents 24 positions in the CDR region, 18 positions are variable (represented by several 
letters, each represent one amino acid), whereas 6 positions are fixed (represented by one large later 
at different positions, which are 2->I, 6->G, 9->T, 16->A, 17->S, 23->P). When there is a large letter on 
top at variable position, it indicates that particular amino acid is strongly selected at this position. For 
example letter R is represented by relatively bigger letter than rest of the letters at position 11, which 
indicate strong selection of arginine amino acid at position 11 in VH- CDR3.   
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reproducibility of ELISA experiment in 96 well plate, we chose all the gold binding clones for 
which positive and negative binders were already identified by use of tube ELISA. Also, we 
managed to improve ELISA conditions by centrifuging the ELISA plate for 1 minute at high 
speed instead of a few seconds in earlier experiment (with CdS powder as target) during 
washing steps and removing the last drag of remaining liquid very carefully (washing buffer, 
primary and secondary antibody solutions). ELISA experiment was done with gold binding 
clones no. 49 to 96 in duplicate (selected randomly as we can perform experiment in 
duplicate for only 48 clones in 96 well plate) and control experiment was done without gold 
powder target (results are shown in figure D5).  
 
The ELISA result in experimental 96 well plate produced same result for positive and 
negative binders as we obtained in tube ELISA. However, the results were surprising as the 
gold binding antibodies also showed binding in control plate where gold target was absent. 
Such results were not expected as we already confirmed specificity of gold binding 
antibodies while using gold as target and also in many control experiments when ELISA was 
performed in polypropylene tube. The reason for such unexpected result is explained in 
following paragraph. 
 
 
Figure D5: ELISA results of clones selected against gold target, performed in 96 well plates  
a) Experimental plate in presence of gold target, clone no 49 to 96 in duplicate. The brown color 
dot is gold powder. b) Control plate, in absence of target. H12 is control with no bacterial clone. 
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Why gold binding antibodies showed binding in control ELISA plate 
 
The ELISA result shown in figure D5 is very interesting as the figure shows the binding of 
positive binders in control 96 well plate in absence of gold powder target. However, the same 
positive binders did not bind in any control polypropylene tubes during tube ELISA. The result 
suggest the possibility of interaction between positive binders and material of the 96 well 
plate, polystyrene in this case and thus demanded a more careful look at the possibility of 
this interaction. We already know that the sequences of our gold binding scFvs (positive 
binders) have arginine amino acid in abundance (see figure D4). Later upon consulting of the 
literature, we found that arginine is also involved in polystyrene binding. Many researchers 
take advantage of this fact in designing polystyrene binding peptides. The polystyrene 
binding peptides are utilised in immobilising proteins on the polystyrene plate. Few example 
of polystyrene peptide tags are PS19-6 (RIIIRRIRR) and PS19-6L (RLLLRRLRR) (Kumada 
et al., 2010) (Kumada, Shiritani, Hamasaki, Ohse, & Kishimoto, 2009). Thus, this all suggest 
the possible interaction of arginine residue present in positive binders and polystrene 
material of 96 well plate. This interaction also explains binding of the postive binders in 96 
well control plate even in absence of gold powder target. It is important to note that this 
interesting result is not an artifact of selection this time, like with streptavidine beads (section 
2.1.1). It is a sheer coincidence that we selected target (gold powder) and used 96 well plate 
(polystrene material) that showed binding affinity towards arginine. However, it is important to 
note that selection of gold binding scFvs was performed in polypropylene tube where we do 
not see any binders in control tubes. 
 
Confirmation of binding of gold binding antibodies to polystyrene material 
 
To confirm the reason summarised in above paragraph, we carried out a control ELISA 
experiment using tubes made up of polypropylene (PP) and polystyrene (PS) materials. In 
this experiment, we tested binding behaviour of one gold binding scFv (11D) in presence and 
absence of gold powder in polypropylene tubes and in absence of gold powder in 
polystyrene tube. The results are shown in figure D6. We observed that 11D (gold binding 
clone) showed binding with gold (gold powder in PP tube) and polystyrene tube (absence of 
gold powder) but no binding with polypropylene tube (absence of gold powder). However, 
intensity of binding correlated with yellow color is relatively less for polystyrene tubes than 
what we have observed previously in control polystyrene 96 well plates. This discrepancy 
can be accounted by difference in polystyrene composition of  PS tube and PS 96 well plate. 
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Figure D6: Control ELISA experiment using polystyrene (PS) and polypropylene (PP) tubes. 
Gold binding clone, 11D showing binding with gold target, little binding with polystyrene tube 
(PS), and no binding with polypropylene tube (PP).  
  
Applications of antibodies selected against micro-particles for the surface chemistry 
of nanoparticles 
Finally, we started testing the possibility of using our anti-gold powder scFvs as ligands to 
gold nanoparticles, which was one of our original aims. We tested one gold powder (micro 
size) binding scFv against citrate stabilised gold nanoparticles (20nm). The citrate stabilised 
gold nanoparticles are known to be  sensitive to salt. At higher concentrations of salt, their 
citrate layer becomes destabilised and nanoparticles start to precipitate. This phenomenon 
can be visualised by the turning of the pink color solution to transparent. We have observed 
that in presence of gold powder (micro size) binding scFv, gold nanoparticles remain 
stabilised even at high NaCl concentration of 50mM. At the same NaCl concentration of 
50mM but without scFv, gold nanoparticles becomes destabilised, which can be observed by 
the disappearance of pink color. This experiment is still in progress. See preliminary result in 
figure D7. 
 
 
Figure D7: (A) tube 1- citrate stabilised gold nanoparticles (pink color is due to Plasmon resonance), 
tube 2 and 3- gold nanoparticles + buffer containing 50mM NaCl. Tube 2 is freshly prepared mixture 
while tube 3 is the same mixture after 18 hours of incubation. (Salt concentration is known to 
destabilise citrate, which results in aggregation of gold nanoparticle, ultimately the pink color 
disappears). (B) Tube a- citrate stabilised gold nanoparticle + gold binding scFv in culture medium, 
tube b- citrate stabilised gold nanoparticle + culture medium without scFv (NaCl concentration, 50mM). 
Salt concentration has destabilised gold nanoparticles in absence of scFv. 
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Conclusion 
 
Although the results with most targets (nano and micro sized) did not appear as we 
expected, we have tried to identify the reason behind it. We need to adapt our protocols 
further to make the selection of antibodies possible for these targets. We achieved success 
in identifying many gold binding antibodies. The gold binding clones are proof of concept for 
our method to select antibodies (binders) for inorganic materials. The screen against gold 
target resulted in 32 distinct sequences of scFvs, which is a huge number in comparison to 
the selection of antibodies against any biological target. The sequence analysis of gold 
binding clones enabled us to identify key amino acid (arginine) that has potential role in gold 
binding.  
 
Our goal was to test binding of antibodies generated against micro size particles to the nano 
size objects. Preliminary results confirm that antibodies selected against micron-sized gold 
particles can be used as ligands for surface modification of  gold nanoparticles. 
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Result 2.2 
 
2.2 Engineering of antibodies and their production in Dd 
(In collaboration with S. Moutel & F. Perez at UMR 144 CNRS/Institute Curie) 
 
Recent advances in antibody selection process led to an increase in the number of targeted 
antibodies. In section 2.1, we have explained generation of antibody fragments (scFvs) using 
phage display method against inorganic targets. These scFvs can be used as a building unit 
to build engineered antibody constructs. However, production and detailed characterisation 
of different antibodies and their engineered products are facilitated by their heterologus 
expression and purification. Applications of the engineered antibodies are limited due to the 
lack of efficient production platform for large size antibodies. Thus, a potential solution to the 
above problem is a better choice of an expression system that would result in sufficient yield 
of large size antibodies and low cost of production.  
 
A variety of expression systems have been developed ranging from prokaryotic system of 
bacterial cells to eukaryotic expression systems (yeast, fungi, plant cells, insect cells and 
mammalian cells) for production of antibodies. Advantages and disadvantages of the above 
mentioned expression systems are described in section 1.4. We have exploited a new 
eukaryotic expression system: Dictyostelium discoideum (Dd) for the production of scFvs and 
engineered antibodies. The new expression system offers many advantages such as fast 
growth and easy genetic manipulations. Being a eukaryotic organism, it has a secretory 
pathway leading to correct protein processing and post-translational modifications. However, 
glycosylation pattern of antibodies expressed in Dd may differ from antibodies produced in 
humans. This could have an effect on use of antibodies produced in Dd for therapeutic 
purposes. 
 
In this thesis, we have attempted to express variety of scFvs and engineered constructs such 
as scFv+Fc, scFv::streptavidine and bispecific antibodies in Dictyostelium discoideum. These 
antibodies were scFvs raised against biological target. The engineered constructs (scFv+Fc, 
scFv::streptavidine and bispecific antibodies) were generated using the scFvs as building 
blocks raised against biological targets. We can apply similar methodology to modify and 
express scFvs and their engineered constructs generated against inorganic materials.  
 
All the scFv and scFv+Fc constructs were expressed functionally in Dd cells and secreted 
into the culture medium. However, the scFv::streptavidine constructs and the bispecific 
antibody constructs were not expressed in Dd cells. The specificity of secreted antibodies 
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was determined by immunofluoroscence analysis. The secreted scFvs were purified from the 
culture supernatant using ion affinity chromatography. Furthermore, one scFv + human Fc 
(engineered antibody) secreted by Dd was purified using protein A and sent for glycosylation 
analysis. 
 
2.2.1 Construction of expression vector 
 
Contrary to the mammalian systems, there are no commercial vectors available for protein 
expression in Dd (Veltman, Akar, Bosgraaf, & Van Haastert, 2009). For the construction of Dd 
vector, we have taken advantage of the presence of extrachromosomal plasmids in Dd cells. 
The extrachromosomal plasmids are capable of producing recombinant proteins in Dd in 
large quantities. The extrachromosomal vectors have high transformation efficiency and they 
eliminate the need for clonal selection. Despite the substantially larger size (approx. 11kb), 
we decided to use Ddp1 based plasmid system. This plasmid eliminates the need for co-
transfection and reduces the cell-to-cell variation of expression.  pTX vector was used as a 
backbone for expression vector construction. The resulting vector is named as pUX vector. 
Detailed method of constructing pUX vector is mentioned in appendix E. The modular map 
for pUX vector is shown in figure 2.1.1a. We have combined favourable features (listed 
below) to construct Dd expression vector (pUX) that can allow secretion of recombinant 
antibodies and their engineered constructs in the culture medium. Following are the desired 
features that we have included in Dd expression vector-  
 
1) Origin of replication for E. coli and Dd   
2) Resistance marker for E. coli (amp) and Dd (G418)  
3) Expression cassette - a) Promoter – actin 15 promoter, to ensure active translation 
during axenic growth b) Start codon - ATG c) Signal peptide- N terminal secretion 
signal peptide of celA to ensure efficient secretion of antibodies. 
4) Wide choices of cloning sites (MCS) -  particularly  NcoI/NotI sites where one can 
subclone any NcoI/NotI excised scFv antibody fragments (this is the common format of 
all of the phage display vectors and vectors used for scFv subcloning in our study), 
NotI/NheI restriction sites (immediate downstream of the scFv fragment)  that allow for 
the C terminal fusion of scFv with other protein or purification tags. 
5) A terminator followed by a stop codon. 
6) Tag for purification- His6 tag for efficient purification  
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Figure 2.1.1a Modular map of pUX vector, any antibody fragment can be inserted at position Nco l - 
Not l, just downstream to this site, Not l - Nhe l site is present, which facilitate C terminal fusion of any 
other protein or purification tag to scFv sequence. 
 
2.2.2 Cloning of the antibody sequences in Dd expression vector 
 
After constructing the suitable expression vector, the next step was to clone antibody genes 
of interest. The pUX expression vector provides multiple cloning sites for easy cloning of the 
antibody genes. All scFv genes and engineered antibody genes were cloned in pUX vector. 
After cloning, plasmids were transformed into E.coli. All constructs were analysed for correct 
insert size of scFv and engineered antibodies. The plasmids DNA of positive clones were 
transformed into the Dd cells. Following is the description of cloning of scFvs and their 
engineered constructs in Dd expression vector. 
 
2.2.2.1 Cloning of scFv sequences  
 
We chose few scFv sequences - anti-alpha tubulin scFv ( F2C),  anti-giantin scFv (TA10), 
anti-myosin IIA scFv ( SF9) [all generated by C.Nizak, (Nizak et al., 2003)] and conformation 
specific anti tubulin scFv (MB11) (Dimitrov et al., 2008). These sequences were excised from 
their original vectors and subcloned into the pUX vector at Nco l – Not l sites (see appendix E 
for the cloning strategy). The pUX plasmids containing these scFv sequences were 
transformed in the Dd cells. We obtained stable transformed Dd cells in two weeks. The 
transformed cells were able to secrete all scFvs in active form in the culture medium 
(detected by Immunofluroscence studies). The cloning of scFv gene was done N terminal to 
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affinity purification tag. As a result, we were able to purify these scFvs from culture 
supernatants (see section 2.2.3, 2.2.4 and 2.2.5 for detailed results).  
 
2.2.2.2 Cloning of engineered scFv fragments  
 
We constructed several engineered antibodies by using scFv sequences mentioned in sub 
section A.  Engineering and cloning of these engineered antibodies have been explained in 
this sub-section.  
 
(A) ScFv +Fc constructs 
 
Traditional antibodies have two principal regions:  A variable region (Fv) and a constant 
region (Fc). The variable region is a part of the binding domain. It is unique to each antibody 
and recognises a specific target antigen. The constant region (Fc) of the antibody is largely 
the same in all antibodies. The function of the Fc-region is to activate effector cells of the 
immune system. Thus, together these two regions work to bind specifically to a target antigen 
as well as to attract the immune system effector cells to eliminate the target antigen.  
 
The scFv+Fc constructs were generated by fusion of Fc regions at Not l – Nhe l sites in the 
same scFv clones generated in sub section A. Not l – Nhe l site is present just downstream 
of scFv sequence cloned into the pUX vector. We went one-step further and fused 
multispecies Fc regions with scFvs. The multispecies fusion made these constructs free from 
species barrier and made them more valuable for various routine analyses in the laboratory. 
All scFv + Fc constructs are depicted in figure 2.2.2a (see appendix E for cloning strategy of 
scFv + Fc constructs). 
  
All of the pUX plasmids containing scFv+Fc sequences (total 16) were transformed in the Dd 
cells. We obtained stable transformed Dd cells for all scFv+Fc constructs. All constructs were 
able to secrete active scFv+Fc antibodies into the culture medium of Dd cells (detected by 
Immunofluroscence studies). See section 2.2.3 and 2.2.4 for further results.  
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(B) ScFv:: Streptavidine constructs 
 
ScFv is a monovalent molecule and sometimes multivalency is preferred for the antibody 
molecules. To achieve multivalency, we fused streptavidine gene at Not l – Nhe l site just 
downstream to scFv sequence already cloned into the pUX vector. Streptavidine is a stable 
tetrameric protein. Pictorial presentation of tetrameric form of scFv :: streptavidine constructs 
are shown in figure 2.2.2b. Different cloning steps performed during construction of scFv:: 
streptavidine constructs are shown in appendix E.  All of these constructs were transformed 
in the Dd cells. Our aim was to produce this tetrameric construct in Dd. We were able to 
obtain stable transformed Dd cells for all of the streptavidine fusion constructs. However, we 
could not achieve any expression of scFv::streptavidine fusion constructs (see section 2.2.3 
and 2.2.4 for explanation).   
 
 
Figure 2.2.2b:  ScFv:: streptadidine construct (ScFv- SF9, TA10, F2C, PVP binding scFv- 
A2,B1,C11,F1) 
 
Figure 2.2.2a: ScFvs – SF9, TA10, F2C, and MB11 have been fused with multispecies (human, 
rabbit, mouse, m cherry) Fc regions.  
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(C) Bispecific constructs 
 
The bispecific antibodies do not naturally occur in nature. The concept of bispecific 
antibodies first emerged for therapeutic purposes (see section 1.3 for details). Apart from the 
therapeutic use, the bispecific antibodies can be utilised in various applications such as a 
bispecific antibody that has specificity towards two materials. They can be used for many 
materials science or sensing applications. The bispecific antibodies can also be used for 
cross linking two cell surface receptors, which can be used as novel cell biology tools. With 
the bispecific antibodies we can explore many new target combinations. Engineering 
bispecific construct requires good skills in molecular biology and genetic engineering. Most of 
the techniques described in literature are based on using primers, which need to be designed 
for each bispecific construct and additionally such strategies increase the cost of 
construction.  
 
Our technique is more general, we can fuse any two antibodies of different specificities, using 
a linker sequence. The main strength of our technique is the use of universal linker. We set 
up a strategy to fuse any two NcoI/NotI excised scFv fragments resulting in a combined 
fragment flanked by NcoI/NotI sites. The design of the linker was inspired from the synthetic 
linker used in BiTE construct.  
 
The Linker has (Gly4 Ser)3 sequence flanked by Eag l and Pag l at extremes. Eag I and Pag I 
sites share common overhang with Not I and Nco I sites respectively. Due to this engineering 
design, internal Nco l and Not l sites get killed. Final bispecific construct still posses Nco l- 
Not l sites, which makes it feasible to subclone into any of our scFv phage display or Dd 
expression vectors (see appendix E for details). 
 
We constructed one bispecific antibody using TA10 and F2C scFvs, later we used the same 
method to make another construct for our project in collaboration with Yamuna Krishna at 
National centre for biological sciences (NCBS), Bangalore, India. There is little literature 
about different arrangement of variable domain chains and its effect on function. To explore 
this area, we made two types of bispecific constructs using one set of two scFvs. For 
example scFv A has VH - VL arrangement, scFv B has VH –VL arrangement, which provides 
opportunities to make two kinds of bispecific antibodies as shown in figure 2.2.2c. After 
making the bispecific constructs, sequences are confirmed by sequencing. The 
transformation of pUX vectors containing bispecific constructs (scFv A + linker + scFv B) was 
done in Dd cells. We were able to obtain stable transformed Dd cells for all of the bispecific 
constructs. However, we could not achieve any expression of bispecific antibodies (details is 
explained in section 2.2.3 and 2.2.4).  
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Figure 2.2.2c: Possibility of two arrangements of any Bispecific antibody , in construct (a), VL of scFv 
“A” is in contact with VH of “B”. Whereas in construct (b), VL of scFv “B” is in contact with VH of “B”.  
 
 
2.2.3 Transformation and selection of antibody fragments and engineered antibodies 
in Dd cells 
 
Plasmid DNA of all positive constructs (scFv and engineered antibodies) cloned in Dd 
expression vector (pUX) was extracted. All the constructs were transformed in AX3 strain of 
Dd cells. Transformation was done by electroporation. Transformed cells were subjected to 
increasing concentration of G418 antibiotic selection from 5 ug/ml to 20 ug/ml. The stable 
cells were propagated in HL5 medium containing 20ug/ml G418.  
 
We were able to transform and obtain stable transformed cells for all scFvs and engineered 
antibody constructs. The selection of cells transformed with scFv was started with 5 ug/ml 
concentration of G418. We were able to achieve stable scFv transformed cells within two 
weeks. However, engineered antibodies constructs (scFv+Fc, scFv::streptavidine and 
bispecific constructs) took longer time (nearly three weeks) to obtain stable transformed Dd 
cells. Moreover, we did not observe any transformed cells for few scFv+Fc constructs when 
selection was started at 5 ug/ml concentration of G418. Therefore, we altered the selection 
condition by reducing the initial amount of G418. The selection was started at 2.5 ug/ml 
concentration of G418.  Under this selection condition, we obtained stable transformed cells 
with scFv+Fc constructs. Further, we adapted similar selection conditions for all engineered 
antibody constructs owing to their larger size than the scFv alone.  The possible reasons for 
slower transformation of engineered antibody constructs and absence of transformed cells 
under selection at high G418 concentration (5ug/ml) might be apparent toxicity of these 
constructs to Dd cells or bigger size of the constructs, which made them costly for Dd cells to 
replicate.  After obtaining stable transformed Dd cells, we tested expression of antibodies in 
Dd supernatant (see the following section).  
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2.2.4 Expression of antibody fragments and engineered antibodies in Dd cells 
 
Transformed cells were grown in axenic medium (HL5) with 20ug/ml G418. The expression 
of scFv and scFV+Fc constructs in AX3 transformants were studied by Immunofluroscence. 
The supernatant of transformed Dd cells were collected and Immunofluroscence studies 
were made using HeLa cell lines. Bright fluorescence signals were observed by supernatant 
of transformed Dd cells confirming the secretion of biologically active antibodies. The 
immunofluroscence (IF) images for actively secreted scFvs are shown in figure 2.2.4a, IF 
images for actively secreted scFv + Fc constructs are shown in figure 2.2.4b. 
 
 
 
Figure 2.2.4a: IF images of secreted scFvs using HeLa cells. Fixed HeLa cells were stained using the 
supernatant of Dd culture secreting respectively an anti-alpha tubulin ScFv (left, F2C), an anti-giantin 
scFv (middle, TA10), and an anti-myosin IIA scFv (right, SF9). ScFv staining is shown in red (detected 
via anti-His6 and secondary antibodies), DNA is stained by DAPI, shown in blue. ScFv staining 
intensity corresponds to the one usually obtained with the same scFv prepared from CHO cells. 
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Figure 2.2.4b: IF images of secreted scFv + Fc constructs using HeLa cells. Fixed HeLa cells were 
stained using the supernatant of Dd culture. anti-alpha tubulin scFv +human  Fc (left, F2C+ hFc), an 
anti-alpha tubulin scFv + mouse Fc (middle, F2C+ mFc), and an anti-giantin scFv+ human Fc (right, 
TA10+hFc).  ScFv+Fc staining is shown in red (detected via secondary antibodies e.g.anti human, anti 
mouse), DNA is stained by DAPI, shown in blue. ScFv+Fc staining corresponds to the one usually 
obtained with the same scFv+Fc prepared from CHO cells. All scFv + Fc constructs were secreted in 
active form in Dd cells, other images are not shown here. 
 
With the positive expression of scFvs and scFv+ Fc constructs we expected to obtain 
positive expression of scFv::streptavidine and bispecific constructs.  But these two constructs 
did not show any expression after stable transformation in Dd cells. We tried to purify these 
constructs using ion affinity chromatography (cobalt resin for histidine tag proteins). We did 
not see any band on SDS PAGE. We tried to detect presence of purified protein using silver 
staining but could not see any band of purified protein. Instead of directly purifying these 
constructs we could have tried to detect presence of expressed antibody constructs directly 
in the supernatant of Dd cells by western blot analysis. The western blot analysis could have 
ensured us for correct expression of these constructs even if they were expressed at low 
level.  
 
If expression of these constructs is really hindered in Dd cells, the potential reasons can be 
larger size of constructs, which make them costly for Dd cells to replicate. However, the non-
expression of scFv::streptavidine and bispecific constructs due to their large sizes can be 
discounted as we were able to functionally express scFv+Fc construct whose size was 
comparable to bispecific construct.  
 
The other reason for non expression of scFv::streptavidine and bispecific constructs might be 
the sequence of these constructs that can stop their transcription in Dd cells. The bispecific 
construct is made up of GC rich linker [(Gly4 Ser)3 ] joining two scFvs. It may be possible that 
Dd cells could not express the bispecific constructs due to the codon bias specially at the 
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linker region (Dd genome is AT rich, and not optimised to express GC rich protein) see 
section 3.2 for detailed explanation. Similarly the streptavidine sequence of scFv:: 
streptavidine fusion constructs has high GC content, with the stretches of glycine and serine 
amino acids. So this constructs might have also faced problem of codon bias in Dd cells. The 
expression of the bispecific construct and the streptavidine fusion construct can be checked 
after codon optimisation of their sequences for Dd cells.  
 
2.2.5 Large scale production and purification of antibodies from Dd supernatant 
 
The large scale production of scFv was carried out in shake flask culture. Transformed Dd 
cells were inoculated in 100 ml of HL5 medium under presence of G418 20ug/ml. This 
culture was incubated in shaking incubator at 22o C till culture reached adequate cell density. 
The Dd cells were checked for their viability under the microscope, this culture was 
transferred to 500 ml HL5 medium containing 20ug/ml G418. The culture was incubated for 
72 hours at 22o C (shaking incubator). At the end of incubation period, the culture was 
harvested. The cells were removed by centrifugation and supernatant processed for 
purification. Cobalt ion affinity chromatography method was used to purify “His tagged” 
protein. Protein was purified using 150 mM imidazol. Purified protein was collected in 
separate aliquots, 25ul of each aliquot were analysed by SDS-PAGE (figure 2.2.5a). Flow 
chart of complete procedure of expression of scFv in Dd is shown in figure 2.2.5b. 
 
 
 
Figure 2.2.5a: SDS-PAGE image of purified scFv (SF9), lane 1- protein molecular weight marker, 
lane 2- 9 different aliquots of purified SF9 scFv eluted with 150mM imidazol, 25ul of each aliquot is 
loaded, expected size of purified scFv is 35KDa, single band is visible in lane 6,7,8. 
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Figure 2.2.5b: Flowchart of production of recombinant proteins in Dd 
 
 
2.2.6 Enzymes involved in glycosylation in Dd genome 
 
We have compiled a list of glycosylation enzymes identified in the Dd genome database. 
Many enzymes involved in glycosylation functions are homologous to the human 
glycosylation enzymes which are involved in the antibody post translational modifications. 
This increased the motivation to develop Dd as an expression system for antibody 
production. All activities in the synthesis of N linked glycan are performed by glycosidase and 
glycosyltransferase enzymes present in endoplasmic reticulum and Golgi. The exact profile 
of such enzymes present in any cell can largely dictate the composition and structure of the 
final oligosaccharide side chains (Walsh & Jefferis, 2006). The presence of such enzymes also 
increased the potential impact of Dd as an expression system for therapeutical antibody 
production. (See table 2.2.6)  
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2.2.7 Analysis of glycosylation pattern in Dd secreted antibody  
 
We performed a 1L scale production of a particular human scFv-Fc (Tn + human Fc) 
construct in Dd in order to compare its glycosylation profile with that of a CHO preparation of 
the same construct. Tn antibody (scFv) is generated against certain type of antigens which 
appear on tumor cell surface. We have received this scFv from Institute Curie, Paris. Later 
we have fused human Fc to Tn scFv and cloned into pUX Dd expression vector. This 
construction displays the classical glycosylation site in the Fc region (Asn297), as well as 
another glycosylation site in the Fv region. We have performed large scale production of the 
Tn scFv+ human Fc according to the protocols we have developed (appendix F). Our 
collaborators have produced the same scFv+Fc in CHO cells and proceeded for protein 
purification of both Dd and CHO produced constructs. The SDS PAGE image of purified 
antibodies is shown in figure 2.2.8. In the image, samples look partially degraded (probably 
due to proteolysis). But antibodies were still functional due to the intact disulfide bonds. The 
band intensities of CHO and Dd purified antibodies are comparable. The yield was 
comparable between CHO and Dd cells, of the order of 1-2mg per L of culture. The purified 
samples of scFv+Fc construct produced in CHO and Dd cells were sent for glycosylation 
analysis to our technical platform at Centre de Biophysique Moléculaire, Orléans. The 
glycosylation analysis process is currently under progress.   
 
                         
Figure 2.2.7 SDS-PAGE image of purified Tn scFv+ human Fc from CHO and Dd cell supernatant. 
The band intensity of purified antibody constructs produced in CHO and Dd cells is comparable (at 1 
and 5 ug concentration of protein). Both samples look partially degraded (probably due to 
proteolysis), but antibodies remained functional. (Source- This gel was run by S. Moutel, 
Institute Curie, Paris) 
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Conclusion  
 
We have successfully developed an antibody production platform based on the Dd as an 
expression system. This system has shown functional secretion of various scFvs. The 
system was able to secrete functionally active large size antibody constructs at low cost (we 
have shown functional secretion of scFv+Fc constructs). The scFvs and scFv-Fc constructs 
were expressed at levels comparable to the mammalian expression system (CHO cells) at a 
much lower cost. However, we could not show the expression of  scFv::streptavidine 
constructs and bispecific constructs. We have mentioned the probable reasons for non-
expression of these constructs; much research is required to narrow down the true reason 
and to optimise the conditions for their expression. Another challenge of antibody production 
is the production of antibodies with correct post translational modifications. Among the 
various post translational modifications, glycosylation is the most crucial modification for 
therapeutically important antibodies. Dictyostelium being a eukaryotic expression system is 
expected to perform correct glycosylation of eukaryotic proteins (e.g. antibodies). We have 
attempted to find a potential of this expression system to produce therapeutically significant 
antibodies. 
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Table. 2.2.6: Dd glycosylation enzymes identified in the Dd genome annotation database. Source: dictybase. 
 
Gene ID Gene name Gene product Gene description 
DDB_G0283965 pigA GlcNAc transferase 
CAZy family GT4; subunit of the transferase that catalyzes the transfer of N-
acetylglucosamine (GlcNAc) from UDP-N-acetylglucosamine to 
phosphatidylinositol (PI) 
DDB_G0271120  
protein kinase C 
substrate 
 
Very similar to the mammalian glucosidase II subunit beta also known as 
protein kinase C substrate 80K-H, which catalyzes the sequential removal 
of two alpha-1,3-linked glucose residues in the second step of N-linked 
oligosaccharide processing; also similar to yeast GTB1; defects in human 
PRKCSH are a cause of polycystic liver disease (PCLD) 
DDB_G0283005 agtA 
Alpha-
galactosyletransferase 
likely catalyzes the alpha addition of galactose to Fuc-Gal-Nac_Hypro143-
Skp1 (FpaA/FpaB) 
 
 
DDB_G0293896 manA_ps pseudogene Putative pseudogene; alpha-mannosidase family protein 
DDB_G0277051 
DDB_G0284395 
DDB_G0268754 
DDB_G0284393 
DDB_G0284391 
    DDB_G0292918 
 
1,2-alpha-
mannosidase 
Catalyzes the hydrolysis of the terminal 1,2-linked alpha-D-mannose 
residues in the oligo-mannose oligosaccharide Man9(GlcNAc)2; some 
members of this family are responsible for protein N-linked glycosylation, 
while other participate in the degradation of misfolded glycoproteins in the 
endoplasmic reticulum 
  110 
3 Discussion 
 
3.1 Towards finding protein based binders (potential ligands) for inorganic 
materials  
 
In the thesis, we have described unique properties of inorganic materials at nanoscale and 
their potential uses in improving various devices such as electronics, sensing devices, bio-
imaging and many more. We also addressed the limitations of current fabrication techniques 
specially for assembly of nanoparticles, and core issues concerning unfavourable surface 
chemistry of nanoparticles (see section 1.5). Full potential of nanomaterial-based products 
are far from being realised because of the above-mentioned challenges. We have suggested 
a potential solution by use of an antibody fragment (scFv) for surface modification of 
nanoparticles. The proposed surface modification can be utilized in making given inorganic 
nanomaterials biocompatible for imaging, and in triggering self-assembly of nanoparticles. 
 
Peptides and antibodies (scFv) are two main protein based binders. Proteins are polymers of 
amino acids that can spontaneously fold into uniquely organised, tightly packed structures 
that self organise thousands of atoms. Such self organised atoms manifest a wide range of 
functional properties. However, among peptides and antibodies (scFvs), it is difficult to 
comment which one of them is a better binder (see section 1.5.9 for details).  
 
3.1.1 ScFvs as surface ligands for inorganic nanoparticles  
 
ScFvs are one of the smallest, stable units of immunoglobulin molecule that can mediate 
function of antigen binding. We have utilised specificity of this small antibody fragment for 
selecting binder against inorganic materials. At the length we intended to use the specific 
scFvs as ligand for modifying surface of inorganic nanoparticles. Here we have summarised 
few advatnges offered by scFvs as inorganic nanoparticle surface ligand. 
 
Further molecular engineering of selected scFv  
 
ScFv is a favourable molecule for genetic engineering because of easy access to its domain 
rearrangement. We can use the antibody-engineering platform developed during this thesis 
to generate artificial antibody constructs such as bispecific antibody constructs using scFv as 
builidng units. One such example of a bispecific antibody construct is shown in section 1.5.11 
for material science applications. Multivalent molecules can also be created by generation of 
streptavidin fusion construct (explained in section 1.3). 
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 Functional expression of scFv  
 
E. coli is an inexpensive expression system to obtain a high yield of protein. Thus, another 
advantage of scFv is its functional and high expression level in E. coli. There are many 
improved vectors available that can facilitate secretion of scFv in soluble form. Many 
polypeptides cannot be produced efficiently in E. coli because of improper folding or 
aggregation in bacterial cytoplasm; however, this is not the case with the scFvs.  
 
3.1.2 Possibility of using other protein scaffolds as surface ligands for inorganic 
nanoparticles 
 
It is possible to use other scaffolds of protein that show specificity with inorganic materials. 
Protein frames, which have structural stability and precise binding affinity for inorganics, can 
replace most commonly used peptide scaffold. Choices of other protein frames is limitless as 
long as gene sequence is known (Werkmeister & Ramshaw, 2012). Easy cloning of the 
target gene and its sufficient expression and further easy purification are the main 
requirements for using any other protein frame. However, depending on application such as 
biomedical purpose, it is important to choose a protein frame that is compatible in the 
biological environment. 
 
3.1.3 Selection of positive binders (scFvs) using one large library: Searching a needle 
in haystack  
 
Phage display technology is a powerful molecular biology tool. The power of this technique 
lies in its ability to efficiently and rapidly identify positive binders in the form of antibody 
fragment. The technique allows us to find specific binder for targets from large population of 
phages displaying various antibody fragments. We have used the Tomlinson (I+J) library of 
scFv for screening against non-biological, inorganic materials. This library has been 
successfully used for many biological targets so far. We have extended application of the 
library for non-biological targets. In this thesis, we have used this library for selecting binders 
against non-biological targets - gold, CdS, CdSe and ZnS powders.  
 
In our laboratory, another colleague has used the same library against synthetic polymer 
(PVP). The screen against gold powder and PVP target resulted in identifying many positive 
clones (more than 40 out of 94 randomly selected clones). Such a high number of positive 
binders allowed us to statistically analyse different selections of amino acids. We used 
sequence data to create sequence logo. The sequence logo obtained from selection of 
positive binders for both non -biological targets are shown in figure 3.1a. Difference in 
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selection of clones against these two targets is very clear. There is a strong bias towards 
selection of tyrosine, glycine, asparagine and aspartic acid in the VH-CDR3 region of PVP-
binding clones, whereas, in most of the CDR regions of gold-binding scFv (more 
concentrated in VH-CDR3) there is a strong bias towards selection of arginine. These results 
are extremely motivating for several reasons. First, it validated our approach to use the same 
antibody library of 108 clonal diversity for selecting binders/ligands to a diverse range of 
targets: protein targets as well as non-biological targets such as synthetic neutral polymers 
and metallic surfaces. It also supports our strategy of using this method (binder selection by 
phage display) to modify the surface of inorganic particles (refer figure D7 of section 2.1). It is 
important to note that the chemical modification of a surface of every type of inorganic 
nanoparticle requires a dedicated strategy. On the other hand, our strategy of selecting 
binders using phage display is expected to be a general strategy, which can be utilised for 
various targets in the future.  
 
 
   Sequence logo for PVP ( Screen against PVP was performed by a colleague in the lab)  
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                                                       Sequence logo for Gold 
Figure 3.1a: Sequence logo representing selection of amino acid at CDR regions of scFvs selected 
against the polymer PVP (top) and gold (bottom). Both screens were performed using the same scFv 
library [Tomlinson (I+J)] and both resulted in nearly 40 positive clones. Sequence logos are showing 
clear differences in selection at the variable positions (they are obviously identical at the fixed 
positions; 2->I, 6->G, 9->T, 16->A, 17->S, 23->P). There is a strong selection for tyrosine, glycine, 
asparagine and aspartic acid in the VH-CDR3 region of PVP-binding clones. Whereas, there is a 
strong selection for arginine at most of the CDR regions of gold-binding scFv (more concentrated in 
VH-CDR3). 
 
 
3.1.4 Perspectives and consequences of using current display library 
 
Less complexity of binders: an advantage 
 
We know that all libraries (display libraries) exhibit some degree of compositional, positional 
and expressional bias, so in such conditions relying on limited number of validated 
methodology for selection is convenient so that we can compare our results.  
 
If a polypeptide is less complex in terms of variability of amino acid and structure, it can 
provide comparative data for different targets. Low complexity of polypeptide also provides 
enough opportunity to manipulate structure for improved binding. Antibodies have more 
complex structure than peptide but antibody fragments of the Tomlinson library have fixed 
variable position (18 out of total 200 amino acids). Because of fixed variable positions, we 
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can compare screening results of very different targets using one library having 108 clonal 
diversity as we did for PVP and gold targets (see fig. 3.1b). 
 
No need for prior surface characterisation of inorganic materials 
 
In most of the screens, it is highly recommended to prepare target carefully. There are 
recommendations for characterisation of target material with surface analysis tool such as X-
ray photon emission spectroscopy, X-ray diffraction spectroscopy, scanning electron 
microscopy and transmission electron microscopy (Seker & Demir, 2011). Methods to find 
binders for inorganic materials such as molecular dynamics study and rationally designed 
ligand require prior surface characterisation. However, method applied in this thesis using 
phage display, does not require prior characterisation of target, in fact screening result can 
provide fundamental information about how proteins specifically bind to inorganic materials.  
 
Exploring the interface between biologics and inorganics 
 
Selected scFvs against any target materials provide us primary information about how these 
biological molecules (scFvs) recognise inorganic materials. By analysing selected scFv 
sequences, we can identify particular amino acid which has appeared more frequently for 
given inorganic materials (like we did for gold binding clones). Such information can help us 
to explore fundamental recognition process between biologics and inorganics. Apart from 
this, it can guide further to design new molecule with improved specificity for the target (as 
shown in one example of potential application, in section 1.5.12) 
 
Single strategy to modify surface chemistry of all types of nanoparticles 
 
Nanoparticles have rough surface, as a result they have high surface energies. Therefore 
nanoparticles need to be stabilised by surface ligands (explained in details in section 1.5). 
The choice of ligands is specific to chemical nature of the nanoparticles. This kind of surface 
modification is crucial to the eventual application of nanopatricles. Most of the chemical 
modifications of a surface of inorganic nanoparticle require a dedicated strategy. On the 
other hand, the strategy of using ligands selected by phage display is general; we can apply 
it to any inorganic/organic targets. We have achieved success in selecting many positive 
binders for gold particles, which can also used as surface ligand.  However, failure in 
selecting binder (potential ligand) for other materials (CdS, CdSe, and ZnS) can be attributed 
due to other reasons, which we have explained in section 3.1.4.  
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Consequences while using the library 
 
Coming to the consequence faced while using the library for selection of binders against 
inorganic surfaces - Each screen produces many binders. Selection of many positive binders 
allows us to perform statistical analysis and identify over or under represented amino acid at 
variable positions. However, characterisation of all binders is not possible. In such a 
condition, we have to restrict ourselves by choosing one or a few positive binders. While 
choosing one best sequence for further characterisation, we may choose sequence, which 
may provide less information about the interface (inorganics/biologics) than other sequences. 
Thus, analysing large number of binders and selective study of a particular binder for its 
specificity are two major area of study and both should be done in parallel. 
 
Another consequences of using the library (for that matter any other library) comes due to 
non-homogeneity of inorganic material target. Sometimes inorganic targets lack homogeneity 
both compositionally and structurally. Because of heterogeneity of the targets, final isolation 
of positive binders “elution step” becomes difficult (refer section 1.2 for phage display 
standard protocol). All positive clones can not be isolated using same elution conditions; as a 
consequence we may miss the best binders. In addition, no prior knowledge about surface 
charge of the target can also affect the selection of binders. Moreover, oxidation film may 
develop when inorganic material is immersed in any buffer, so careful attention must be paid 
while preparing incubation buffer (Seker & Demir, 2011). To the best of our knowledge, the 
Tomlinson library has never been used for inorganic targets, so there is no established 
protocol to follow. However, inspiration can be taken from screening done for biological 
targets and protocol can be tuned according to the target materials. In this thesis, we have 
described a few adaptations of protocols for screening of inorganic materials using the 
Tomlinson library. 
 
3.1.5 Failure of selection of binders for CdS QDs and gold nanoparticles 
 
We could not select any binder for the nanoparticles. The most probable reason for failure of 
these results was inefficient biotinylation of their surface. As a consequence we selected 
antibodies against streptavidine surface (refer result section 2.1.1 for details). On the other 
hand if nanoparticles were biotinylated in excess, we might have ended up with selection of 
anti-biotin antibodies. So overall this approach is not safe, due to increased chances of 
selection of non-specific antibodies.   
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3.1.6 Failure of selection against micron sized CdS, CdSe, and ZnS semiconductor 
materials 
 
We could not select any binder for CdS, CdSe, and ZnS semiconductor materials. The 
screening against CdS and CdSe semiconductor materials resulted into selection of mutated, 
damaged scFv binders (refer result section 2.1.2, C). Whereas the screening against ZnS 
semiconductor material could not provide any positive binder but selected scFv sequences 
were not mutated or damaged.  
 
We did not observe enrichment of positive clones during three rounds of selections for ZnS 
and CdSe semiconductor materials [refer result section 2.1.2 (A and B)] ; this might be due to 
less immunogenic profile of these targets or absense of binders (scFvs) agaist these targets 
in the pool of the Tomlinson library.  
 
The apperance of damaged or mutated scFv sequences for CdS and CdSe semiconductor 
materials may be addressed due to toxicity generated by cadmium based semiconductor 
materials. It is hard to find a straight answer to these results. There are reports supporting 
plausible toxic effect of cadmium-based semiconductors. The reasons could be release of 
toxic metal from core of nanoparticle or generation of reactive oxygen species (ROS) or both. 
A single free radical can break deoxyribose unit. In one communication, plasmid DNA 
damage is reported on incubation with CdSe quantum dots (Green & Howman, 2005). 
Another evidence for cell damage due to reactive oxygen species is reported by Dusica et al 
by showing reduction in CdTe induced cytotoxicity by adding milimolar concentration of 
antioxidant chemical (Lovrić et al., 2005). This group also reported that cytotoxicity was 
partially dependent on size of nanoparticles. Another group has reported that if CdSe QD is 
well protected by polymer or protein, it exerts little harm on cells in comparison to bare QD 
(Derfus, Chan, & Bhatia, 2004). However, there is no concrete evidence to provide definitive 
answer therefore to circumvent the apparent toxicity or mutagenic effects of Cd; we propose 
to modify our screening protocol by avoiding contact between Cd based materials and 
bacteria during phage recovery, or by reducing the amount of CdS or CdSe pwder used for 
screening or by using some anti oxidant reagents (to circumvent suspect due to generation 
of ROS) while incubating of these powders with phages. 
 
3.1.7 Success of selection of binders for gold powder (a proof of concept) 
 
The screening result of selecting positive binders against gold powder resulted in great 
success; we obtained nearly 50% of positive clones (refer result section 2.1.2, D). Many 
control experiments ensured the specificity of gold binding antibodies (binders). After 
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sequencing, we identified 32 distinct sequences which showed binding with gold surface (this 
is a huge number in comparison to number of binders obtained against biological targets, 
they result in maximum 10 different clones, usually 2 or 3 ).The gold binding scFvs are proof 
of concept for our ability to select biological binder for inorganic entities.  
 
The selection of many positive binders provided us data to do statistical analysis. We 
observed clear selection of arginine (R) at many positions. In particular at the VH and VL 
CDR3 regions (see figure 3.1a). These regions are the most variable and are directly 
involved in contacting the target antigens. The selection of Arg by many positive binders, 
clearly indicate role of this amino acid for gold binding. This predominant selection made us 
explore about specific interaction of arginine with gold surface (similar evidences are 
mentioned in the following text). 
 
Interestingly we were not aware of the specificity of Arg for gold surface before our phage 
display screen. We started our screen with unbiased library of phage displaying scFvs. Our 
result showing abundance of arginine in gold binding antibody agrees to studies performed 
by other group using sophisticated tools. The result of selecting binders against gold powder 
strongly supports our case of using the strategy for other inorganic target, whose surface 
characteristics are unknown. 
 
Evidence of Arginine showing affinity for gold surface 
 
The Amino acid sequence of CDR in gold binding antibody reported by Kumagai group 
(Watanabe et al., 2008) is shown below. 
 
 
 
Arginine is present in the VH CDR3 and VL CDR3, as well as at two other CDRs in their anti 
gold antibody. But they did not draw any conclusion for role of Arginine for gold binding 
because they had only one antibody sequence; so they do not have statistics to support role 
of arginine in gold binding.  
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Sarikaya group studied absorption behaviour of gold binding peptide (Hnilova, Oren, Seker, 
Wilson, Collino, Evans, Tamerler, & Sarikaya, 2008b). They compared the amino acid 
composition of strong, moderate, and weak binder (peptide) for gold selected using FliTrx 
random peptide display library. They calculated the relative abundances of amino acids 
among them (see figure 3.1b).  
                                  
Figure 3.1b: Relative abundance of amino acids in strong- and weak binding groups of gold-binding 
peptides. The residues are coloured as blue (basic), red (acidic), green (hydrogen-bonding 
donor/acceptor), and grey (nonpolar). Source - (Hnilova, Oren, Seker, Wilson, Collino, Evans, 
Tamerler, & Sarikaya, 2008b) 
 
Their result suggested that amino acids, Arg, Cys, Trp, and Tyr were over represented and 
Asn, Lys, Pro, and Thr under represented among strong binder sequences for gold. Arg was 
over represented not only among the strong gold-binding peptides but also among the weak-
binding peptides. 
 
Simulations carried out by Martin Hoefling and his group (Hoefling, Iori, Corni, & Gottschalk, 
2010) on adsorption behaviour of  20 amino acids on gold surface (111) using molecular 
dynamics showed strong dependence for the binding affinities on the chemical character of 
the amino acids. Interaction free energy in KJ/mol of non covalent association of amino acids 
with gold surface (111) shown in table 3.1c. 
 
Table 3.1c: Interaction free energy in KJ/mol of non covalent association of amino acid with gold 
surface (111) Source - (Hoefling et al., 2010) 
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The detailed insight of the energy landscape of the amino acids shown in above table 
provide hints for their behavior when they are in contact with gold surface. During their 
simulation, they observed that Arg made one of the first contacts, due to length of its side 
chain. This observation leads them to conclude that Arg may be important for adsorption of 
protein on gold. However, cooperative effect of all amino acids in particular conformation 
might lead to other conclusion. 
 
In extension to the above mentioned question, Hoefling et al showed interaction of 
polypeptides with a gold surface (111) using molecular dynamics simulations (Hoefling, 
Monti, Corni, & Gottschalk, 2011). This study was performed in polarisable gold model in 
explicit water. They used two kinds of polypeptides: peptide having beta sheet conformation 
and biologically important protein having two beta sheet domains. They summarised their 
result as adsorption occur in stepwise mechanism for both kind of polypeptides. The initial 
contact formation is initiated by positive charged amino acid Arginine (Arg), while overall 
charge on polypeptide was neutral. These results also open one debate on selectivity of any 
peptide on gold due to charge on gold surface as electrostatic interaction could be one 
reason for strong affinity of peptide to any inorganic surface. Recently group of Sarikaya 
explored this question (Donatan, Sarikaya, Tamerler, & Urgen, 2012), and their finding 
suggests that under each charged condition, binding behaviour of gold binding peptide 
demonstrated quantitative differences in terms of adsorbed peptide amount, surface 
coverage ratio. This finding can be used as a potential tuning parameter of peptide 
adsorption. 
 
Another article published in soft matter in 2010, where they studied adsorption mechanism of 
single amino acid and other surfactant molecules (which are essential for stabilisation of gold 
nanoparticles) on gold surface (111) in aqueous solution. Their result also favored role of 
arginine for gold binding (Feng et al., 2011). The amino acid and surfactant molecule which 
were most attracted by gold surface were large molecules and with planar sp2 hybridized 
group (e.g. Arg, Trp, Gln,Met, Asn,and PPh3) , whereas  short aliphatic molecule with sp3 
hybridized group exhibit weak attraction (see figure 3.1d).  
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Figure 3.1d: Computed (free) energy of adsorption of single amino acids and single surfactant 
molecules on an even Au {111} surface in dilute aqueous solution at pH ¼ 7 using the CHARMM–
METAL force field. Large molecules with planar sp2-hybridized groups show stronger adsorption and 
short aliphatic molecules with sp3-hybridized groups exhibit weaker adsorption. HDAC - 
hexadecylammonium chloride, CTAB - hexadecyltrimethylammonium bromide. Source - (Feng et al., 
2011) 
. 
Insight of how Arginine might favor gold binding 
 
Work of Feng et al suggested that strong affinity of arginine for gold can be attributed to 
guanidium group present in arginine structure. Strongly binding amino acids moved by a 
hoping mechanism in which surface attached group (guanidinium group of Arg ), moved from 
one favorable coordination pattern on the surface to another in intervals on the order of one 
hundread picoseconds (Feng et al., 2011). Favorable binding condition of Guanidinium group 
of Arg with gold is shown in figure 3.1e. 
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Figure 3.1e: Representative snapshot of Arg on the Au {111} surface. The guanidinium group is found 
most of the time in a favorable coordination pattern with numerous epitaxial sites which leads to strong 
adsorption (pink highlights). Diffusion on the surface occurs by stepwise hopping of the guanidinium 
group to similar epitaxial environments. Source - (Feng et al., 2011) 
 
 
3.1.8 Potential implications of arginine binding to gold  
 
The above mentioned information on arginine showing affinity for gold surface can be used 
to design proteins which can be adsorbed on to gold with a specific orientation and also 
provide possibilities to rationally control the binding of protein on gold. Knowledge of this 
specific interaction can be used to improve biosensors. Immunoassay measure of antigen-
antibody interaction is mostly done on solid support such as gold, glass or polymer based 
surfaces.  Many techniques have been developed for efficient binding of antibody on gold 
surface but most of them suffer from random orientation and denaturation of attached 
antibody. Simple ways to construct a well-oriented layer of antibody binding proteins are still 
missing. Cystein mediated protein immobilisation is widely used method in the construction 
of many biosensors (Lee et al., 2007). Arginine could be another candidate for inducing 
oriented interaction between antibody or any protein and the gold surface. 
 
3.1.9 Potential application of gold binding scFv for surface modification of gold 
nanoparticles 
 
We have also tested our gold powder (micron size) binding scFvs against gold nanoparticles 
(size 20 nm) stabilised by citrate. The citrate layer on gold particles is sensitive to salt 
concentration in environment, at high salt concentration it get destablised and cause gold 
nanoparticle aggregation. We observed such destabilisation and aggregation of citrate 
stabilised gold nanoparticles at 50mM NaCl concentration. However, when these gold 
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nanoparticles were incubated with gold powder (micron size) binding scFv and 50 mM NaCl 
concentration, the gold nanoparticles were found to be much more stable (see figure D7 in 
result section 2.1). After further characterisation, it will be interesting to use gold binding scFv 
as ligand for surface modification of gold nanoparticles. ScFv as ligand is expected to 
provide photostable, bio-compatible, small, specific, and water soluble surface to gold 
nanoparticles. Such suface modified gold nanoparticles can be used as probe in bio-imaging. 
 
3.1.10 From bench to bedside 
 
There is a significant increase in the number of publications on nanotechnology and that has 
led to better understanding of the fundamentals. Nearly every economic centre has shown 
interest in development of nanotechnology and some have already made huge commitment 
towards research in field of nanotechnology (Mazzola, 2003).  Nanotechnology research 
promises a lot of potential in fields encompassing energy, environment and health sectors. 
However, caution must be taken to avoid claim revolutionising the field of application with 
every single piece of nanotechnology research. On the other hand to suspect potential of 
every research achievement in nanotechnology should also be avoided. To this point, there 
are few nanotechnological products available for consumers. Most of the nanotechnology 
concepts including ours remain at a concept level and research is required to transform this 
concept into a viable products. Further, once the technical capabilities are established, the 
products have to go through safety regulations for reaching the markets and public 
acceptance. It would be a mistake to underestimate the impact of public acceptance as we 
can see present scenario with genetically modified crops, stem cell research etc.  
 
There are ongoing public debates on environmental and toxicological effects of 
nanoparticles. Risk assessment of these effects is difficult as the field of nanotechnology is 
too diverse and thus the data are non-comparable. For a solution to this problem 
interpretation of the terms “nanobiotechnology”, “nanomedicine” and “nanotechnology” 
should be very clear. This interpretation is nicely discussed in an excellent review by Duncan 
and Gasper (Duncan & Gaspar, 2011), and also during discussion at European Science 
Foundation conference with authors of this review.  
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3.2 Production of recombinant antibodies and their engineered constructs in 
Dd 
 
3.2.1 Dd as an alternate eukayotic expression system 
 
Dictyostelium discoideum (Dd) can be used as a promising eukaryotic alternative expression 
system for production of recombinant proteins that are big in size and require post 
translational modifications. Major advantages of using Dd as an expression system are 
adequate genomic knowledge, fast growth, easy maintenance, relatively cheaper medium 
than other eukaryotic systems (e.g. mammalian system), post translational modifications, 
and secretory pathway that may lead to easy and cost effective downstream processing. 
 
Our study has validated Dd as an expression system for production of antibody fragments 
(scFvs). We have expressed biologically active recombinant antibody fragments (scFvs) in 
secreted form using Dd cells and purified it. However, antibody fragment (scFv) is 
comparatively small molecule, and in many cases it is not glycosylated. Thus, the expression 
of scFv does not impose many challenges in Dd (E. coli is also good option for expression of 
scFvs which are not glycosylated). However, expression of engineered antibodies (scFv+Fc, 
scFv::streptavidine and bispecific constructs) is expected to be challenging in any expression 
system due to their bigger size. We attempted to express big size antibody constructs (in 
comparision to 30-35 KDa scFv) such as scFv+ Fc, scFv::streptavidine and bispecific 
constructs in Dd cells.  We achieved success in expression of scFv+Fc constructs in Dd 
cells. The same scFv+Fc antibody construct was produced using CHO cells and expression 
yield of this antibody construct was compared between CHO cells and Dd cells. The data 
suggest comparable expression yield in both systems (nearly 1-2mg/ L). If we compare cost 
and time to produce any recombinant protein in CHO and Dd cell, then there is a big 
difference (refer table 1.4a in section 1.4). To obtain a stable cell line in CHO, it takes more 
than a month, whereas in Dd, stable (transformed) cells were obtained within 2 to 3 weeks 
for all constructs.  There is large difference in cost of production in both systems. However 
we could not express scFv::streptavidine and bispecific antibody constructs in Dd cells.   
 
Another challenge for any expression system is to provide correct glycosylation pattern to the 
expressed recombinant proteins (or recombinant antibodies). Glycosylation is an important 
modification of protein, particularly for therapeutic recombinant antibodies. Glycosylation 
affect potency of any therapeutic candidate (glycans can have a marked influence on 
antibody Fc mediated effector functions). We have attempted to study glycosylation pattern 
of one scFv+Fc construct, this work is still under progress at our technical platform (Centre 
de Biophysique Moléculaire, Orléans). In the antibody molecule, Fc region bear conserved N 
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linked glycosylation. Apart from the Fc region, sometimes the antigen binding domain (Fab) 
may also bear glycan.  If this awaited result can prove correct glycosylation pattern of 
antibody molecule produced in Dd cells, then Dd can be establish as very attractive alternate 
eukayotic expression system for recombinant proteins or antibodies. 
 
Although Dd certainly posses many attractive features as a eukaryotic expression system, 
there is lot of research needed to improve this system. For instance, we could not 
successfully express a few engineered antibody constructs (scFv::streptavidine and 
bispecific antibody constructs). We have tried to find potential reasons for these failures and 
a few solutions are mentioned to troubleshoot this problem in section 3.2.3. Apart from this, 
there are many possible ways to improve this system for better expression of recombinant 
proteins (in terms of yield and quality).   
 
3.2.2 Further improvements to establish Dd as better expression system 
 
Optimisation of culture conditions 
 
So far, we have not tried optimised culture conditions for culture of Dd cells. We expect that 
with optimised culture parameters, one can obtain better yield of recombinant proteins/ 
antibodies.  We have used HL5 medium for culturing Dd cells. HL5 medium is a non-defined 
complex medium, main component of this medium are peptone, tryptone, and yeast extract.  
As an alternate, synthetically defined medium such as FM and SIH mediums are also 
available for Dd cells. FM and SIH mediums have well defined composition of mineral salts, 
vitamin and amino acids. FM medium can support growth of most of the strains which can 
grow in HL5 medium, SIH medium is modified version of FM medium (source- Formedium). 
We expect that these synthetically defined medium can also provide optimum growth 
conditions to the Dd cells. Additionally, these synthetically defined medium do not contain 
any protein of animal origin, so it can eliminate chances of infection due to use of protein of 
other animal origin. Many mutant strains of Dd are available which can be grown using 
axenic media. We have exploited only AX3 strain, but other strains can also be used as an 
expression system. So far, we have grown Dd cells in shake flask, optimising culture 
conditions for using fermentor for Dd cells might dramatically increase the final yield. 
 
Optimisation of Dd expression vector 
 
We have constructed a new Dd expression vector (pUX vector). In our study, the pUX vector 
has allowed successful transformation and secretion of recombinant antibodies. However, 
certainly this vector can be improved in many ways for better expression of recombinant 
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antibodies. The size of pUX vector is quite big (approx 11kb), hence this vector can be 
replaced by any small size vector that can provide sufficient expression level. In addition, 
expression cassette of existing vector can be optimised for better expression yield. We have 
utilised Histidine tag for purification of recombinant antibodies, we could try another tag 
system which can benefit purification of eukaryotic recombinant antibodies in better way. 
Last but not the least, different promoter and signal sequences can be used to obtain better 
expression yield. 
 
Codon optimisation 
 
We already know from the genomic analysis that Dd has different codon preference than 
humans, AT content of Dd genome is 77.59% whereas AT content of humans is 60%. The 
correlation between codon usage and the expression level is not very clear. There are few 
biased reports for E. coli on correlation between codon usage and expression level, same 
concept was used by Sharp and Devine to study codon usage in Dd for expression. Their 
study suggests that highly expressed gene do prefer optimal codon (Sharp & Devine, 1989). 
This idea was partly studied at Groningen university (Vervoort et al., 2000), where they 
studied importance of 5’ codon adaptation for hetrologous expression in Dd. They also 
optimised start codon of Dd with kozak sequence of vertebrates to evaluate expression level 
of human chorionic gonadotropin hormone (Dd do not share same kozak sequence with 
vertebrates). Their data suggest that first 10-15 codon optimisation is sufficient to show 
increased expression level. The Kozak sequence adaptation resulted in 1.5 fold increases in 
the expression of hCG. Therefore, codon optimisation could be one area of improvement for 
establishing Dd as better expression system. This could help in expression of GC rich 
protein. 
 
3.2.3 Probable reasons of non-expression of scFv::streptavidine and bispecific 
antibody constructs  
 
There could be two possible constraints for failure of production of scFv::streptavidine 
constructs and bispecific antibody constructs: bigger size or sequence itself. The first 
constraint cannot be justified as we have already shown active secretion of big construct in 
Dd; plasmid size of scFv+ Fc is 11.8 Kb, one of the Fc fusion construct (scFv+ mCherry Fc, 
12.7 Kb) was even bigger than bispecific construct (12 Kb).  Second constraint of sequence 
can be partially justified. We made bispecific construct with F2C and TA10 scFvs, we already 
shown active secretion of these individual scFvs. Nevertheless, in bispecific construct we 
have introduced linker sequence (Gly4Ser)3, which is rich in glycine and serine. Similarly 
streptavidine gene sequence of scFv::streptavidine constructs also posses’ glycine and 
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serine in continuous stretches. As mentioned in the above paragraph, higher GC content of 
any sequence might impose problem in Dd cells for expression of protein. Probably higher 
GC content in the bispecific constructs and scFv::streptavidine constructs is the reason for 
inability to express them in Dd cells. Several attempts were made to purify bispecific antibody 
from Dd supernatant but we never achieved any yield.  
 
3.2.4 Glycosylation pattern in Dd  
 
Major concern with this expression system is its ability to perform correct glycosylation. 
Glycosylation pattern is not studied in details in Dd system; this pattern might be similar or 
different from native human protein. Our results for glycosylation pattern of recombinant 
antibodies secreted by Dd cells are still pending. Correct glycosylation pattern may establish 
Dd system as an important eukaryotic expression system for production of therapeutic 
proteins/antibodies. However, therapeutic antibodies expressed in Dd cell might still face 
hurdles for FDA approval. There is no report till date of any protein produced in Dd at any 
stage of clinical development (R. Arya, Bhattacharya, & Saini, 2008). Also, glycosylation 
pattern of antibodies produced in Dd and for that matter in any expression system has to be 
viewed holistically to draw any conclusion on antibodies’ suitability for therapeutic use. The 
details are discussed in the following paragraphs.  
 
Is glycosylation pattern variation a problem for therapeutic candidate? 
 
In section 1.4, we have described the importance of glycosylation for therapeutic proteins 
and antibodies. We have also described the existence of different glycoforms. Source of 
different glycoforms for any one kind of recombinant protein is not just restricted to its 
production in different organisms, sometimes different cell of same organism can also 
produce different glycoforms. The variation can also arise from downstream processing 
(selective purification of particular glycoform).  Debate is whether to consider different 
glycosylation pattern in proteins or antibodies as a possible cause of concern or not? There 
are concerns of immunogenicity for all recombinant proteins used as drugs. However, a few 
examples have shown to have no effect on functionality in spite of having different 
glycosylation pattern than native human one.  
 
For example, recombinant factor VIII is a protein approved for treatment of haemophilia A. 
This protein is available in market with different brand name by different pharmaceutical 
company; Kogenate (by Bayer, Germany) and Bioclate (by AventisPasteur, PA, USA). 
Kogenate is produced in baby hamster kidney (BHK) cells and purified by several 
chromatographic steps. On the other hand, Bioclate is produced in CHO cells and is purified 
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using a monoclonal affinity chromatography. These products have difference in their 
glycosylation profile, yet both have proved to be safe and effective. This example highlight 
that variation is glycosylation might not hinder the efficacy and safety of therapeutic proteins 
in all cases (Walsh & Jefferis, 2006). 
 
With currently available expression systems and downstream process, we are still far from 
producing recombinant protein exactly the same way as human body produce them. 
However, there is a scope of introducing structural changes in proteins/antibodies for 
improving their pharmacokinetics as done in second generation fast acting insulins (Theo 
Dingermann, 2008). This can be done regardless of production platform. However, 
precaution must be taken against immunogenicity while altering the protein/antibody 
structures. Hence, while evaluating a potential recombinant protein as drug candidate, 
emphasis must be given to functional and safety parameter of different variants, rather than 
structural authenticity of recombinant protein with natural one. The actual concern related to 
different glycoform should be judged by clinical studies. This is further encouragement for 
development of Dd as expression system for therapeutic antibodies. 
 
3.2.5 Absence of universal expression system for production of recombinant proteins  
 
There is general view about recombinant proteins that one expression system cannot 
produce all kind of recombinant proteins. Each set of amino acid in recombinant protein 
challenge expression system in different way. So accordingly, one should choose the best 
system for each particular protein. In this thesis, Dd is described as an alternate eukaryotic 
system that offers several benefits over currently existing expression systems. With further 
research, we can address some challenges faced by this expression system and hope to 
produce many recombinant proteins/antibodies in this expression system. 
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Appendix A: Chemicals, biologicals and vector used in phage display experiment 
 
A) Chemicals 
 
PBS ( 5.84 g NaCl, 4.72 g Na2HPO4 and 2.64 g NaH2PO4.2H20, pH 7.2, in 1 litre), 2xTY 
medium (16g Tryptone, 10g Yeast Extract and 5g NaCl in 1 litre), M9 medium ,Glycerol, 
tween-20,  'Marvel' dried skimmed milk powder, magnetic beads (M280 streptavidine 
dynabead), TMB (3,3’,5,5’-tetramethylbenzidine ,Sigma), H2O2 (sigma), Glucose, IPTG 
(Sigma), TEA- Triethylamine, PEG-8000  
 
B) Materials and antibodies  
 
Magnet, falcon tube, 1.5 ml polypropylene tube, 96 well plate (2ml deep well), ELISA plate 
(normal and streptavidine coated, Nunc), Large and small petri dishes, anti His antibody, anti 
mouse HRP 
 
C) Bacterial strains and vector, display library 
 
TG1 E.coli stock (grown in nonsupplemented thiamin containing M9 medium to maintain 
selection on the F’ pilus), M13KO7 helper phage (GE- Healthcare), pIT2 vector, Tomlinson 
(I+J) library (see details on next page) 
 
D) Phage display targets 
 
Inorganic material 
Physical 
state 
Size Source 
DHLA- SB capped CdS QD 
(biotinylated) Suspension 
10-10.5 nm, 
hydrodynamic radius 
ESPCI, Paris 
DHLA- PEG capped gold 
nanoparticles (biotinylated) Suspension  ESPCI, Paris 
ZnS Powder 10 µm 
SigmaAldrich, 
244627 
CdS Powder  Sigma Aldrich, 208183 
CdSe Powder ~10 µm 
SigmaAldrich, 
244600 
gold Powder <10 µm Sigma Aldrich, 326585 
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Tomlinson (I+J) library  
 
We used Tomlinson I+J library during all screens done in this thesis. This is a single pot, 
synthetic library. Success of using this library can be traced by generation of scFv against 
many targets (mostly biological). (Tomlinson I and J) libraries are distributed by BioScience 
LifeSciences. Antibody fragments are displayed on M13 filamentous phage. 18 different 
amino acid positions in the antigen-binding sites are mutated to introduce diversity in library. 
Two different mutation strategies result in library sizes of 1.47x108(Library I) and 
1.37x108(Library J). These clones are present in ampicilline resistant phagemid vector, which 
is transformed into TG1 cells. Both libraries are based on a single human framework for VH 
(V3-23/DP-47 and JH4b) and Vκ (O12/O2/DPK9 and Jκ1) with side chain diversity at fixed 
position in antigen binding site. 18 variable positions are ; (H50, H52, H52a, H53, H55, H56, 
H58, H95, H96, H97, H98, L50, L53, L91, L92, L93, L94 and L96). The CDR3 of the heavy 
chain was designed to be as short as possible yet still able to form an antigen binding 
surface. The scFv-phage in Tomlinson I + J libraries is monomeric, which in practice means 
that only one copy of scFv is attached on each phage (de Wildt, Mundy, Gorick, & 
Tomlinson, 2000). 
 
Phagemid vector (pIT2) 
 
 
Vector map of pIT2 phagemid vector from the Tomlinson scFv library. RBS - ribosome binding site. 
pelB leader peptide sequence promotes export of the scFv protein. Variable Heavy and Variable Light 
peptide sequences are fused together by a glycine-serine linker. An amber stop codon is at the 
junction of the c-myc tag and the g3 gene to enable conditional expression of the scFv-p3 fusion in an 
amber suppressor strain. The M13 origin of replication enables packaging into M13 phage particles, 
the bla gene encodes ampicillin resistance, and the colE1 origin of replication enables 
maintenance as a plasmid in E. coli. 
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Helper phage  
 
Helper phage is used to produce phagemid particles. There are many variations of helper 
phages, we have used M13KO7.  It is a derivative of M13 that has a couple of differences 
including a kanamycin resistance gene and the P15A origin of replication, which allows the 
genome to be replicated as a plasmid in E. coli. Helper phages supply all of the genes 
necessary for production of phagemid particles.  
 
 
  142 
Appendix B: Phage display protocols  
 
We performed three successive rounds of selection for each target, during each round we 
monitored output/input phage ratio by systematic titration of phages by infecting them in 
E.coli and counting bacterial colonies appeared on selection plate. Protocol is adapted from 
the Tomlinson (I+J) library user’s manual with some modification according to the targets 
properties. 
 
Step 1: Preparation of input 
 
1) An aliquot of the library in TG1 is diluted at OD= 0.05 and incubated at 370c in 2xTY+ 
amp+ 1% glucose until it reached OD=0.5. 
2) 25 ml of above culture with exponentially growing bacteria were mixed with 20x excess of 
helper phage. Mixing was done gently to prevent breaking of bacterial pili (essential for M13 
infection). Mixture was quickly put in water bath incubation (standing) at 370c for 30 min. 
3)  Cells were centrifuged at 3300xg for 20 min, infected bacteria are resuspended in 500ml 
of 2xTY+amp+kan and incubated at 300c overnight. (Kanamycin is used for selection of 
positively infected bacteria, low temperature (300c) is maintained to help scFv folding). 
4) Phages are separated from overnight culture by mixing one fifth volume of PEG 
8000/NaCl to culture supernatant and then followed by ice incubation for 1 hr. Later mixture 
was centrifuged at 10,800xg for 10 min. Pellet was resuspended in 40 ml H2O + 8 ml 
PEG/NaCl followed by second incubation on ice for 20 min. Pellet was again centrifuged to 
remove last drop of PEG/NaCl. Finally pellet was resuspended in 1ml PBS and centrifuged at 
11,600xg for 10 min to remove bacterial debris. Supernatant is input phage solution. It can 
be mixed with 15% glycerol for long term storage at -700c. 
 
Step 2: selection of specific binders (scFvs) against different targets 
 
The targets used during this thesis are unusual for phage display methods. The Tomlinson 
library has been used more frequently for biological targets. Therefore, method of screening 
is well described for biological targets. In our experiment we adapted several techniques on 
need to use basis, of course inspiration was taken from well described methods of selection 
against biological targets. Preparation of target is important step in display technology. In 
screening against biological target, target/antigen is adsorbed onto plastic surfaces like 
immunotubes or ELISA plates. Alternate approach is using antigen/ target in solution. 
Antigen/target can be labelled with biotin, and then phage antibody can be selected against 
biotinylated antigen. After selection phages bound to labelled antigen can be recovered with 
avidin or streptavidine coated paramagnetic beads. One disadvantage of this technique is 
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the possibility of selection of anti streptavidine antibodies. Inorganic materials can be 
obtained in powder form, crushed sheet, single crystal, or polycrystalline form. Nanoparticles 
are generally stabilised by some chemical agent. Surface chemistry and crystal structure can 
play important role in antibody selection. One research group in Israel has demonstrated the 
specificity of antibody for a crystalline facet of GaAs semiconductor (Schnirman, Zahavi, 
Yeger, & Rosenfeld, 2006).Depending on the physical state of the target material used in 
screen, we adapted different strategy to prepare target. 
 
Step 2.1: Selection protocol for surface modified and biotinylated nanoparticle 
 
Surface modified and biotinylated targets (CdS QDs and gold nanoparticles) were 
immobilised on streptavidine coated paramagnetic beads. Magnetic beads having the target 
immobilised on their surface were used for interaction with antibody phage library. To avoid 
nonspecific selection we incubated antibody phage library with streptavidine coated 
paramagnetic beads prior to its incubation with target. Detailed protocol is as followed- 
 
1) To remove potential nonspecific binder, equal amount of Tomlinson I and Tomlinson J 
library in (total 1 ml) was taken in low protein bind eppendorf tube and 250ul of MPBST (PBS 
+ 0.1% tween-20 + 2% milk) was also added. 50 ul of streptavidine M280 dynabeads were 
washed twice with PBST and mixed with phage mixture and  incubated of 90 min on small 
rotator. At the end of incubation, phages were aspirated carefully and mixed with target (as 
explained in next step). 
 
2) Magnetic beads were washed twice with PBST (PBS+ 0.1% tween) and mixed with 
biotinylated targets. Mixture was incubated for 30 min in standing position and occasional 
tapping of tube. (25 ul of biotinylated CdS QD + 50 ul of magnetic beads) (125 ul of 
biotinylated gold nanoparticles + 50 ul of magnetic beads). At the end of incubation, targets 
were aspirated out, and beads were washed twice with PBST and mixed with phages 
(preabsobed with magnetic beads).  
 
3) Mixture of phages and immobilised target on beads were incubated for 90 min on rotator 
and 30 min in standing position. At the end of incubation, buffer was taken out carefully (with 
the help of magnet). Beads were mixed with 1ml PBST and transferred to falcon tube 
containing 7 ml PBST.  
 
4) Beads were washed rapidly with 8 ml PBST (10 times for first round of selection) in 
subsequent rounds of selection washing was performed 20 times. 
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There is good chance to miss important clone during first round of panning, as each clone is 
present in 104 to 105 copies, which determine selection co-efficient of specific binder as 10-4, 
this is one reason to keep selection stringency low during first round of selection. It is more 
likely that during third round of selection, specific clones are enriched and become major part 
of population.  
 
5) After last wash, elution step was performed. 1 ml of freshly prepared TEA (140ul of TEA in 
10 ml H2O) was added to beads, and mixture was incubated for 10 min by gentle agitation 
on rotor. After 10 min, 500 ul of TEA was recovered (on the magnet) and neutralised in 500 
ul of 1M Tris, pH 7, after additional 10 min incubation, the remaining 500 ul of TEA was 
recovered and neutralised in same tube containing Tris. The beads were also neutralised 
with 200 ul Tris, and kept separately.  
 
6) The rescue and amplification of selected phages were achieved by infecting TG1 bacteria. 
10 ml of exponentially growing TG1 bacteria (OD=0.5) were mixed with 750 ul of neutralised 
eluted phages. 4 ml TG1 culture was added to neutralised beads. Both mixtures were 
incubated in water bath at 370c for 30 min. Rest of unused neutralised phages were also 
saved and stored at -40c. at the end of incubation both mixtures were pooled (100ul of this 
mixture is saved for titration of eluted phages), and centrifuged at 3300xg for 10 min. Pellet 
was resuspended with appropriate amount of 2xTY medium to spread infected bacteria on 3x 
15 cm 2xTY +amp+ 1% glucose plates. 
 
7)  10-10 dilution of input phages solution was infected with exponentially growing TG1 cells, 
infected TG1 cells were also spread on 2XTY amp 1%Glu plates for input titration (10-1, 10-2, 
10-3 dilutions). 
 
8)  Eluted phages saved during step 6 were also infected with exponentially growing TG1 
cells, infected TG1 cells were also spread on 2XTY+ amp +1%Glu plates for output titration 
(10-1, 10-2, 10-3 dilutions). Negative controls were done by spreading 2xTY medium, TG1 on 
amp and kanamycin plates. All the plates were incubated at 370c overnight. 
 
9) Next day, all colonies appeared on input and output plates were counted to determine 
yield. 
 
10) Large plates were scraped with 6 ml 2xTY + 30% glycerol and  stored in separate 
aliquots. Next round of selection was started by dilution of this culture to OD=0.05 in 100 ml 
2xTY+amp+1%glu, culture was incubated at 37oc until OD=0.5. 
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11) 20-fold excess of helper phages were added to 10 ml of this culture and mixed gently 
and incubated in water bath at 370c for 30 min. After incubation, the culture was centrifuged 
and resuspended in 50ml 2xTY+amp+kan (no glucose)and incubated at 300c overnight to 
produce phages for another round of selection. Phage solution was prepared exactly same 
as explained in step1 (preparation of input). 
 
12) Random 94 bacterial colonies were picked from titration plates obtained for output of last 
(third) round of selection. Alternatively, it can be performed later by spreading glycerol stock 
of last round output, n picking clones. Each colony was transferred to 2 ml deep well (in 96 
well plate) containing 500 ul 2xTY+amp+ 1% glu, and incubated overnight at 370c. Next day 
storing solution prepared by adding 50% glycerol and 50% 2xTY medium was added into 
each well (500ul each) to make glycerol stock. Well no A1 and H12 were kept as control (no 
bacterial colony). This plate was the master plate, other replica plates were prepared for 
further experiments.  
 
Step 2.2: Selection protocol for powder form targets 
 
Micron size particles (ZnS, CdS, CdSE and gold) came in powder form. Physical state of 
these crystals facilitated ease in screening as these powders get sediment in few Seconds 
by centrifuging for few seconds. Quantity of target used for screening was 21 mg CdS, 21 mg 
gold, 30 mg ZnS and 30 mg CdSe powder. Most of the steps performed for selection were 
same as mentioned for biotinylated target, except, preparation of target, washing and elution 
steps. Powdered form targets were directly mixed with library of phages, washing and elution 
steps were performed by centrifuging the tube containing target for few second using table 
centrifuge. After last round of selection, 94 random clones were picked for each target. 
 
Step 3: Identification of positive clones 
 
ELISA (enzyme linked immunosorbent assay) was performed to identify positive (target 
specific) clones. The protocol for ELISA was also adapted according to the physical state of 
target. Biotinylated targets were immobilised on streptavidine coated ELISA plate (Nunc), 
after that ELISA experiment was performed as mentioned in next paragraph. Powder form of  
target imposed problem in ELISA experiment because they can not be immobilised on plate, 
which make washing step technically difficult (washing is done by quick rinsing and then by 
inverting and tapping the plate, for powder form target inverting was not possible,  rinsing 
each well without loosing target was difficult task). Therefore, ELISA was performed using 
1.5 ml polypropylene tubes. Each clone was tested in tube ELISA, which took several days 
instead of one day in ELISA plate. ELISA was performed with bacterial supernatant 
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containing secreted scFvs. Supernatants were obtained by systematically induction of each 
clone as explained below- 
 
All clones were replicated from glycerol stock of randomly picked clones in 
2xTY+amp+1%glucose in 96 well plate (2ml deep well). Cultures were started by inoculating 
10 ul of each clone in 1 ml 2xTY+amp+ 0.1% glucose followed by incubation at 370c until OD 
reached 0.5 (Glucose level was reduced to 0.1% for scFv expression). At this stage, cultures 
were induced by 1mM IPTG and transferred to 300c incubator for overnight. Next day 96 well 
plate was centrifuged at 5000xg for 10 min. Supernatants of each clones were used for 
ELISA experiment. 
 
ELISA in 96 well plate 
 
ELISA experiment for biotinylated target was performed in 96 well streptavidine coated plate. 
Plate was rinsed quickly with PBST (1xPBS+ 0.05% tween) and coated with targets, targets 
were mixed with PBST and distributed equally in each well.  [25ul of CdS QD+ 10.5 ml PBST 
(1xPBS+ 0.05%tween), 100 ul of gold nanoparticles +10.5 ml PBST]. 100 ul of each target 
sample was coated in 96 wells of plate. Coating was done by 1 hr incubation at room 
temperature on table rocker. Plates were rinsed quickly 2 times with PBST (1xPBS+ 0.05% 
tween). Plate was blocked by using blocking buffer (2% milk+ 1xPBS+ 0.1% tween) for 1 
hour. Later blocking buffer was removed by inverting and tapping the plate. 100 ul scFv 
culture supernatant was added in each well; plate was covered and incubated for 1 hr at 
rocker. After incubation supernatants were discarded and plate was washed with PBST ( 
1xPBS+ 0.1% tween). Primary antibody (anti His antibody) is diluted 1:1000 times in blocking 
buffer and added into each well (100ul/well) and incubated for 1 hr. After incubation, primary 
antibody was discarded, and plate was washed three time using PBST. Plate was incubated 
with secondary antibody (anti mouse HRP, 1:3000 dilutions) for 1 hr. After incubation 
secondary antibody solution was discarded and plate was washed. Later 100 ul of 
developing solution ( 70 ml acetate buffer pH 6+ 15ul H2O2 +7 mg TMB+ 700 ul DMSO) was 
added in each well, plate was incubated in dark for 10 min. In presence of specific 
antigen/antibody interaction color signal appeared. Reaction was stopped by using 1M HCl 
(50 ul/well), which turned positive color signal (blue) into yellow color.  
 
ELISA in tubes 
 
Tube ELISA was performed in 1.5 ml polypropylene tube. Targets (powder) and tubes used 
for ELISA were blocked by using blocking buffer (2% milk+ 1xPBS+ 0.1% tween) for 1 hour. 
Later blocking buffer was removed by centrifuging the tubes. Targets were equally distributed 
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in each tube (approx 1 mg/tube). 100 ul scFv culture supernatant was added in each tube, 
and incubated for 1 hr at rocker. After incubation supernatants were discarded and targets in 
tube were washed with PBST ( 1xPBS+ 0.1% tween) by mixing and then by centrifuging. 
Primary antibody (anti His antibody) is diluted 1:1000 times in blocking buffer and added into 
each tube (100ul/tube) and incubated for 1 hr. After incubation, primary antibody was 
discarded, and tubes were washed three time using PBST. Targets in tube were  incubated 
with secondary antibody (anti mouse HRP, 1:3000 dilutions) for 1 hr. After incubation 
secondary antibody solution was discarded and targets were washed. Later 100 ul of 
developing solution ( 70 ml acetate buffer pH 6+ 15ul H2O2 +7 mg TMB+ 700 ul DMSO) was 
added in each tube, followed by incubation in dark for 10 min. In presence of specific 
antigen/antibody interaction color signal appeared. Reaction was stopped by using 1M HCl 
(50 ul/well), which turned positive color signal (blue) into yellow color. Colored solutions were 
taken into 96 well plate for taking picture on ELISA result. 
 
Step 4: Production of soluble scFv antibodies in E. coli 
 
Phagemids can allow either soluble expression of recombinant protein (antibody fragment) in 
bacteria, or the production of the fusion protein encapsulated on the phage tip (thus forming 
the phage antibody). This is possible because an AMBER stop codon with TAG sequence, 
which is placed between the foreign protein (scFv) gene and g3. In some E. coli strains (as 
HB2151), the TAG codon can be read as a stop signal thus determining soluble expression 
of the recombinant protein. These bacteria are termed “non-suppressor”. On the contrary, in 
“suppressor” E. coli strains such as TG1, TAG codon is read as glutamic acid so that 
transcription is not stopped and foreign protein-p3 fusion protein is synthesized. The 
phagemid is also designed to have polyhistidine tag fused to express scFv, which allows 
purification of antibodies by using metal affinity chromatography. Depending on clone and 
bacterial strain, one can obtain soluble antibodies in culture supernatant, periplasm or inside 
the bacterial cell, (we obtain most of the scFvs  secreted in culture medium in sufficient 
amount ). 
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Appendix C: Alignment of anti-gold scFv sequences 
 
We had Identified 45 clones showing binding to gold target, DNA of these clones was 
extracted and sent to sequencing company. Sequence of some clones were repeated, we 
identified 32 unique sequences. Unique 32 sequences with symbol are presented below.   
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Appendix D: Chemicals, biologicals and vector used in production of recombinant 
antibody in Dd 
 
A) Chemicals/ media 
 
HL5 medium ( peptone 5 gm, tryptone 5 gm, yeast extract 5 gm, KH2PO4 0.35 gm, 
Na2HPO4 0.35gm, glucose 10 gm for 1 L), 2XTY medium, G418, ampicilline , cobalt resin 
(Thermo scientific), imidazol (sigma), enzymes (Fermentas, fast digest), electroporation 
buffer (50 mM Sucrose, 10 mM NaPO4, pH 6.1) 
 
B) Dd strain and vector 
 
AX3 Dd strain, pTX-GFP vector, pUX vector, pUC vector,  DH10B bacterial strains 
 
C) ScFv sequences 
 
NCBI accession no- (TA10 - AY348549.1), (SF9 - AY348548.1), (F2C- AY348545.1), (MB11- 
AA842745.1) 
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Appendix E: Design of Dd expression vector and cloning strategy of engineered 
fragments in Dd expression vector. 
 
A) Dd vector cloning 
 
Ddp1 plasmid based pTX-GFP vector was used as backbone. The vector plasmid already 
carries cassette for G418 selection in Dd under actin 6 promoter, amp resistance marker for 
E. coli, Dd origin of replication, and E.coli origin of replication, actin 15 promoter sequences. 
Our collaborator at Curie institute ordered a sequence from gene synthesis Company, this 
sequence contains actin 15 promoters sequence, start codon sequence, Cel- A signal 
peptide sequence of Dd origin, few additional sequences for multiple cloning site. We 
received the synthesized sequence cloned into pUC-57 vector. The sequence was PCR 
amplified from pUC 57 vector and further digested with Xba l and Sal l restriction enzymes, 
and gel purified. pTX –GFP vector was digested with Sal l – Xba l enzymes, resulting in 
removal of original actin 15 promoter sequence and MCS sequence. Backbone of pTX–GFP 
vector and synthesized gene sequence were ligated using ligation enzyme. The ligated 
product was transformed into competent DH10B strain of E.coli.  The positive clone was 
confirmed by extraction of plasmid DNA of few selected E.coli transformed colonies 
appeared on selection plate and further, checking the correct insert size by digestion with Sal 
l and Xba l restriction enzymes. Design of Dd Expression vector construction and different 
cloning steps are shown in figure E1. 
 
 
 
 
 
 
 
 
 
 
 
 
  153 
 
                                         design of expression vector( pUX) 
                         
 
       
Figure E1: Construction of pUX vector, a) before ligation pTX and synthesized gene (Sal l-Xba l cut), 
b) confirmation of positive clone by restriction digestion (expected insert size 500bp) M-DNA marker, 
lane 1-10 transformants of ligated product (synthesized gene+ pTX backbone), digested with Sal l and 
Xba l, clone no 9 is positive clone with the insert size nearly 500bp. 
 
 
B) Cloning of scFv in Dd expression vector 
 
cDNA correspond to scFvs -SF9, TA10, F2C, MB11 were excised from phen vector and then 
subcloned into Dd expression vector ( pUX) between Nco l and Not l restriction sites. The 
pUC 57 with dicty gene insert pTX –GFP vector
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  154 
ligated product was transformed into competent DH10B strain of E.coli.  The positive clone 
was confirmed by extraction of plasmid DNA of few selected E.coli transformed colonies 
appeared on selection plate and further, by checking the correct insert size by digestion with 
Nco l –Not l restriction enzymes. Design of scFv cloning in Dd expression vector and 
different cloning steps are shown in figure E2.  The plasmid DNA of positive clone was 
transformed in Dd cells (see appendix F). Vector map of pUX- scFv is shown in figure E3. 
 
                               
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                
                   c 
 
                                  b                                                                                                                                     
Figure E2:  (a) design of pUX - scFv construct, (b) before ligation of scFv insert into pUX vector, 1- 
SF9, 2- TA10, 3 – F2C, 4- pUX vector uncut, 5 – pUX vector digested with Nco l – Not l, M – DNA 
marker, (c) Screening of positive clone by restriction digestion (Nco l – Not l), M- DNA marker, 1 – 
pUX- F2C transformed clone (uncut), lane 2 to 11 – pUX-F2C transformed clones digested with Nco l 
– Not l. expected insert size 750 bp, all clones are positive except clone 10. Similarly, we obtained 
positive clones with SF9, TA10, MB11 cloning, data not shown here. 
 
Phen vector with ScFv
(SF9,F2C,TA10,MB11) gene insert
pUX vector
Ligation
Digestion with restriction enzymes
Nco l – Not l
pUX + ScFv
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                                                     Figure E3:  pUX - F2C scFv vector map 
 
 
 
C) Cloning of scFv+Fc constructs in Dd expression vector 
 
This cloning was done in one step by using previously generated pUX-scFv constructs. We 
have fused multispecies Fc regions with various scFvs. This work has given additional value 
to antibody fragment by making it free from species specificity barrier. Multispecies Fc 
(human, rabbit, mouse) and mCherry Fc are extracted from phen vector by restriction 
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digestion with Not l – Nhe l.  All Fc fragments were ligated in pUX vector at Not l – Nhe l 
sites, just downstream to scFv sequence in pUX vector. The ligated product was transformed 
into competent DH10B strain of E.coli. The positive clone was confirmed by extraction of 
plasmid DNA of few selected E.coli transformed colonies appeared on selection plate and 
further, checking the correct insert size of Fc region by digestion with Not l- Nhe l restriction 
enzymes. Design of scFv+Fc cloning in Dd expression vector and different cloning steps are 
shown in figure E4.  The plasmid DNA of positive clone was transformed in Dd cells (see 
appendix F). Vector map of pUX- scFv+Fc is shown in figure E5. 
  
 
 
 
Figure E4: (a,b) isolation of multispecies Fc from phen vector by digesting with Not l - Nhe l restriction 
enzymes, (c) Screening of clones by restriction digestion using Not l - Nhe l, M – DNA marker, lane 1-6 
(pUX TA10+ Mouse Fc) expected insert 700 bp. Lane 8- 11 (pUX TA10+ mCherry Fc) expected insert 
1.6kb, (d) Screening of clones by restriction digestion using Not l - Nhe l, lane 1-4 (pUX TA10 + 
Human Fc) expected insert size 700bp, lane 5-7 (pUX TA10 + Rabbit Fc) expected insert size 700bp. 
The screening results and vector map are shown for only one scFv (TA10). Positive constructs were 
obtained with other scFvs – SF9, F2C, MB11, data not shown here. 
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D) Cloning of scFv:: streptavidine construct in Dd expression vector  
 
In order to get tetrameric construct, streptavidine gene was fused with scFv sequence. The 
streptavidine gene was isolated from PSTE2 vector by digestion with Not l- Nhe l restriction 
enzymes (fig.E6).  DNA of pUX scFvs   (scFv- F2C, TA10, SF9) were digested with Not l- 
Nhe l restriction enzymes and dephosphorylated. The streptavidinde gene was ligated at  Not 
l - Nhe l sites , just downstream to scFv in pUX vector. The ligated product was transformed 
into competent DH10B strain of E.coli. The positive clone was confirmed by extraction of 
plasmid DNA of few selected E.coli transformed colonies appeared on selection plate and 
further, checking the correct insert size by digestion with Not l- Nhe l restriction enzymes. 
Different cloning steps are shown in figure E7.  The plasmid DNA of positive clone was 
 
Figure E5: pUX SF9 + mouse Fc vector map 
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transformed in Dd cells (see appendix F). Vector map of pUX- scFv::streptavidine is shown in 
figure E9. 
 
PVP binding scFvs were also fused with streptavidine, this cloning was done by replacing 
scFv construct which were already fused with streptavidine , replacement was done at Nco l- 
Not l site. The ligated product was transformed into competent DH10B strain of E.coli. The 
positive clone was confirmed as described above but this time we checked the insert pattern 
of scFvs by digesting construct with Nco l – Not l enzymes. Different cloning steps are shown 
in figure E8. The plasmid DNA of positive clone was transformed in Dd cells (see appendix 
F).   
 
 
Figure E6: Cloning of streptavidine gene, M – DNA marker, lane 1- PSTE2 vector digested with Not l- 
Nhe l (size of streptavidine insert 500bp) 
 
 
 
Figure E7: ScFv:: streptavidine cloning (a) Before ligation of streptavidine gene, M – DNA marker, 
lane 1- PSTE2 (Not l- Nhe l cut), Lane 2, 3- pUX TA10,pUX F2C respectively (Not l-Nhe l digested, 
dephosphorylated) (b) Screening of positive clone for pUX F2C :: streptavidine clones, M – DNA 
marker, lane 1-5 pUX F2C:: streptavidine clones digested with Not l-Nhe l restriction enzymes, 
expected insert size (500bp). We obtained positive streptavidine fusion constructs with other scFvs, 
results are not shown here. 
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Figure E8: PVP binding scFv:: streptavidine (a) Before ligation of streptavidine gene and PVP ScFv, 
M- DNA marker, 1- pUX SF9 :: streptavidine clone (Nco l- Not l digested, dephosphorylated)expected 
insert (10kb and 750bp), lane 2- B1 scFV (expected size 500bp),lane 3- A2 ScFv(750bp), lane 4- C11 
ScFv (500bp), lane 5- F1 ScFv (750bp) (b) Screening of positive clones for PVP ScFv:: streptavidine, 
digestion with Nco l- Not l 
Lane 1,2,3 (upper gel) pUX B1::streptavidine (expected insert size, 500bp) 
Lane 6 (upper gel) - control (no insert DNA),Lane 7 (upper gel)- DNA marker, 
lane 10,11,12 (upper gel)pUX C11::streptavidine (expected insert size ,500bp) 
lane 1,2,3 (lower gel) pUX A2:: streptavidine (expected insert size, 750bp) 
lane 6 (lower gel)  DNA marker, 7 (lower gel) – control, 
lane 10,11,12 (lower gel) pUX F1:: streptavidine (expected insert size 750bp) 
 
E) Cloning of bispecific antibody constructs in Dd expression vector  
 
We have set up a strategy to fuse any two NcoI/NotI excised scFv fragments, resulting in a 
combined fragment flanked by NcoI/NotI sites. We used one flexible linker to attach two 
scFvs. 
 
Design of linker 
 
In bispecific construct, two scFvs are separated by a linker. We suspected that linker should 
not interfere with binding activity of both scFvs. Therefore, naturally occurring flexible linker 
sequence was chosen, which was highly rich in glycine and serine. Primers were ordered for 
linker sequence. Linker has (G4 S)3 sequence in middle flanking by Eag l at 5’ end and Pag l 
at 3’ end. These extreme ends were introduced in order to design linker to facilitate joining of 
any two scFvs having Nco l and Not l sites at the extremes. Eag l share same overhanging 
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region with Not l site. Pag l share same overhanging region with Nco l site. Primers were 
annealed by boiling at 95oc for 15 min, and by cooling overnight. Size of annealed fragment 
is small, so digestion with Eag l and Pag l enzymes was performed separately. 
 
Construction of bispecific antibody 
 
The pUX vector backbone was used for construction of bispecific antibody constructs.  
Advantage was taken from earlier cloning of scFv in pUX vector. In pUX-scFv construct, scFv 
is present at Nco l and Not l sites. (General scheme is described for two scFvs, where two 
scFvs are denoted with A and B, please refer figure E10 ) pUX scFv A was digested with Not 
l and Nhe l restriction enzymes and dephosphorylated, this was used as backbone. scFv B 
was extracted from pUX vector from site Nco l – Xba l, and dephosphorylated.  Digested 
fragment of scFv B was ligated with linker. 
 
Pag l site and Nco l site share same overhang as mentioned in above paragraph. Pag l end 
of linker and Nco l end of scFv B were ligated. Resulting ligated product had Eag l and Xba l 
sites. Newly ligated product had one end phosphorylated (Eag l) and other end 
dephosphorylated (Xba l). For ligation reaction one end required to be phosphorylated and 
other end dephosphorylated. For last ligation in backbone with scFv A, which has Not l and 
Nhe l sites (dephosphorylated), compatible ends were prepared in ligated product. scFv B+ 
linker is digested with Nhe l enzyme, resulting fragment has Eag l and Nhe l sites, which 
were compatible for ligation with backbone having scFv A (Eag l and Not l share same 
overhang). Ligation resulted in bispecific construct, present at Nco l and Nhe l. Screening 
was done by transformation into DH10B strain of E.coli. Few transformed clones were 
selected, their plasmid DNA were isolation and digested with restriction enzymes Nco l and 
Nhe l, to check correct insert size (which should be 1.5Kb). See figure E 11 for screening 
result. Later sequence of bispecific construct was confirmed by sequence analysis. 
Transformation of pUX vector containing bispecific construct (ScFv A + linker + ScFv B) was 
done in Dd cells. We did not observe expression of this construct in Dd . Potential reason is 
mentioned in discussion ,section 3.2. 
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                                Figure E10 Scheme of bispecific construct design 
 
 
                         
Figure E11, Screening for bispecific construct by digestion with Nco l- Not l 
This cloning was difficult, only one clone out of many clones was positive. Correct size of             
bispecific insert is 1.5 kb, positive clone is shown with the arrow. 
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Appendix F: Generation and characterisation of Dd cell lines expressing recombinant 
antibodies  
 
Expression and purification of scFv and engineered scFv fragment in Dd 
 
A) Transformation of AX3 cells by electroporation 
 
The expression vector used in this case was named as pUX that harbors the G418 
resistance marker. The convenient feature of the vector is the fact that the gene of interest 
can be inserted using Nco l – Not l restriction sites in the multiple cloning sites under the 
actin 15 promoter which allows high level of recombinant gene expression. A signal 
sequence (Cel A) is present downstream of the actin 15 promoter which enables efficient 
secretion of the recombinant antibodies into the medium. The vector also contains 
sequences required for selection and propagation of the plasmid in the bacterial system. 
 
The recombinant plasmid was purified using Nucleo Spin (Macherey nagel) kit. 
Transformation was carried out using electroporation method recommended by the Biored 
micro pulser with some modifications. Briefly, AX3 cell was grown in (T75 tissue culture flask) 
HL5 medium at 220C incubator. When cells reached exponential state, they were harvested 
(scrapped) and incubated on ice for 30 min. later centrifugation at 500×g for 5 minutes at 40C 
was performed. Supernatant was discarded and cells were resuspended in 850 ul of 
electroporation buffer (50 mM Sucrose, 10 mM NaPO4, pH 6.1). An aliquot (850 µl) of the 
resuspended competent cells was transferred to a 4mm gap electroporation cuvette 
(Molecular Bio Products) for transformation. Cuvette was already incubated for 10 min on ice 
with 30 ug of plasmid DNA (Dd expression vector) to be transformed. DNA and competent 
cells were mixed, cells were subjected to electroporation in a Gene PulserR electroporator 
(Bio‐Rad Laboratories, Hercules, CA, USA) using a charging voltage of, 1KV; resistance, 
200Ω; capacitance, 25µF for about one milliseconds (2 pulses, 3 second apart). Immediately 
after electroporation, contents of cuvette were transferred to T 75 tissue culture flask 
containing HL5 medium. Flask was incubated at 220C in incubator for 14-15 hours for 
recovery. After recovery period medium was changed, successive dose of G418 was added.  
 
B) Screening of the Dd transformants 
 
 Dd transformants were obtained after successive increased dose of G418. Dose was 
increased from 5 ug/ml to 20 ug/ml. Few transformants could not tolerate initial dose of 5 
ug/ml, so we restarted transformation with dose 2.5 ug/ml. Cells were screened for their 
ability to secrete scFv and other engineered scFv products in medium (HL5) under selection 
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of G418. After getting confluent at 20 ug of G418, The supernatants of the transformed cells 
was analysed by immunofluroscence. The clone secreting scFv was used for scaling up the 
production in shake flask culture. 
 
C) Immunofluorescence assay 
 
Immunofluorescence labelling was performed on HeLa cells. Cells were fixed in 3% 
paraformaldehyde and permeabilized with PBS and 0.1% saponin for 4 min at -20°C. scFv 
and engineered scFv containing supernatants were used at different dilution from 1/20 to 
1/1000 times and incubated for 1 hr on cells( along with primary antibody anti-His6 in PBS 
and+saponin). Cells were then rinsed twice with PBS and incubated with secondary 
antibodies for 30 min. After two short rinsing steps, cover slips were mounted onto slides in 
mowiol. (Immunoflurescence assay were performed at Institute Curie, Paris) 
 
D) Large scale expression of the antibody in Dd cells 
 
Expression of scFv was scaled up in shake flask culture. Selected clones were first grown in 
tissue culture flask (T75, nunc) at 220c incubator in HL5 medium and 20ug/ml G418. After 
attaining certain growth, cells were scrapped and transferred into flask containing 100ml HL5 
medium and 20 ug/ml.  Flask was incubated at 220c shaking incubator. After two days when 
cells grow in density from initial inoculums, culture is transferred into bigger flask with 500ml 
HL5 medium and G418 (20ug/ml). Cells were grown until 72 hours. At this stage cells were 
harvested and centrifuged at 8000 RPM for 30 min at 40c (Sigma centrifuge). Supernatant 
was collected and further processed for purification.  
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Appendix G: Purification of Dd expressed antibodies 
 
500ml Dd supernatant was used to purify scFv. Column was prepared with cobalt resin (2 ml 
bed volume), column was previously equilibrated with phosphate buffer (5.84 g NaCl, 4.72 g 
Na2HPO4 and 2.64 g NaH2PO4.2H20, pH 7.2, in 1 litre). Column was again washed 2 times 
with 20ml phosphate buffer. Dictyostelium culture supernatant was applied to column, flow 
through was collected. Purification procedure was performed at 40c. Flow through was again 
applied on column and collected. Column was washed with 2x20 ml volume of phosphate 
buffer. Elution was carried out with 150mM imidazole. Different elution fractions were 
analysed by SDS-PAGE. One of scFv+ Fc construct was purified by S. Moutel at Institute 
Curie by using protein A, this sample was later sent for glycosylation analysis. 
 
SDS-PAGE analysis 
 
The purified proteins (25ul of each fraction) were analyzed on 10% SDS-PAGE under 
reducing conditions, followed by coomassie brilliant blue staining and subsequent destaining. 
For SDS-PAGE, all the chemicals were purchased from biored.   
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Appendix H: Glycosylation    
 
The glycans synthesized by human cells are composed of seven monosaccharide units: 
1. glucose(Glc) 
2. galactose (Gal) 
3. mannose (Man) 
4. fucose (Fuc) 
5. N-acetylglucosamine (GlcNAc) 
6. N-acetylgalactosamine (GalNAc) 
7. Sialic or neuraminic acids (SA). 
 
These units can be joined in linear or branching manner of two and many hundreds 
monosaccharide units. The monosaccharide may be linked together by either α- or β-
linkages, and bonds can be formed between the hydroxyl groups associated with different 
carbon atoms of the molecules. This gives a range of possible linkages, including 1→3, 1→6 
and 2→3 linkages. This combination of seven monosaccharide, different linkages between 
them, and the potential for linear or branching chains of different lengths gives a large 
number of possible glycan structures(Brooks, 2004). All of these structures actually do not 
occur in nature, but naturally occurring glycans are still extremely varied and heterogeneous.  
Glycosylation types are classified according to the identity of the atom of the amino acid 
which binds the carbohydrate chain, i.e. C-linked, N-linked or O-linked. (adaptation- 
http://www.uniprot.org) 
 
1. N-linked glycosylation 
 
N-linked glycosylation refers to the attachment of oligosaccharides to a nitrogen atom, 
usually the N4 of asparagine residues. The consensus sequence for N-glycosylation is Asn-
Xaa-Ser/Thr (where Xaa is amino acid except Pro) N-glycosylation occurs on secreted or 
membrane bound proteins, mainly in eukaryotes and archaea – most bacteria do not carry 
out this modification.  
 
2. O-linked glycosylation 
 
O-linked glycosylation of secreted and membrane bound proteins is a post-translational 
event that takes place in the cis-Golgi compartment after N-glycosylation and folding of the 
protein. It refers to the attachment of glycans to serine and threonine, and, to a lesser extent, 
to hydroxyproline and hydroxylysine. 
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3. C-linked glycosylation 
 
C-linked glycosylation refers to the covalent attachment of a mannose residue to a 
tryptophan residue within an extracellular protein.  
 
4. Glycation 
 
Glycation refers to the non-enzymatic attachment of reducing sugars to the nitrogen atoms of 
proteins (both to the N-terminus and to lysine and histidine side chains).  
Biosynthesis of N linked glycosylation-  
  
 
 
 
Figure G1: Overview of the biosynthesis of protein N-linked glycan side chains.  The nascent 
glycoprotein enters the endoplasmic reticulum (ER), a preformed oligosaccharide, dolicol phosphate 
precursor (DPP) is attached cotranslationally to some asparagine residues that are part of the 
consensus sequence. All the activities in synthesis of N linked glycan are performed by glycosidases 
and glycosyltransferases enzymes present in endoplasmic reticulum and golgi. The exact profile of 
such enzymes present in the cell will largely dictate the composition and structure of the final 
oligosaccharide side chain(Walsh & Jefferis, 2006) 
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Synopsis en français 
 
Sous forme agrégée, les matériaux inorganiques sont utilisés dans de nombreux domaines, 
tels que le domaine médical, énergétique, environnemental ou productique. Cependant à 
l'échelle nanométrique (1-100nm), leurs propriétés optiques, électriques, photo-électriques, 
magnétiques, mécaniques, chimiques, et biologiques diffèrent. Ils ne peuvent donc plus être 
exploités de la même manière. 
 
Dans ces travaux, nous nous sommes intéressés à deux applications potentielles de ces 
nanomatériaux inorganiques : d'une part, l'utilisation de nanoparticules métalliques ou semi-
conductrices comme sondes pour l'imagerie biologique ; d'autre part, la production de 
structures/systèmes autoassemblés basés sur les nanoparticules. Pour chacune de ces 
deux applications, la surface chimique des nanomatériaux doit être rigoureusement 
contrôlée. Dans ce but, nous proposons une nouvelle stratégie qui altère la surface des 
nanoparticules par le biais de ligands/sondes correspondant à des protéines, plus 
précisémment des anticorps. 
 
Pour réussir à ainsi améliorer la surface chimique des nanoparticules, il est primordial de 
bien comprendre les mécanismes de liaisons spécifiques des protéines aux matériaux 
inorganiques. Nous avons donc étudier les interactions protéine-matériaux inorganiques. 
Pour ce faire, nous avons utilisé une technique combinatoire : le phage display d'anticorps. 
Dans cette technique, une librairie combinatoire et aléatoire d'anticorps recombinants mime 
le répertoire imune. Cette librairie est scannée in-vitro pour sélectionner les anticorps qui se 
lient à une cible d'intérêt : cela permet d'isoler les anticorps qui se lient spécifiquement, ainsi 
que la sequence génétique qui leur correspond. 
 
A l'instar des méthodes conventionnelles, le phage display d'anticorps offre la possibilité de 
contrôler in-vitro les conditions utilisées pour sélectionner les ligands : l'environnement 
physique et chimique peut être ajusté par l'expérimentateur pour créer une pression de 
sélection. Par ailleurs, cette technique ne nécessite pas de caractériseriser préalablement la 
cible nanométrique. Dans le cas de cibles qui possèdent une surface inorganiques, ceci est 
particuliérement avantageux par rapport aux méthodes conventionnelles qui reposent sur un 
design rationel de la surface inorganique des ligands (avec, par exemple, des simulations 
dynamiques moléculaires). 
 
Dans cette thèse,  les cibles utilisées sont des matériaux inorganiques, et elles sont 
diverses. Donc à priori, n'importe quel matériaux (organique/inorganique) peut être ciblé. 
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Dans ces conditions, les anticorps spécifiques (protéines) qui visent le matériau d'intérêt 
peuvent être identifiés. 
 
A ce jour, en scannant une librairie de 10^8 séquences aléatoires d'anticorps, nous avons 
réussi à identifier 32 séquences d'anticorps qui se lient spécifiquement aux particules d'or de 
taille micrométrique. Une analyse statistique de ces 32 séquences nous a permis d'identifier 
des amino acides particuliers qui sont fortement sélectionnés dans les positions aléatoires 
des séquences d'anticorps. L'Arginine a été sélectionnée de manière prédominante à 
plusieurs positions dans les anticorps qui se lient spécifiquement à l'or. Ce résultat est 
cohérent avec les observations de collègues qui utilisent des stratégies plus sophistiquées et 
méticuleuses, telles que les simulations dynamiques moléculaires. Cette cohérence conforte 
notre stratégie pour l'étude des matériaux, qui est elle, basée sur une technique relativement 
simple : le phage display. 
 
Nous avons ensuite voulu utiliser nos anticorps spécifiques de l'or comme ligands, le but 
étant d'améliorer la surface chimique des nanoparticules d'or (de taille -20nm). Les résultats 
préliminaires sont encourageants : ils attestent de la faisabilité du concept. 
 
Nous n'avons pas réussi à identifier des anticorps spécifiques d'autres cibles inorganiques. 
Toutefois, les raisons en ont été partiellement identifiées, et ce dernier défit peut être relevé 
en optimisant simplement les protocoles pour les autres cibles inorganiques. 
 
Dans une deuxième étape, nous avons attachés à modifier la séquence des anticorps 
sélectionnés en utilisant l'ingénierie de recombinaison d'anticorps. Les anticorps peuvent 
être construits pour acquérir de nouvelles fonctions. La séquence des deux scFvs peuvent 
être fusionnée dans le but de produire des adapteurs :des  anticorps spécifiques capables de 
se lier simultanément à deux cibles. 
 
Toutes les applications qui visent à modifier la surface chimique des nanoparticules en se 
basant sur le système de sondes-anticorps nécessitent de produire les anticorps 
sélectionnées et/ou construits. Etant donnée la structure sophistiquée et la taille des 
anticorps, c'est un réél défit ! Dans cette thèse, nous avons voulu relever ce défit. Pour ce 
faire, nous avons développé un nouveau système de production d'anticorps recombinants 
dans l'organisme eucaryotique Dictyostellium discoideum. A ce jour, ce système nous a 
permis de produire deux formes d'anticorps artificiels. Nous avons commencé à étudier les 
avantages que procure ce système pour la production d'anticorps thérapeutiques. 
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Cette thèse est divisée en quatre parties, qui commencent chacunes par une description 
briève de son contenu. 
 
La section 1.1 est une introduction générale sur les anticorps, leur structure, leur fonction, 
ainsi que sur le développement des technologies qui en découlent, avec notamment 
l'utilisation d'anticorps comme ligands et comme sondes. 
 
Dans la section 1.2 nous présentons la biotechnique combinatoire qu'est le phage display. 
Nous expliquons comment utiliser cette technique pour sélectionner in vitro, parmis une 
librairie aléatoire d'anticorps, les anticorps recombinants qui se lient à des cibles biologiques 
et non-biologiques. 
 
Dans la section 1.3, nous détaillons les étapes de construction qui permettent d'aboutir à un 
anticorps capable de fusionner avec une autre moitié biologique et chimique, y compris avec 
un autre anticorps. 
 
Dans la section 1.4, nous décrivons les systèmes d'expression utilisés pour produire ces 
anticorps recombinants, ainsi que la forme qui leur est octroyée. Nous présentons aussi le 
système eucaryotique hôte (Dictyostelium discoideum) que nous avons mis en place pour 
pouvoir construire ces anticorps . 
 
La section 1.5 illustre l'approche biomimétique généralement adoptée pour fabriquer et 
fonctionaliser des nanomatériaux inorganiques, avec une attention plus particuliére sur 
l'utilisation de ligands protéiques qui permettent aux nanoparticules inorganiques de générer 
de nouveaux matériaux. 
 
Dans la section 2, nous présentons nos résultats en deux parties. La première partie (2.1) 
décrit la sélection par phage display d'anticorps capables de se recombiner à des matériaux 
inorganiques. Nous décrivons aussi l'utilisation probable de ces anticorps comme ligands de 
nanoparticules inorganiques. Dans la deuxième partie (2.2), nous présentons le système 
expérimental mis en place pour l'expression et la production dans  Dictyostelium discoideum 
d'anticorps recombinants et de leurs constructions dérivées. 
 
Enfin, dans la section 3, nous discutons nos résultats. Une première discussion (3.1) porte 
sur la sélection réussie d'anticorps recombinant contre l'or, et ses applications potentielles 
dans le domaine des nanosciences inspirée du biomimétisme. La deuxième partie (3.2) 
insiste sur le potentiel d'utiliser Dictyostelium comme système de production, que ce soit 
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pour les anticorps recombinants ou pour les constructions élaborée à partir d'anticorps à 
applications thérapeutiques ou dans le domaine des nanosciences. 
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